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The transmembrane protein with epidermal growth factor and two follistatin motifs 2 
(TMEFF2) is an evolutionarily conserved type I transmembrane protein expressed in the embryo 
and limited adult tissues, mainly the brain and the prostate. The ectodomain of TMEFF2 can be 
cleaved from the membrane in an ADAM17/γ-secretase-dependent fashion and consists of an 
epidermal growth factor-like motif and two follistatin motifs. The cytoplasmic portion contains a 
potential G protein-activating (GA) domain. Given its elevated expression in primary and 
metastatic prostate cancer, TMEFF2 has been implicated to play a role in this disease. However, 
the exact biological function of TMEFF2 is rather controversial, with conflicting reports 
supporting both tumor-suppressing and growth-promoting activities of TMEFF2.  
In the present study, we demonstrate a dual mode of action for TMEFF2. Ectopic expression 
of wild-type full-length TMEFF2 inhibits monolayer and anchorage-independent cell growth, 
cellular invasion and migration, and increases cellular sensitivity to apoptosis. In contrast, 
expression of TMEFF2 ectodomain or addition of conditioned medium containing the 
ectodomain increases cell proliferation, in line with previous results using recombinant TMEFF2 
  
ectodomain protein. Furthermore, we investigate the molecular mechanisms involved in the 
function of TMEFF2. TMEFF2 interacts with sarcosine dehydrogenase and modulates cellular 
levels of sarcosine, a differential metabolite that increases during prostate cancer progression. 
The tumor suppressor activity of TMEFF2 correlates in part with its ability to modulate sarcosine 
levels. Moreover, TMEFF2 expression decreases prostate cancer cell spreading and migration, 
particularly on vitronectin, with a concomitant decrease in focal adhesion and stress fiber 
formation. Consistently, TMEFF2 inhibits RHOA activation – RHOA activation is known to 
induce stress fiber formation -- and downregulates expression of several integrins including β1 
and the major receptor for vitronectin -- αvβ3. All these effects require the presence of the GA 
domain, as expression of a TMEFF2 mutant lacking the GA domain does not affect RHOA 
activation or integrin expression. Finally, we show that different forms of TMEFF2 differentially 
regulate AKT and ERK activation. While the full-length TMEFF2 protein promotes ERK 
phosphorylation in response to growth factors EGF and PDGF-AA, the ectodomain activates 
AKT and inhibits ERK phosphorylation, which may contribute to the distinct cellular responses 
of tumor suppression or proliferation. Altogether, these data provide significant knowledge on 
the molecular mechanisms of TMEFF2 action, shedding light on the seemingly conflicting roles 
of various TMEFF2 forms. 
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CHAPTER ONE: Introduction 
The prostate gland and prostate cancer 
As part of the male reproductive system, the prostate gland is a walnut-sized exocrine gland 
that secretes important components of the seminal fluid. Although the adult prostate lacks 
discernible lobular structure, it can be divided into three zones: peripheral, transition, and central 
(McNeal 1988). There are at least three distinct cell types within the prostatic epithelium: 
luminal, basal, and neuroendocrine (Figure 1).  The luminal cells form a continuous layer of 
columnar cells, serving a secretory function to produce prostatic fluid. Basal cells are located 
between the luminal cells and the underlying basement membrane. Neuroendocrine cells are rare 
cells of uncertain origin and function dispersed throughout the basal layer. Both basal and 
luminal cells have been shown to contain putative prostate stem cells (Goldstein et al. 2008; 
Leong et al. 2008; Richardson et al. 2004; Wang et al. 2009).  
Prostate cancer has become a major public health concern in developed countries. It is the 
most commonly diagnosed cancer and the second leading cause of cancer deaths in American 
men. The American Cancer Society has estimated that in 2013, in the United States alone, there 
will be 238,590 new cases diagnosed, with 29,720 prostate cancer deaths (Siegel et al. 2013).  
Prostate cancer originates mostly in the peripheral zone and is a heterogeneous and multifocal 
disease. Within a given section of prostate cancer tissue, there can be benign glands, 
preneoplastic foci, and neoplastic foci of varying severity juxtaposed to each other. Moreover, 
individual neoplastic foci can be genetically distinct (nonclonal) even in close proximity (Abate-
Shen and Shen 2000). The vast majority of prostate cancer is classified pathologically as 
adenocarcinoma, characterized by a luminal phenotype and the disappearance of the basal layer. 
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Figure 1. Schematic depiction of the cell types within the prostatic duct (Abate-Shen and 
Shen 2000).  
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If prostate cancer metastasizes, it most frequently goes to bone, followed in frequency by liver, 
lymph nodes, and lungs (Shah et al. 2004).  
Currently the mainstay for early detection of prostate cancer is a blood PSA test. PSA is a 
kallikrein serine protease secreted by luminal cells of the prostatic epithelium. The blood level of 
PSA is often elevated in men with prostate cancer, as a consequence of disruption of normal 
prostate architecture (Lilja et al. 2008); however, other benign prostate conditions such as benign 
prostatic hyperplasia (BPH) or prostatitis can also cause an elevation in PSA levels. In addition, 
some men who have prostate cancer do not have elevated PSA, making PSA tests prone to both 
false-positive and false-negative results. Moreover, the potential risk of over-diagnosis and over-
treatment may outweigh the benefits of screening because much of PSA-detected prostate cancer 
is clinically indolent and requires only conservative management (Linn et al. 2007). 
Nevertheless, an abnormality found after the PSA test in men at high risk prompts a 
recommendation that the man undergo prostate biopsy to assess the potential presence of prostate 
cancer. Following biopsy, the severity of the cancer is evaluated by the Gleason grading system. 
A Gleason score is the sum of the two most prevalent patterns, which classify tumors from 1 to 5 
(well to poorly differentiated). If prostate cancer is diagnosed when it is confined to the prostatic 
capsule, it is potentially curable by surgical intervention and/or radiation therapy. However, if 
not detected and left untreated, prostate carcinoma may advance to more aggressive forms 
characterized by local invasion of the seminal vesicles, followed by metastasis primarily to the 
bone. Since the tumor is initially dependent on androgens for growth, the standard treatment for 
advanced prostate cancer is androgen deprivation therapy (ADT), either by surgical or chemical 
castration. Unfortunately, the disease almost inevitably recurs as castration resistant prostate 
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cancer (CRPC), which is currently untreatable and finally results in lethality (Abate-Shen and 
Shen 2000). 
There are four major challenges in diagnosing and treating prostate cancer. First, just as 
mentioned above, although ADT is initially effective in causing tumors to regress, recurrence to 
CRPC is inevitable and conventional chemotherapeutic regimens for CRPC have been at most 
palliative. It has become apparent that AR signaling remains active in CRPC through a variety of 
mechanisms, including: (1) de novo androgen biosynthesis and conversion of adrenal androgen 
precursors in tumor tissues (Chang et al. 2013; Locke et al. 2008; Montgomery et al. 2008; 
Stanbrough et al. 2006), (2) AR hypersensitivity via AR gene amplification, protein stabilization, 
or increased recruitment of AR coactivators (Fujimoto et al. 2007; Gregory et al. 2001; Linja et 
al. 2001), (3) AR gene mutations leading to promiscuous AR activation by noncognate ligands or 
ligand-independent activation (Culig et al. 1993; Dehm et al. 2007; Steinkamp et al. 2009; Thin 
et al. 2003; Zhao et al. 2000), (4) expression of AR alternative splice isoforms that are 
constitutively active (Dehm et al. 2008; Guo et al. 2009; Hu et al. 2009), and (5) growth factor-
mediated ligand-independent AR activation and increased AR transcription activity (Gao et al. 
2006; Guo et al. 2006; Jiao et al. 2007; Xu et al. 2009). Based on these findings, novel therapies 
targeting the AR pathway (i.e. androgen synthesis inhibitors, AR antagonists) have become 
available and have been proven to significantly increase survival in phase III clinical trials (de 
Bono et al. 2011; Ryan et al. 2013; Scher et al. 2012). 
Second, prostate cancer metastasizes primarily to bone with osteoblastic lesions, which is the 
main cause of patient morbidity and mortality. It has been established that during metastasis, 
cancer cells carry out the following sequence of events, often referred to as the metastatic 
cascade: they break away from their neighboring cells and the basement membrane, invade 
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through the interstitial stroma, intravasate into the lymph or blood system, survive in the 
circulation, extravasate from the bloodstream, and proliferate in the new microenvironment to 
form secondary tumors. The molecular mechanisms underlying the bone tropism of prostate 
cancer is very poorly understood, but is likely to involve bone endothelium attachment and 
extravasation, and colonization in the bone. In fact, in vitro binding experiments have shown that 
prostate cancer cells have higher affinity to human bone marrow endothelial (HBME) cells than 
to other endothelial cells (Lehr and Pienta 1998; Cooper et al. 2000). The binding of prostate 
cancer cells to HBME cells was inhibited by integrin β1 antibody but not antibodies to other 
integrins, suggesting that interaction between prostate cancer cells and bone marrow endothelium 
is primarily mediated by integrin β1 (Scott et al. 2001). In addition, bone matrix components 
such as osteonectin and osteopontin (Jacob et al. 1999; Khodavirdi et al. 2006) attract prostate 
cancer cells and promote their spreading and growth in the bone. Integrin αvβ3 is heavily 
implicated in this process, as it is the receptor for these bone matrix proteins. Functional integrin 
αvβ3 promoted prostate cancer cell migration to the bone matrix and enabled tumor growth in 
the bone in a mouse xenograft model, whereas inactive or constitutively active αvβ3 mutants did 
not (McCabe et al. 2007). 
Third, there is a lack of accurate biomarkers for prostate cancer diagnosis and prognosis. 
While the advent of serum PSA screening for prostate cancer has dramatically increased cancer 
detection, the limitations of serum PSA screening as mentioned earlier have fueled the search for 
new prostate cancer biomarkers. A number of potential biomarkers have emerged. Notably, urine 
prostate cancer antigen 3 (PCA3), a noncoding prostate-specific transcript overexpressed in 
greater than 95% of prostate cancers (Bussemakers et al. 1999) has proven to be useful as an 
adjunct to serum PSA for prostate cancer detection (Deras et al. 2008; Groskopf et al. 2006). 
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Furthermore, about 50% of prostate cancers harbor the TMPRSS2:ERG fusion gene as a result of 
chromosomal rearrangement (Tomlins et al. 2009). Urine TMPRSS2:ERG transcript was shown 
to be associated with the presence of clinically significant cancer and the combined measurement 
of TMPRSS2:ERG and PCA3 in urine outperformed serum PSA for prostate cancer diagnosis 
(Tomlins et al. 2011).  
In 2009, a study (Sreekumar et al. 2009) revealing sarcosine as a promising prostate cancer 
biomarker aroused considerable enthusiasm in the biomarker field. The study showed that 
sarcosine, also known as N-methylglycine, was significantly increased in prostate cancer 
specimens compared to benign adjacent prostate samples, and was even higher in metastatic 
tissues. Additionally, sarcosine levels were significantly higher in urine samples from biopsy-
positive than biopsy-negative individuals, performing better than PSA when restricted to samples 
having PSA in the clinical grey zone of 2-10 ng/ml. In prostate cell lines, there was a correlation 
between sarcosine levels and cell invasiveness, and the mere addition of exogenous sarcosine 
imparted an invasive phenotype to benign prostate epithelial cells. One can also alter cell 
invasiveness by modulating enzymes regulating sarcosine metabolism (Figure 2), as knockdown 
of glycine N-methyltransferase (GNMT) or dimethylglycine dehydrogenase (DMGDH), 
enzymes responsible for sarcosine formation, resulted in a significant reduction in cell invasion, 
while knockdown of sarcosine dehydrogense (SARDH), which converts sarcosine back to 
glycine, increased cell invasion. Since the publication of these findings, the potential use of 
sarcosine as a prostate cancer biomarker has been tested by many different groups, either 
challenging (Jentzmik et al. 2010, 2011; Colleselli et al. 2010; Struys et al. 2010; Wu et al. 2011; 
Bohm et al. 2012) or supporting (Bianchi et al. 2011; Lucarelli et al. 2012, 2013; Koutros et al. 
2013) these findings (reviewed in Issaq and Veenstra 2011; Cernei et al. 2013). The conflicting 
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Figure 2. Schematic of the sarcosine pathway and its potential link to prostate cancer 
(adapted from Sreekumar et al. 2009). 
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data in these studies are likely due to a cumulative effect of differences in assay methods, sample 
selection, handling, storage and analysis. Currently the role of sarcosine as a biomarker for 
prostate cancer remains unclear. 
Lastly, although a high Gleason score is indicative of rapid progression and poor prognosis in 
prostate cancer and requires immediate treatment, the appropriate treatment for patients with a 
low Gleason score remains ambiguous. Most of these patients may only require conservative 
management, since their tumors are relatively indolent, while a small fraction of them progress 
rapidly to an aggressive disease. Thus, there is a critical need to distinguish most of the low 
Gleason score tumors that will remain indolent from the few that are truly aggressive. This is 
part of the challenge in the previous point – lack of reliable biomarker with prognostic 
information. Much research has been focused on identifying molecular signatures that 
distinguish indolent versus aggressive forms of prostate cancer. For example, Markert et al. 
(2011) stratified patients with low Gleason score on the basis of their mRNA microarray 
signature profiles. Their classification demonstrates that a subset of tumors with stem-like 
signatures together with TP53 and PTEN inactivation is associated very poor survival outcome, 
while a second group characterized by the TMPRSS2:ERG fusion has intermediate survival 
outcome. In a recent study using gene set enrichment analysis and decision tree algorism, Irshad 
et al. (2013) identified a three-gene biomarker panel -- FGFR1, PMP22, and CDKN1A -- that is 
predicative of indolent prostate cancer of low Gleason score.  
Unlike other epithelial tumors such as breast cancer, prostate cancer lacks distinguishable 
histopathological subtypes that differ in their prognosis and treatment response. Molecular 
classification of prostate cancer subtypes could help identify genetic changes that drive tumor 
progression and potentially benefit prognosis and treatment. In addition to point mutations like 
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most cancers are associated with, the prostate cancer genome is extraordinarily complex, with 
large-scale genomic rearrangements and extensive copy number alterations (Barbieri et al. 
2012a; Berger et al. 2011). With the help of next generation sequencing, prostate cancer genomic 
profiling has already identified several molecular subtypes. For example, as mentioned earlier, 
about 50% of prostate cancers have TMPRSS2:ERG rearrangement. Tumors without 
TMPRSS2:ERG rearrangement can be further categorized on the basis of SPINK1 
overexpression (Tomlins et al. 2008), SPOP mutations (Barbieri et al. 2012b), and CHD1 
deletions (Liu et al. 2012), which are often mutually exclusive. Although prognostic implications 
of these genetic alterations remain to be determined, it is hopeful that prostate cancer might soon 
transition from a poorly understood, clinically heterogeneous disease to a collection of 
homogeneous subtypes identifiable by distinct molecular signatures and vulnerable to targeted 
therapies. 
Overall, it is clear that prostate cancer is not driven by one or two gene mutations. It is, rather, 
due to an accumulation of mutations in tumor-related genes driving transformation of normal 
prostate epithelium to prostatic intraepithelial neoplasia (PIN), adenocarcinoma, and eventually 
to metastasis. Developing better biomarkers and therapeutic interventions relies on the 
understanding of the basic biology of the prostate and the molecular mechanisms underlying 
prostate cancer initiation and progression. The goal of the present study is to investigate the 
molecular basis of a protein highly expressed in prostate cancer -- TMEFF2. In the next section 
we will present the background information about this protein. 
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TMEFF2  
    TMEFF2 (Transmembrane protein with epidermal growth factor and two follistatin motifs 2) 
was first characterized by Uchida et al. in 1999 in search of novel epidermal growth factor 
(EGF)-like proteins. It is a type I transmembrane protein with several biologically important 
features (Figure 3): An EGF-like and two follistatin domains are located within the extracellular 
portion of the protein, the ectodomain, which can be cleaved from the membrane in an 
ADAM17/γ-secretase-dependent fashion induced by proinflammatory cytokines (Ali and 
Knaüper 2007; Lin et al. 2003). Also located within the ectodomain are several potential 
glycosylation sites (Glynne-Jones et al. 2001; Uchida et al. 1999; Horie et al. 2000). The short 
cytoplasmic tail of TMEFF2 contains a potential G protein-activating domain (Uchida et al. 1999) 
and the TMEFF2 transmembrane domain has rhodopsin-like G protein-coupled receptor (GPCR) 
superfamily signature. 
    TMEFF2 is selectively expressed in the embryo and limited adult tissues, mainly the brain and 
the prostate, and overexpressed in prostate cancer (Liang et al. 2000; Glynne-Jones et al. 2001; 
Gery et al. 2002; Afar et al. 2004; Zhao et al. 2005). Because of its restricted expression profile 
and increased expression in prostate cancer, TMEFF2 has been implicated to play a role in this 
disease and has received considerable attention as a promising immunotherapeutic target for 
prostate cancer (Zhao et al. 2005; Afar et al. 2004; Zhao et al. 2008a; Boswell et al. 2012, 2013). 
However, the exact biological function of TMEFF2 in this disease remains elusive and rather 
controversial.  
Elevated expression associated with higher prostate cancer grade (Zhao et al. 2005; Glynne-
Jones et al. 2001; Afar et al. 2004) suggests that TMEFF2 promotes tumorigenesis. Supporting 
this, soluble TMEFF2 ectodomain was shown to increase survival of primary cultured neurons 
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Figure 3. Schematic representation of three TMEFF2 isoforms. Isoform 1 is the full-length 
TMEFF2 and has been chosen as the canonical sequence. Isoform 2 differs from isoform 1 in 
that it is missing the last 27 amino acids that encompass the putative G protein-activating 
motif, and that it has a KCP to AKL substitution in the three amino acids prior to the deletion. 
Isoform 3 contains only one follistatin domain and a 29-amino-acid C-terminal specific 
sequence. FST, follistatin domain; EGF, EGF-like domain; TM, transmembrane domain; GA, 
G protein-activating domain; N, N-linked glycosylation sites; O, O-linked glycosylation sites. 
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from the hippocampus and mesencephalon (Horie et al. 2000) and HEK293 human embryonic 
kidney cell proliferation, while knockdown of endogenous TMEFF2 by siRNA in LNCaP 
prostate cancer cells or TMEFF2-expressing HEK293 cells inhibited proliferation (Ali and 
Knaüper 2007).  
In contrast, others have demonstrated a tumor suppressive function of TMEFF2. 
Overexpression of TMEFF2 in HCT116 colon cancer cells blocked tumor growth in vivo in nude 
mice and exerted anti-proliferative effects in vitro in cell culture (Elahi et al. 2008). In two 
prostate cancer cell lines DU145 and PC3, overexpression of TMEFF2 inhibited cell growth 
(Gery et al. 2002). Moreover, the promoter region of the TMEFF2 gene is frequently 
hypermethylated in many cancers (Liang et al. 2000; Lin et al. 2011; Lee et al. 2012; Nagata et 
al. 2012; Selamat et al. 2011; Park et al. 2011; Tsunoda et al. 2009; Zhao et al. 2008b; Brücher et 
al. 2006; Suzuki et al. 2005; Ebert et al. 2005; Hanabata et al. 2004; Sato et al. 2002), suggesting 
a potential role of TMEFF2 as a tumor suppressor. 
The complex roles of TMEFF2 in cancer may be attributed to the complexity of the TMEFF2 
molecule. TMEFF2 could signal as a ligand precursor, a membrane bound receptor and/or a 
binding protein for growth factors (Glynne-Jones et al. 2001). Several isoforms of TMEFF2 have 
been described that differ in their C-termini (Figure 3; Quayle and Sadar 2006; Uchida et al. 
1999; Horie et al. 2000) and probably their ability to signal and/or being modified. It is possible 
that functionally distinct isoforms are differentially expressed throughout prostate cancer 
establishment and progression. In addition, bioavailability of either the whole molecule or the 
cleavage products, as well as their ligands/receptors, may explain the opposing results in the 
context of different cell types.  
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Besides prostate cancer, studies have been focused on the role of TMEFF2 in pathologic 
conditions affecting the brain, based on the fact that TMEFF2 is expressed in human adult brain 
(Horie et al. 2000; Glynne-Jones et al. 2001; Uchida et al. 1999; Gery et al. 2002; Liang et al. 
2000; Zhao et al. 2005; Afar et al. 2004). As mentioned earlier, soluble TMEFF2 ectodomain 
promoted the survival of hippocampal and mesencephalic neurons and stimulated dendrite 
growth of the latter (Horie et al. 2000), making TMEFF2 an attractive candidate in treating 
neurodegenerative disorders such as Parkinson’s disease. TMEFF2 has also been hypothesized to 
contribute to the pathogenesis of Alzheimer’s disease, as it was found present in plaques in 
Alzheimer’s disease brain (Siegel et al. 2006). Lastly, Lin et al. (2011) showed TMEFF2 was 
downregulated in human brain cancers and was negatively correlated with TMEFF2 gene 
methylation and PDGF-AA expression.  
    Two independent groups have generated TMEFF2 knockout mice and both reported that 
TMEFF2 homozygous knockout mice were born normal, but showed retarded growth and died 
around weaning age (Kanemoto et al. 2001; Chen et al. 2012). The histology of the prostate 
gland appeared normal in TMEFF2 homozygous knockout mice and they also had structurally 
normal central, peripheral and enteric nervous systems and normal neuronal differentiation. The 
cause of growth retardation and lethality of the knockout mice is unknown, but it is speculated 
that the functions of certain neurons were compromised due to TMEFF2 deficiency, which 
impaired the ability to feed. The aged heterozygous knockout mice did not develop any cancer 
(Chen et al. 2012).  
    Little is known about the molecular mechanism underlying TMEFF2’s function in 
tumorigenesis. Due to the presence of an EGF-like motif in its ectodomain, TMEFF2 was 
examined for its ability to activate EGF receptor family members. In HEK293 human embryonic 
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kidney and MKN 28 gastric cancer cells, soluble TMEFF2 ectodomain stimulated ERK1/2 
phosphorylation in an erbB-1-dependent manner (Ali and Knaüper 2007) and erbB-4 
phosphorylation (Uchida et al. 1999), respectively, consistent with a growth-promoting role of 
the ectodomain. However, it is worth noting that there is a replacement in the EGF-like domain 
of TMEFF2 (arginine  histidine; Uchida et al. 1999; Horie et al. 2000) that can drastically 
reduce the affinity of EGF for its receptor (Engler et al. 1990; Hommel et al. 1991). 
    As mentioned earlier, TMEFF2 overexpression exerted anti-proliferative effects in HCT116 
colon cancer cells, inducing apoptosis and suppressing anchorage-independent growth (Elahi et 
al. 2008). Gene expression changes associated with TMEFF2 overexpression examined by 
microarray analysis showed that STAT1 as well as a large number of associated interferon-
inducible genes were upregulated. Furthermore, STAT1 knockdown restored proliferation and 
colony formation potential in soft agar of TMEFF2-overexpressing HCT116 cells, suggesting 
TMEFF2-mediated tumor suppression requires activation of STAT1 pathways. 
    More recently, Lin et al. (2011) reported that TMEFF2 interacts with PDGF-AA and the 
interaction requires N-terminal follistatin domain and cannot be mediated by the EGF-like 
domain alone. Although PDGF-AA downstream signaling pathways were not directly examined, 
soluble TMEFF2 ectodomain interfered with PDGF-AA-stimulated fibroblast proliferation, 
suggesting TMEFF2 modulates PDGF-AA signaling. 
    As the only other member in the TMEFF family, TMEFF1 shares 35.8% identity with 
TMEFF2 at the amino acid level (Horie et al. 2000). Similar to TMEFF2, TMEFF1 is a type I 
transmembrane protein that consists of one EGF-like and two follistatin domains in the 
extracellular region and a potential G protein-activating domain in the short cytoplasmic tail. 
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TMEFF1 is expressed in the embryo and adult tissues predominantly the brain (Eib et al. 2000; 
Gery et al. 2003). Although both TMEFF genes are widely expressed in the brain, they exhibit 
different patterns of expression, suggesting that they play region-specific roles in the central 
nervous system (Kanemoto et al. 2001).  
    Functionally, TMEFF1 was suggested to promote growth in hematopoietic cells since an 
antibody against it induced apoptosis in a cAMP/PKA-dependent manner (Penning et al. 2006). 
However, overexpressiong of TMEFF1 in brain cancer cells resulted in their growth inhibition 
and 96% of brain tumors had lower levels of TMEFF1 expression than normal brain tissue (Gery 
et al. 2003). It is possible that TMEFF1 may function as a tumor suppressor in the brain but not 
in other tissues.  
In addition, TMEFF1 has an important role in development involving TGF-β signaling. In 
early Xenopus embryos, TMEFF1 regulates TGF-β family members nodal and BMP signaling. 
TMEFF1 inhibits nodal signaling through binding to the nodal co-receptor Cripto (Harms and 
Chang 2003) and the inhibition requires the follistatin, EGF-like and transmembrane domains, 
but not the cytoplasmic region of TMEFF1 (Chang et al. 2003), suggesting TMEFF1 that blocks 
nodal signaling at the ligand/receptor level. TMEFF1 can also block BMP signaling and the 
activity is dependent only on the presence of its cytoplasmic tail (Chang et al. 2003), suggesting 
TMEFF1 may activate an intracellular pathway to inhibit BMP function. During hair follicle 
regeneration, TMEFF1 was found to be a direct TGF-β/SMAD2/3 target gene that mediates the 
antagonistic crosstalk between TGF-β and BMP signaling (Oshimori and Fuchs 2012). 
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The role of TMEFF2 in cell migration involves integrins 
As described in later chapters of the present study, the role of TMEFF2 in tumor biology is 
phenotypically manifested in vitro by cell proliferation, apoptosis, colony formation, and 
migration/invasion assays. Sustained growth signaling, evasion of apoptosis, and tissue invasion 
and metastasis are some of the hallmarks of cancer (Hanahan and Weinberg 2011). In Chapter 4, 
we specifically focus on the role of TMEFF2 in cell migration. Cell migration plays a central 
role in many biological and pathological processes, such as embryonic morphogenesis, wound 
healing, immune surveillance, and cancer metastasis (Lauffenburger and Horwitz 1996). In 
general, migration can be viewed as a multistep cycle, which includes extension of protrusions in 
the direction of migration, formation of new adhesions at the leading edge, contraction and 
translocation of the cell body forward, and disassembly of adhesions at the cell rear, allowing it 
to detach (Ridley et al. 2003). Thus, cell migration requires new adhesions form at the leading 
edge and old ones break at the trailing edge. Adhesion is mediated primarily by a family of cell-
surface molecules known as integrins. In some cases, cell migration requires very little integrin-
mediated adhesion on the substratum and can even be integrin-independent, as seen in highly 
motile cells including neutrophils, dendritic cells, and lymphocytes (Friedl et al. 1998; 
Lämmermann et al. 2008; Malawista et al. 1997; Woolf et al. 2007).  
Integrins  
    Integrins are transmembrane heterodimers composed of noncovalantly associated α and β 
subunits. So far, 18 α subunits and 8 β subunits have been identified, forming 24 complexes with 
distinct ligand binding specificities and tissue distribution. In addition, alternatively spliced 
forms of the α (α3, α6, α7) and β (β1, β3, β4, β5) integrin cytoplasmic domains are expressed in 
a cell- or tissue-type specific manner (Fornaro and Languino 1997).  
17 
 
    Two major cellular functions of integrins are cell adhesion and signal transduction. Integrins 
are the main receptors that mediate cell linkage to the extracellular matrix (ECM). A single 
integrin heterodimer can bind a variety of ECM proteins, and many ECM proteins have multiple 
integrin receptors. On the cytoplasmic side, integrins can be linked to actin cytoskeleton via a 
multi-protein complex that contains over 150 different signaling and adaptor proteins (Zaidel-
Bar et al. 2007). Often collectively called focal adhesions, these protein complex structures can 
be subcategorized into focal complexes, focal adhesions, and fibrillar adhesions (Geiger et al. 
2001; Zaidel-Bar et al. 2004; Geiger and Yamada 2011) that are different in size, localization, 
and morphology. Serving as traction sites by linking extracellular substratum to actin 
cytoskeleton, integrin-based adhesion plays a crucial role in regulating cell migration. 
Although lacking intrinsic catalytic activity, upon adhesion, integrins recruit and activate 
kinases such as focal adhesion kinase (FAK) and SRC family kinases (SFKs) to relay signals. 
Ligand binding to integrins induces autophosphorylation of FAK at tyrosine 397, creating a 
binding site for the SRC-homology 2 (SH2) domain of SRC. Binding of SRC to FAK stabilizes 
the active conformation of SRC, leading to increased kinase activity which further 
phosphorylates additional tyrosine residues on FAK, resulting in full activation of both kinases 
and additional protein binding sites for assembly of focal adhesions (Huveneers and Danen 2009; 
Legate et al. 2009). Formation of focal adhesion complexes mediates a network of signaling 
pathways, which affect many cellular processes including proliferation, migration, survival, and 
differentiation (Figure 4). These signaling pathways can be extremely complicated and roughly 
divided into the p130CAS-CRK, RAS-RAF-MEK-ERK, and PI3K-AKT signaling pathways 
(Guo and Giancotti 2004). Notably, the p130CAS-CRK pathway activates DOCK180, an 
unconventional GEF for RAC (Brugnera et al. 2002; Côté and Vuori 2002; Kiyokawa et al. 
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Figure 4. Integrin signaling – autonomous integrin signaling and joint integrin-RTK signaling 
(Guo and Giancotti 2004).  
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1998). Transient activation of RAC upon integrin ligation stimulates membrane protrusions and 
induces phosphorylation of p190RHOGAP and suppression of RHOA activity, via a reactive 
oxygen species (ROS)-dependent mechanism (Nimnual et al. 2003), relieving cytoskeletal 
tension during early cell spreading.  
Extensive crosstalk exists between receptor tyrosine kinases (RTKs) and integrins (Huveneers 
and Danen 2009; Soung et al. 2010; Eliceiri 2001; Chan et al. 2006; Ross 2004; Schwartz and 
Ginsberg 2002). For example, integrin-mediated adhesion strengthens and lengthens ERK 
activation from growth factor stimulation; in the absence of adhesion cues, growth factor-
mediated ERK activation is weak and transient (Roovers et al. 1999; Miyamoto et al. 1996). 
Integrin-mediated adhesion can also activate epidermal growth factor receptor (EGFR) 
independently of EGF binding (Moro et al. 1998), although adhesion-dependent phosphorylation 
sites on EGFR are different from EGF binding-induced phosphorylation sites (Boeri Erba et al. 
2005).  
By participating in cellular adhesion and signal transduction, integrins play a critical role in 
many physiological processes involved in tumor growth and metastasis. It is, therefore, not 
surprising that cancer cells often have an abnormal integrin repertoire. Changes in integrin 
expression during tumor progression have been documented in numerous studies and are thought 
to contribute to tumor growth and metastasis. For example, expression of integrin αvβ3 is 
associated with disease progression and metastatic potential of many carcinomas including breast 
(Sloan et al. 2006; Felding-Habermann et al. 2001; Zhao et al. 2007), cervix (Chattopadhyay and 
Chatterjee 2001), colon (Vonlaufen et al. 2001), prostate (Zheng et al. 1999; McCabe et al. 
2007), pancreas (Hosotani et al. 2002), and ovary (Landen et al. 2008). Interestingly, integrin 
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αvβ3 is usually only expressed in macrophages, platelets, endothelial cells, and osteoclasts but 
not in epithelial cells.  
Integrins affect tumor invasion and metastasis by regulating cell migration. Additionally, 
integrins activate matrix metalloproteinases (MMPs) that are required for ECM degradation and 
enable tumor cells to adhere to and traverse the blood vessel of the target organ Moreover, 
integrin binding to ECM ligands initiates anti-apoptotic pathways to ensure survival of invasive 
cells to distal tissues (Hood and Cheresh 2002; Guo and Giancotti 2004). However, not all 
integrins are pro-neoplastic and pro-metastatic. For example, expression of integrin α5β1 
suppresses the tumorigenic properties of several cell lines (Giancotti and Ruoslahti 1990; Varner 
et al. 1995). Similarly, loss of integrin α2β1 promotes breast cancer cell metastasis in vivo 
(Ramirez et al. 2011), and re-expression of α2β1 in breast cancer cells abrogates the malignant 
phenotype of the cells (Zutter et al. 1995), suggesting that integrin α2β1 is a metastasis 
suppressor. In contrast, integrin α2β1 promotes prostate cancer cell metastasis to the bone (Hall 
et al. 2006; Sottnik et al. 2013). These data suggest that the role of integrin in cancer is cell type- 
and context-dependent. 
 
Overview and objectives 
TMEFF2 is a type I transmembrane protein that harbors a potential G protein-activating 
domain in the cytoplasmic tail and contains an EGF-like and two follistatin motifs in the 
ectodomain, which is subject to ADAM17/γ-secretase-mediated cleavage. TMEFF2 is 
predominantly expressed in normal brain and prostate, and is overexpressed in prostate cancer, 
suggestive of its involvement in this disease.  However, the biological function of TMEFF2 is 
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uncertain, with conflicting reports supporting both tumor-suppressing and growth-promoting 
activities. In the following chapters, we will examine the molecular mechanisms of TMEFF2 
action, with the ultimate goal of elucidating the role of TMEFF2 in prostate cancer and exploring 
its potential as a therapeutic target. 
 
 
CHAPTER TWO: Experimental Procedures 
Plasmid construction 
    C-terminal MYC-HIS fusions to SARDH, TMEFF2, TMEFF2-ECTO, and TMEFF2-∆GA, 
were made by inserting the relevant sequences into the eukaryotic expression plasmid 
pSecTag2A (Invitrogen). The untagged SARDH expressed under the CMV promoter was 
constructed using the pCMV-GLuc expression plasmid (NEB) and substituting the GLuc 
sequence for the SARDH sequence. The untagged TMEFF2 ectodomain (TMEFF2-ECTO) and 
TMEFF2 used for immunofluorescence analysis were constructed by cloning the respective 
sequences in the pcDNA5-FRT cloning vector (Invitrogen) under the control of the CMV 
promoter. Fluorescent protein fusion constructs to the C-terminus of TMEFF2 and SARDH were 
made in pECFP-N1 and pEYFP-N1 (BD Biosciences) respectively. To inducibly express 
TMEFF2 and TMEFF2-∆GA in RWPE1 and RWPE2 cells, TMEFF2 sequences were cloned 
into the pRetroX-Tight-Pur vector (Clontech). All these constructs were made using PCR and 
standard cloning strategies (see Table 1) and sequences verified.  
Table 1. Primers used for plasmid construction. 
Construct name Primer sequence (5’3’) 
pCMV-SARDH a) TAAGATCTCCACTGGGCAAGCCACAC 
b) TATCTAGACCTGTGAGAATGGATGG 
SARDH-MYC-HIS a)TAGCTAGCCCCCATGGCCTCACTGAG 
b)TAGCGGCCGCGTAGATTCCCTTCACCC 
TMEFF2-MYC-HIS a) TAGCTAGCAGTCATGGTGCTGTGGG  
b) TACTCGAGAGATTAACCTCGTGGACG  
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ECTO-MYC-HIS a) TAGCTAGCAGTCATGGTGCTGTGGG  
b) TACTCGAGCATACTGAAATCGTACAGG  
∆GA-MYC-HIS a) TAGCTAGCAGTCATGGTGCTGTGGG 
b) TACCATGGTGTGATGCAGAGGACC 
c) TACCATGGCAAAATACAGGGCACTAC 
d) TACTCGAGAGATTAACCTCGTGGACG 
TMEFF2-CFP a) TAGCTAGCAGTCATGGTGCTGTGGG  
b) TACTCGAGGATTAACCTCGTGGACG  
SARDH-YFP a) TAGCTAGCCCCCATGGCCTCACTGAG  
b) TAAAGCTTGTAGATTCCCTTCACCC  
pRetroX-TMEFF2 a) TAGGATCCCTCCACCCTGCCTCCTCG  
b) TAACGCGTGTCTATAATACTGTATTGTGTAGTC  
pRetroX-∆GA a) TAGGATCCCTCCACCCTGCCTCCTCG  
b) TAACGCGTGTCTATAATACTGTATTGTGTAGTC 
 
Cell culture, transfection, and transduction 
The HEK293T, LNCaP, 22Rv1, RWPE1 and RWPE2 cell lines were purchased from 
American Type Culture Collection (ATCC). HEK293T cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM; Gibco) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Gemini Bio Products), 2mM L-glutamine (Gemini Bio Products), 100 U/ml 
penicillin (Gemini Bio Products), 100 μg/ml streptomycin (Gemini Bio Products), and 1.25 
μg/ml amphotericin B (Gemini Bio Products) at 37°C in 5% CO2. LNCaP and 22Rv1 cells were 
maintained in RPMI-1640 medium (Gibco) supplemented with the same ingredients. RWPE1 
and RWPE2 cells were cultured in keratinocyte serum-free medium (K-SFM; Gibco) 
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supplemented with EGF and bovine pituitary extract provided in the medium kit and 50 U/ml 
penicillin, 50 μg/ml streptomycin, and 2.5 μg/ml amphotericin B. Transfection of HEK293T 
cells was achieved using Lipofectamine 2000 transfection reagent (Invitrogen) according to 
manufacturer’s instructions. Stable cell lines were generated by drug resistance followed by 
clonal selection. The selected clones were further characterized for expression of the specific 
protein by western blot. Several clones were used to rule out insertion effects. Development of a 
system for inducible expression of the TMEFF2 gene in RWPE1 and RWPE2 cells was achieved 
using the Clontech’s Tet-On advanced system that requires two consecutive transductions. The 
first is to introduce the Tet-On plasmid, which contains the regulatory gene encoding the 
transcription activator under the control of a CMV promoter. The second is to introduce the 
TMEFF2 gene under the control of the TRE-element and a minimal CMV promoter and that was 
constructed using standard PCR and cloning strategies. The TRE-element is activated when it 
binds to the transactivator in a doxycycline dependent manner. To inducibly express TMEFF2 
and TMEFF2-∆GA, cultures were grown in the presence of doxycycline (250 ng/ml; Sigma). 
22Rv1 cells transduced with pLKO.1 vectors containing shRNA to TMEFF2 or scramble control 
were described elsewhere (Green et al. 2013). Briefly, pLKO.1 vectors containing shRNA to 
TMEFF2 and scramble control were obtained from Open Biosystems and viral stocks were 
prepared using HEK293T and plasmids psPAX2 and VSV-G (Addgene) for viral packaging. 
22Rv1 cells were transduced with each shRNA viral stock and 6 mg/ml polybrene (Millipore). 
After 48 hr, the transduced 22Rv1 cells were stably selected with 5 mg/ml puromycin 
(Millipore). 
In Chapter 5, for experiments in which conditioned medium was added, RWPE1 cells were 
growing in basal K-SFM without supplements for 30 min before growth medium was replaced 
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with the specified conditioned medium. Cells were then incubated for 30 min, unless otherwise 
specified, before lysis. Conditioned medium was obtained from HEK293T cells stably 
transfected with TMEFF2-MYC-HIS, ECTO-MYC-HIS, or the empty vector. Cells were grown 
at 70%-80% confluency, starved overnight and the conditioned medium collected and utilized to 
replace the growth medium. For PDGF-AA treatment, RWPE1 cells were grown in basal K-SFM 
without supplements for 30 min before treated with the indicated amount of PGDF-AA for 10 
min, unless otherwise specified. For EGF treatment, RWPE1 cells were grown in basal K-SFM 
without supplements for 3 h before treatment with 10 ng/ml EGF for 10 min. 
 
Affinity chromatography and mass spectrometry analysis  
    The FreeStyle 293-F cell line was purchased from Invitrogen and maintained in FreeStyle 293 
expression medium at 37°C in 8% CO2. TMEFF2-MYC-HIS was transfected into FreeStyle 293-
F cells using FreeStyle Max reagent (Invitrogen) according to manufacturer’s instructions and 
captured on Nickel Sepharose 6 Fast Flow beads (GE Healthcare) using 20 mM imidazole-
containing buffer. Beads were washed in 20 mM imidazole-containing buffer and TMEFF2-
MYC-HIS complexes eluted with 500-800 mM imidazole-containing buffer. Eluted proteins 
were resolved by SDS-PAGE on 4-12% NuPAGE Novex Bis-Tris gel (Invitrogen) and stained 
with Imperial protein stain (Pierce). Bands of interest were excised and digested with trypsin 
(Sigma) and subjected to MALDI-Mass Spectrometry proteomic analysis using a Voyager DE 
Pro-MALDI-TOF Mass Spectrometer. Protein database searching was performed with Mascot 
Peptide mass Fingerprint (Matrix Science) against the human SwissProt protein database. 
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Co-immunoprecipitation 
    Dynabeads Antibody Coupling Kit (Invitrogen) was used according to manufacturer’s 
instructions for the immobilization of antibody on magnet beads. The antibodies used for the 
immunoprecipitation (IP) were anti-TMEFF2 (Abcam ab77038), anti-MYC (Invitrogen R950-
25), anti-EIF4E (Santa Cruz) and anti-4EBP1 (Santa Cruz). HEK293T cells were transfected 
with the indicated constructs and lysed in Cell Lysis Buffer (Cell Signaling). The lysate (50 μg) 
was incubated with antibody-coupled Dynabeads for 30 min at 4 °C. Beads were washed with 
PBS, and the immunoprecipitated proteins, remaining on the beads, were eluted by heating at 70 
°C for 10 min in NuPAGE LDS sample buffer (Invitrogen), resolved by SDS-PAGE, and 
analyzed by western blot using appropriate primary horseradish peroxidase (HRP)-conjugated 
antibody prepared with Lightning-Link HRP Conjugation Kit (Novus). The antibodies used to 
conjugate to the HRP were anti-TMEFF2 (Abcam ab50002) and anti-SARDH (Sigma 
AV42344). For co-immunoprecipitation analysis using LNCaP or 22Rv1 lysates, 100-250 μg of 
total protein was used and elution of the target protein was in SDS sample buffer. To increase the 
sensitivity, subsequent western blot analysis was performed using the appropriate primary 
antibody and a light-chain specific secondary antibody (Jackson ImmunoResearch). 
 
Western blotting 
For western blot analysis, cells or mouse prostate lobes were lysed in 
radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM 
sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor 
cocktail (Sigma P8340), sodium orthovanadate and beta-glycerophosphate. Equal amounts of 
proteins were resolved by SDS-PAGE and transferred to Immobilon transfer membrane 
27 
 
(Millipore). Blots were blocked in 5% non-fat milk or bovine serum albumin (BSA; Sigma) and 
probed with the appropriate antibodies. Immunoreactive bands were visualized using ECL plus 
western blotting detection system (GE Healthcare), SuperSignal West Pico or Femto 
chemiluminescent substrate (Thermo Scientific). The following antibodies were used: antibodies 
to TMEFF2 (for cell lines; Abcam ab50002 and Sigma HPA015587), TMEFF2 (for mouse 
tissues; SDIX, custom antibody), SV40 T-antigen (1:100, Abcam ab16879), ITGAV (1:1000, 
BD Biosciences 611012), ITGB3 (for human cell lines, 1:1000, BD Biosciences 611140), ITGB3 
(for mouse tissue, 1:500, Sigma Ab-773), ITGA5 (1:500, Millipore AB1949), ITGB1 (1:1000, 
BD Biosciences 610467), RPS6 (1:1000, Cell Signaling 2217), ACTB (1:1000, Cell Signaling 
4970), phospho-FAK (Tyr394, 1:1000, Cell Signaling 3283), FAK (1:1000, Cell Signaling 
3285), phospho-AKT (Ser473, 1:1000, Cell Signaling 4060), AKT (1:1000, Cell Signaling 
9272), phospho-ERK1/2 (Thr202/Tyr204, 1:2000, Cell Signaling 4370), ERK1/2 (1:1000, Cell 
Signaling 4695), phospho-SMAD2 (Ser465/467, 1:1000, Cell Signaling 3101). Secondary 
antibodies: goat anti-mouse IgG-HRP (Santa Cruz sc-2005), goat anti-rabbit IgG-HRP (Santa 
Cruz sc-2004). 
 
Immunofluorescence and cell spreading assay  
    In Chapter 3, HEK293T cells were seeded on poly-L-lysine and laminin (Sigma)-coated cover 
glass, transfected with TMEFF2 and SARDH-MYC-HIS expression constructs and incubated for 
24-48 h. Cells were fixed with cold 4% paraformaldehyde in PBS (USB Products), 
permeabilized with 0.1% Triton X-100 (Bio-Rad) in PBS (PBS-T) and blocked with 5% normal 
goat serum (Invitrogen) in 0.1% PBS-T. Samples were incubated with the indicated primary 
antibodies overnight at 4°C and then with the corresponding goat anti-mouse FITC (Santa Cruz) 
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or goat anti-rabbit Alexa 568 (Invitrogen) secondary antibody at room temperature and mounted 
with medium containing DAPI (Santa Cruz). Images were obtained with a Zeiss LSM 510 
confocal microscope. For live cell imaging, HEK293T cells were seeded in collagen coated glass 
bottom culture dishes (MatTek), transfected with SARDH-YFP and TMEFF2-CFP and 
incubated for 24-48 h. 
In Chapter 4, cover glass (Fisher Scientific) were coated with collagen (40 μg/ml; BD 
Biosciences), laminin (10 μg/ml; Sigma), fibronectin (40 μg/ml; Millipore), or vitronectin (2 
μg/ml; Promega) in a 12-well plate at 4 °C overnight and rinsed twice with PBS before 40,000 
cells/well were seeded. Following a 3 h incubation, pictures were taken for 10 random fields in 
each well using an EVOS FL cell imaging system (AMG) and spread/round cells were counted. 
After counting, cells were then fixed with 4% paraformaldehyde in PBS (USB Products) for 10 
min, permeabilized with 0.5% Triton X-100 (Bio-Rad) in PBS (PBS-T) for 5 min, and blocked 
with 5% normal goat serum (Invitrogen) in PBS-T for 30 min. Samples were incubated with anti-
vinculin antibody (1:300; Sigma V9131) at 4 °C overnight followed by goat anti-mouse Alexa 
Fluor 488 (1:500; Invitrogen) and rhodamine phalloidin (Cytoskeleton) for 1 h. Nuclei were 
counterstained with DAPI (Santa Cruz). For immunofluorescence analysis with only rhodamine 
phalloidin staining, cells were seeded in 8 well glass slides (Lab-Tek) and the primary antibody 
and the corresponding secondary antibody were omitted. Immunofluorescent images were taken 
on an Optiphot-2 fluorescent microscope (Nikon) with an AxioCam MRm digital camera (Zeiss). 
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Cell migration assay 
Cell migration assays were performed in the presence of 1 μg/ml aphidicolin (Sigma) to 
prevent proliferation. For wound healing assays, 70 μl of cells were applied to each well of the 
culture inserts (ibidi) at 3-7x10
5
 cells/ml. The culture inserts were removed the next day to allow 
cell migration. Wound healing process was monitored by taking pictures at 0 h, 10 h, 24 h, or 48 
h using an EVOS FL cell imaging system (AMG). When specified, 2 μg/ml of CT04 
(Cytoskeleton) was added to the fresh medium after insert removal. Cell migration was also 
assayed using Boyden chambers (BD Biosciences). 50,000 cells were added to the upper 
chamber and the lower chamber was filled with 500 μl of medium containing 20% FBS. The 
culture was maintained overnight. For the assay of cell migration towards vitronectin or 
fibronectin, Boyden chambers were coated with 10 μg/ml indicated ECM proteins in PBS at 4 °C 
overnight. 0.5-1x10
5
 cells were added to the upper chamber with basal K-SFM and the lower 
chamber was filled with the same medium. The culture was maintained for 2 days. Cells were 
then fixed with 70% ethanol for 10 min, stained with 0.1% crystal violet for 1 h. Migrated cells 
were then fixed with 70% ethanol for 10 min, stained with 0.1% crystal violet, and 
photographed. 
 
MTT assay 
RWPE1 or RWPE2 cells were seeded at 3,000-5,000 cells/well in 96-well plates. After 48 h of 
incubation, MTT reagent (Sigma) was added at a concentration of 5 mg/ml in phenol red-free 
RPMI containing 1% FBS. Following a 3 h incubation at 37 °C, 200 μl of dimethyl sulfoxide 
(DMSO; Sigma) was added to each well, and optical density was measured at 562 nm. 
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Sarcosine assay 
    Cells were washed with PBS, lysed in sarcosine assay buffer (MBL International), and briefly 
sonicated. Insoluble material was removed by centrifugation at 4 °C. The cellular levels of 
sarcosine were measured in the supernatant using a sarcosine assay kit (MBL International), and 
the data were normalized to the level of total L-amino acid present in the same supernatant (L-
amino acid quantification kit, MBL International). 
 
RT² Profiler PCR Array 
The Human Focal Adhesion RT² Profiler PCR Array (SABiosciences) was used to determine 
cellular adhesion-related gene expression affected by TMEFF2 according to the manufacturer's 
instructions. Briefly, total RNA was extracted from RWPE2 cells expressing TMEFF2 or the 
vector with RNeasy mini kit (Qiagen) and cDNA was synthesized with RT
2
 First Strand Kit 
(Qiagen). The cDNA was combined with RT
2
 SYBR Green Mastermix (Qiagen) and dispensed 
into the RT² Profiler PCR Array. Real-time PCR was performed on an iQ5 instrument (Bio-Rad). 
 
G-LISA RHOA activation assay 
    RWPE2 cells were incubated in serum free EpiLife CF/PRF medium (Invitrogen) for 3 d and 
then stimulated with 10% FBS for 2 min. RHOA activity was determined using a colorimetric G-
LISA RHOA activation assay biochem kit (Cytoskeleton) according to the manufacturer's 
instructions.  
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Mouse strain 
Animals were maintained in accordance with the Institutional Animal Care and Use 
Committee of East Carolina University. Transgenic TMEFF2 mice (129/Sv background, 
Lineberger Cancer Center Transgenic mouse facility) and maintained in a C57BL/6 background 
(backcrossed for over 7 generations to C57BL/6). TRAMP mice (FVB background) were 
purchased from the Jackson laboratory (stock number 008215) and crossed to C57Bl/6J (stock 
number 000664). The F1 derived from this cross, was then crossed to the transgenic TMEFF2 
mouse and TRAMP/TMEFF2 and TRAMP progeny selected after genotyping by PCR of tail 
genomic DNA. 
 
Statistical analysis 
Data are presented as mean ± SD (standard deviation). Student's t test (paired, two-tailed) was 
used to compare two groups of independent samples. P values under 0.05 or 0.01 were 
considered significant. 
 
CHAPTER THREE: The Tumor Suppressor Activity of TMEFF2 Correlates with Its 
Ability to Modulate Sarcosine Levels
1
 
 Introduction 
    TMEFF2 (transmembrane protein with epidermal growth factor and two follistatin motifs 2) is 
an evolutionarily conserved type I transmembrane protein expressed in the embryo (Heanue and 
Pachnis 2006; Uchida et al. 1999) and selectively in the adult brain and prostate (Afar et al. 
2004; Gery et al. 2002; Glynne-Jones et al. 2001; Zhao et al. 2005; Liang et al. 2000). The 
extracellular (ecto-) domain can be cleaved from the membrane in an ADAM17/γ-secretase-
dependent fashion (Ali and Knaüper 2007; Lin et al. 2003) and consists of an epidermal growth 
factor-like and two follistatin domains. The cytoplasmic domain contains a potential G protein-
activating motif (Uchida et al. 1999). A critical role for TMEFF2 in tumorigenesis is suggested 
by the fact that it is upregulated in primary and metastatic prostate tumors (Afar et al. 2004; 
Glynne-Jones et al. 2001; Zhao et al. 2005). In fact, ectopic expression or addition of purified 
recombinant TMEFF2 ectodomain promotes neuronal cell survival (Horie et al. 2000), cell 
proliferation (Ali and Knaüper 2007), and phosphorylation of erbB4 and ERK1/2 (Uchida et al. 
1999; Ali and Knaüper 2007). However, it has also been suggested that TMEFF2 functions as a 
tumor suppressor because ectopic expression of full-length TMEFF2 demonstrates in vitro anti-
proliferative effects (Gery et al. 2002; Elahi et al. 2008) and suppresses tumor growth in vivo in 
nude mouse xenografts (Elahi et al. 2008). Consistent with a tumor suppressor activity, TMEFF2 
has been shown to be hypermethylated in a number of cancer types (Liang et al. 2000; Lin et al. 
                                                 
1 This chapter contains previously published work. Xiaofei Chen, Ryan Overcash, Thomas Green, Donald Hoffman, 
Adam S. Asch and Maria J. Ruiz-Echevarría. The tumor suppressor activity of the transmembrane protein with 
epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine 
levels. J Biol Chem. 2011 May 6;286(18):16091-100. doi: 10.1074/jbc.M110.193805. Epub 2011 Mar 10. 
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2011; Lee et al. 2012; Nagata et al. 2012; Selamat et al. 2011; Park et al. 2011; Tsunoda et al. 
2009; Zhao et al. 2008b; Brücher et al. 2006; Suzuki et al. 2005; Ebert et al. 2005; Hanabata et 
al. 2002; Sato et al. 2002). Results from our lab show that TMEFF2 has a dual mode of action. 
On the one hand, ectopic expression of wild-type full-length TMEFF2 inhibits monolayer and 
anchorage-independent cell growth, cellular invasion and migration, and increases cellular 
sensitivity to apoptosis. On the other hand, expression of TMEFF2 ectodomain or addition of 
conditioned medium containing the ectodomain increases cell proliferation. 
Recently, sarcosine, a glycine derivative, was identified as a potential marker of prostate 
cancer progression (Sreekumar et al. 2009). Sarcosine levels were highest in metastatic cancer, 
and in urine its levels were higher in men with prostate cancer than in controls. Importantly, 
using cell lines, Sreekumar et al. provided evidence that the enzymes involved in sarcosine 
metabolism act as regulators of cell invasion and therefore as potential therapeutic targets for 
prostate cancer. The addition of sarcosine or knockdown of sarcosine dehydrogenase (SARDH), 
the enzyme that converts sarcosine into glycine, in benign prostate epithelial cells enhanced 
invasion. Conversely, lowering the levels of glycine N-methyltransferase (GNMT), the enzyme 
that catalyzes the conversion of glycine into sarcosine, in DU145 prostate cancer cells reduced 
their invasiveness.  
In this chapter we present data to demonstrate that TMEFF2 interacts with SARDH and 
regulates the cellular levels of sarcosine. The data also indicate that there is an association 
between the ability of TMEFF2 to bind SARDH and modulate the level of sarcosine and its 
ability to act as a tumor suppressor. Further, this activity requires the transmembrane and/or 
cytoplasmic portion of the protein. Ectopic expression of TMEFF2 results in monolayer and 
anchorage-independent growth inhibition and decreased sarcosine-induced cellular motility. 
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However, the TMEFF2 ectodomain fails to bind to SARDH and to modulate the cellular levels 
of sarcosine and reverses the tumor suppressor phenotype, demonstrating no effect on 
anchorage-independent growth and an increase in monolayer growth. 
 
Results 
TMEFF2 binds specifically to SARDH 
    To gain insight into the molecular mechanisms of TMEFF2 action, we sought to search for 
candidate functional partners of TMEFF2 by screening TMEFF2 affinity complexes using mass 
spectrometry (MS). FreeStyle 293-F cells were transfected with TMEFF2-MYC-HIS, and 
TMEFF2 complexes were purified using a histidine affinity column, resolved in a 
polyacrylamide gel, and subjected to MALDI-TOF/MS analysis. Binding to and elution of the 
TMEFF2 protein from the column were verified by western blot (Figure 5). To identify specific 
TMEFF2 interactors, we compared TMEFF2 and empty vector affinity eluates and chose those 
bands that were mainly present only in the TMEFF2 affinity eluates. Furthermore, to qualify as a 
specific interactor, a protein had to be identified in at least two out of four independent TMEFF2 
affinity/MS analysis. With six peptides displaying a probability-based Mowse score of 53 
(Pappin et al. 1993), one of the candidate proteins identified was SARDH. Additional searches 
provided up to nine different peptides corresponding to SARDH (Table 2). Besides SARDH, 
TMEFF2 affinity/MS analysis revealed two other TMEFF2-interacting proteins – β-actin 
(ACTB) and α-tubulin (TUBA) that are relevant in subsequent studies not in the scope of this 
chapter (Green et al. 2013). 
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Figure 5. Strategies to study co-immunoprecipitation of TMEFF2 and SARDH. A) Schematic 
of the MYC-HIS-tagged TMEFF2 constructs used in this study. FST, follistatin domain; EGF, 
EGF-like domain; TM, transmembrane domain; GA, G protein-activating domain. B) Western 
blot of TMEFF2-MYC-HIS (top) and ECTO-MYC-HIS (bottom) proteins bound to a nickel 
affinity column. Whole cell extracts of HEK293T cells expressing TMEFF2-MYC-HIS or 
ECTO-MYC-HIS (input) were applied to a nickel column. The column was washed with 10-
20 mM imidazole and bound proteins were eluted with 500-800 mM imidazole. The presence 
of TMEFF2 sequences in the eluate was detected with an anti-MYC antibody. The smaller 
bands are the cytoplasmic fragments that result from TMEFF2 shedding. C) Co-
immunoprecipitation of SARDH using TMEFF2 specific antibodies. Cell lysates from 
HEK293T cells overexpressing SARDH and TMEFF2-MYC-HIS were immunoprecipitated 
(IP) with anti-TMEFF2 antibody and immunoblotted (IB) with anti-SARDH horseradish 
peroxidase (HRP) conjugated antibody. The size of the bands corresponding to SARDH 
(black arrows) after strong elution (50 mM glycine pH 2.8 and LDS buffer) lies between the 
55-70 kDa and the 70-100 kDa markers. WCL, whole cell lysate. D) Analysis of protein 
binding to antibody affinity columns. Cell lysates from HEK293T cells overexpressing 
TMEFF2-MYC-HIS, ECTO-MYC-HIS or the empty vector as a control were 
immunoprecipitated (IP) with anti-MYC antibody coupled dynabeads and immunoblotted 
(IB) with anti-TMEFF2 antibody. In addition, cell lysates from LNCaP or 22Rv1 cells were 
immunoprecipitated (IP) with anti-TMEFF2 antibody coupled dynabeads and immunoblotted 
(IB) with anti-TMEFF2 antibody.  
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Table 2. SARDH peptides identified by mass spectrometry analysis of TMEFF2 affinity 
complexes.  
Start to end m/z Peptide sequence 
167-173 804.0 RLMSLGK 
174-188 1,588.8 AYGVESHVLSPAETK 
189-222 3,771.0 TLYPLMNVDDLYGTLYVPHDGTMDPAGCTTLAR 
228-241 1,514.4 GAQVIENCPVTGIR 
242-251 1,250.1 VWTDDFGVRR 
286-300 1,737.8 VPLVAMHHAYVVTER 
312-320 1,076.2 DHDASVYLR 
467-484 2,101.4 NYSVVFPHDEPLAGRNMR 
566-587 2,398.8 GAAAVFDMSYFGKFYLVGLDAR 
 
    An interaction between TMEFF2 and SARDH was confirmed by co-immunoprecipitation (co-
IP) analysis (Figure 6). A plasmid expressing SARDH from a CMV promoter (pCMV-SARDH) 
was transiently transfected into HEK293T cells stably expressing the TMEFF2-MYC-HIS 
protein or the empty vector, and anti-TMEFF2 immunocomplexes were analyzed for the 
presence of SARDH by western blotting. SARDH was clearly detected by the SARDH antibody 
in the TMEFF2 immunoprecipitates from cells expressing the TMEFF2-MYC-HIS construct 
(Figure 6A, lanes 1 and 3), but not the empty vector (Figure 6A, lanes 2 and 4), demonstrating 
that the presence of TMEFF2 is required to detect SARDH. Two different antibodies, MYC and 
a TMEFF2-specific antibody, were used to immunoprecipitate the TMEFF2-MYC-HIS protein 
with the same results (Figure 6A, compare lanes 1 and 2 with lanes 3 and 4). As negative 
controls, two isotype-matched, anti-4EBP1 (now shown) and anti-EIF4E (Figure 6A, lane 6) 
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Figure 6. TMEFF2 interacts with sarcosine dehydrogenase. A) TMEFF2 associates with 
SARDH in cells. Cell lysates from HEK293T cells overexpressing SARDH and TMEFF2-
MYC-HIS or the empty vector as a control were immunoprecipitated with the indicated 
antibodies (IP) anti-MYC, anti-TMEFF2, anti-SARDH, or anti-EIF4E (control) and 
immunoblotted (IB) with anti-SARDH or anti-TMEFF2 HRP-conjugated antibodies. The size 
of the band corresponding to SARDH (black arrowhead) lies between the 55-70 kDa marker. 
The size of the band corresponding to TMEFF2 (empty arrowhead) lies between the 40-55 
kDa marker. B) TMEFF2 ectodomain fails to associate with SARDH in cells. Cell lysate from 
HEK293T cells overexpressing SARDH and ECTO-MYC-HIS were immunoprecipitated 
with anti-MYC or anti-4EBP1 (control) and immunoblotted with anti-SARDH-HRP antibody. 
SARDH is indicated with a black arrowhead. C) Association of endogenous TMEFF2 and 
SARDH proteins. Cell lysates from LNCaP or 22Rv1 cells were immunoprecipitated with 
anti-TMEFF2 antibody or IgG as a control and immunoblotted with anti-SARDH antibody. 
The wedge shape indicates increasing amount of lysate used (150-250 µg of total protein). 
The arrows indicate the position of the major SARDH bands (between the 55-70 and 70-100 
kDa markers). The small arrowhead indicates a band with migration similar to the IgG heavy 
chain (star). WCL, whole cell lysate. 
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antibodies were utilized for the IP step. SARDH was not co-immunoprecipitated when either one 
of these antibodies was used for the IP step, demonstrating that the interaction between SARDH 
and TMEFF2 is specific. Reciprocal co-IP experiments using anti-SARDH for 
immunoprecipitation and anti-TMEFF2-HRP for western blot were also performed (Figure 6A, 
lanes 7–10) and confirmed the TMEFF2-SARDH interaction (Figure 6A, lane 10). 
    To further validate the specificity of the TMEFF2-SARDH interaction, we performed co-IP 
studies as described above with cells that ectopically express the TMEFF2 ectodomain (ECTO-
MYC-HIS; Figure 5A). The results indicate that SARDH was not present in the co-
immunoprecipitates obtained from the ECTO-MYC-HIS-expressing cells (Figure 6B, lanes 1–5). 
The ECTO-MYC-HIS protein is readily secreted into the medium, but it is also abundant in the 
cellular lysates and able to bind to the nickel or antibody affinity columns (Figure 5), ruling out 
that the lack of interaction reflects the absence of intracellular protein or failure to bind to the 
columns. 
    To better establish the physiological relevance of the above results, the TMEFF2-SARDH 
interaction was also analyzed in two prostate cancer cell lines, LNCaP and 22Rv1, known to 
express some endogenous TMEFF2. Co-IP studies indicated that SARDH is present in the 
TMEFF2 co-immunoprecipitates obtained using LNCaP or 22Rv1 cell lysates and therefore that 
the interaction occurs and is detectable even with the low endogenous levels of these proteins 
(Figure 6C). Polyclonal rabbit immunoglobulin G (IgG) was used as a negative control. The 
ability of endogenous TMEFF2 to bind to the antibody affinity column was verified (Figure 5D). 
Collectively, these results indicate that TMEFF2 specifically interacts with SARDH and that the 
presence of the transmembrane and/or cytoplasmic domains is essential for this interaction. 
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TMEFF2 co-localizes with SARDH 
    The possibility that TMEFF2 and SARDH can temporarily localize to the same cellular 
compartment was examined by immunofluorescence co-localization studies. HEK293T cells 
ectopically expressing TMEFF2 were transiently transfected with a tagged SARDH-MYC-HIS 
construct and incubated with polyclonal TMEFF2 antibody (to detect TMEFF2) and monoclonal 
MYC antibody (to detect SARDH). The localization of the proteins was subsequently visualized 
by confocal microscopy using Alexa Fluor 568 and FITC-conjugated secondary antibodies. Cells 
expressing TMEFF2 exhibited fluorescence concentrated at the plasma membrane but also in the 
cytoplasm in a punctate pattern (Figure 7A, 8B). Confirming published observations, SARDH 
mainly localized to the mitochondria (Bergeron et al. 1998), with less fluorescence detected in 
the cytoplasm (Figure 8A). Co-localization of the proteins in the cytoplasm was evidenced by 
overlapping fluorescence signals (Figure 7A, 8B). As anticipated based on the results from the 
co-IP analysis, the ectodomain of TMEFF2 did not demonstrate co-localization with SARDH 
(Figure 7B).  
    Co-localization of TMEFF2 and SARDH was also examined in living cells. For this purpose, 
TMEFF2 and SARDH were C-terminally tagged with cyan (CFP) and yellow fluorescent 
proteins (YFP) to generate TMEFF2-CFP and SARDH-YFP, respectively. The resulting fusion 
proteins were expressed in HEK293T cells, and the localization of the fluorescent proteins was 
imaged by confocal microscopy (Figure 7C, 8C). Interestingly, when TMEFF2-CFP and 
SARDH-YFP were co-expressed, they co-localize in an area surrounding the nuclear envelope 
that could correspond to the Golgi apparatus.      
Overexpression of the full-length TMEFF2 results in decreased cellular sarcosine levels 
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Figure 7. TMEFF2 co-localizes with sarcosine dehydrogenase. A) HEK293T cells ectopically 
expressing TMEFF2 and SARDH-MYC-HIS were fixed and stained with anti-TMEFF2 and 
anti-MYC (to detect SARDH) antibodies. Thin and thick filled arrows point to the 
membranous and vesicular localization of TMEFF2, respectively. B) HEK293T cells 
ectopically expressing the TMEFF2 ectodomain (TMEFF2-ECTO) and SARDH-MYC-HIS 
were treated and processed for Immunofluorescent staining as in A. C) In vivo co-localization 
of TMEFF2 and SARDH. HEK293T cells were transfected with TMEFF2-CFP and SARDH-
YFP fusion constructs, and living cells were observed 24 h later. CFP fluorescence is shown 
as green signal, YFP fluorescence is shown as red signal, and co-localization of CFP and YFP 
is illustrated by yellow signal. The confocal images in each panel are representative of more 
than 40 fields observed over four or five different experiments. Scale bars, 10 µm. 
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Figure 8. TMEFF2 and SARDH co-localize in HEK293T cells. A) Confocal microscopy of 
HEK293T/SARDH-MYC-HIS cells stained with anti-MYC. Mitochondria were stained with 
MitoTracker Red. The merge image demonstrates the localization of SARDH in mitochondria 
(yellow signal). B) Confocal Z-stack sequential images (left to right) of the co-localization 
(yellow) of TMEFF2 (red) and SARDH-MYC-HIS (green) in HEK293T fixed cells. C) 
Confocal Z-stack sequential images (left to right, top to bottom) of the in vivo co-localization 
(yellow) of TMEFF2-CFP (green) and SARDH-YFP (red) in HEK293T cells.  
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    SARDH catalyzes sarcosine to glycine conversion and, consequently, siRNA to SARDH 
results in increased sarcosine levels. Interestingly, this also results in an increase in the invasion 
potential of the cells, linking sarcosine metabolism with tumorigenesis (Sreekumar et al. 2009). 
Because TMEFF2 interacts with SARDH, we hypothesized that TMEFF2 modulates SARDH 
activity to promote changes in cell growth and/or invasion. We analyzed changes in sarcosine 
levels in response to TMEFF2 overexpression. Lysates were prepared from HEK293T cells 
stably transfected with the TMEFF2-MYC-HIS and ECTO-MYC-HIS expression constructs or 
with the empty vector as a control, and sarcosine levels were determined in the resulting cell 
lines. Overexpression of the ectodomain (ECTO-MYC-HIS) does not affect sarcosine levels 
(Figure 9). However, overexpression of TMEFF2 resulted in a significant decrease in the amount 
of sarcosine with respect to the lysates expressing the empty vector control (Figure 9), whereas 
having no effect on SARDH expression as measured by western blot (not shown). Although it is 
possible that the observed decrease in sarcosine levels is due to an indirect effect of TMEFF2, 
the physical interaction between SARDH and TMEFF2 demonstrated above suggests that the 
reduction in sarcosine may be due to an increase in SARDH activity mediated by its interaction 
with TMEFF2.  
 
(The following experiments were performed by other members of the lab but are included here 
for better understanding of this chapter.) 
Increased expression of TMEFF2 inhibits cell growth in HEK293T cells 
To investigate the function of TMEFF2 in tumorigenesis, we determined whether ectopic 
expression of this protein could affect cellular proliferation. HEK293T cells stably expressing 
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Figure 9. TMEFF2 affects the levels of cellular sarcosine. Overexpression of TMEFF2 
significantly reduces the levels of sarcosine in HEK293T cells. Dots on the box plot indicate 
outliers. Data shown are the result of six different experiments with multiple replicates. 
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untagged or MYC-HIS-tagged TMEFF2 proteins, along with control cells transfected with empty 
vector or untransfected cells, were generated for this purpose. Overexpression of either untagged 
(Figure 10A) or C-terminal MYC-HIS-tagged TMEFF2 (Figure 10B) in HEK293T cells 
decreased cell numbers by 20-30% with respect to the untransfected cells or the cells transfected 
with the empty vector. The presence of the C-terminal MYC-HIS tag did not change the effect of 
TMEFF2 on cell growth. Therefore, subsequent experiments were done using the MYC-HIS-
tagged form of the protein. 
To further characterize the nature of the alteration in proliferation rate, FACS analysis was 
used to investigate the effect of TMEFF2 in apoptosis and cell cycle progression. HEK293T cells 
stably transfected with TMEFF2-MYC-HIS or with the empty vector as a control were induced 
to undergo apoptosis with staurosporine, a protein kinase inhibitor that triggers both caspase-
dependent and caspase-independent apoptotic pathways (Belmokhtar et al. 2001; Zhang et al. 
2004). The presence of TMEFF2 in HEK293T cells had no effect on the number of apoptotic 
cells. However, it increased the sensitivity of the cells to staurosporine-induced apoptosis when 
compared with empty vector transfected cells (Figure 10C, D). TMEFF2 had a small effect on 
cell cycle, resulting in a slightly increased cell number in G1 (not shown). Supporting this 
observation, our preliminary array data indicate that overexpressing TMEFF2 resulted in 
increased expression of the cyclin-dependent kinase inhibitor p15 and decreased expression of 
cyclin E2 (not shown). 
To further investigate the tumor suppressor potential of TMEFF2, we assessed its ability to 
promote anchorage-independent growth using a soft agar growth assay. HEK293T cells stably 
expressing TMEFF2-MYC-HIS formed ∼5-fold fewer colonies, which were of smaller size than 
cells carrying the empty vector (Figure 10E, F). Thus, TMEFF2 suppresses the formation and the 
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growth of HEK293T colonies in soft agar. Overexpression of TMEFF2 had no effect on the 
migration or invasion ability of HEK293T cells as measured using Boyden chambers (not 
shown). 
TMEFF2 inhibits sarcosine-induced cell migration of prostate epithelial cells 
    Because the expression of TMEFF2 is mainly restricted to brain and prostate, we sought to 
analyze the effect of TMEFF2 overexpression in prostate cells. We selected RWPE1 cells, 
derived from non-neoplastic human prostatic epithelial cells (Bello et al. 1997), which express 
very low levels of endogenous TMEFF2 as demonstrated by quantitative real time PCR (not 
shown). Full-length TMEFF2 was introduced into the RWPE1 cells by retroviral gene transfer to 
generate an RWPE1 cell line that inducibly expresses TMEFF2 with the addition of doxycycline 
to the growth medium (RWPE1-TMEFF2i). Control cells were transduced with the transactivator 
construct only (RWPE1-tet). High level of expression of TMEFF2 in the RWPE1-TMEFF2i cell 
line upon the addition of doxycycline was demonstrated (Figure 11A). To test whether TMEFF2 
affects the growth rate of RWPE1 cells, RWPE1-TMEFF2i cells were grown in the absence (no 
TMEFF2 expression) and presence (TMEFF2 expression) of doxycycline, and the effect of 
TMEFF2 on the growth rate was determined. No significant effect of TMEFF2 on the growth 
rate of RWPE1 cells was observed when compared with the RWPE1-tet cells (Figure 11B). 
The addition of sarcosine to RWPE cells increases the migration and invasion ability of these 
cells (Sreekumar et al. 2009).We therefore tested whether TMEFF2 can reverse the sarcosine-
induced migration effect. Briefly, RWPE1-TMEFF2i cells were grown in the presence of 
sarcosine or alanine and doxycycline to induce TMEFF2 expression before their migration 
potential was analyzed using a wound-healing assay. The effect of TMEFF2 was investigated by 
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Figure 10. TMEFF2 inhibits proliferation and anchorage-independent growth and sensitizes 
cells to apoptosis. Stable expression of untagged (A) or MYC-HIS (B-F)-tagged TMEFF2 
decreases proliferation of HEK293T cells (A, B), sensitizes the cell to an apoptotic stimulus 
(C, D), and inhibits anchorage-independent growth (E, F). A, B) Overexpression of TMEFF2 
was confirmed by western blot analysis. The effect of TMEFF2 on growth was determined 
using an MTT assay after 96 h of growth. The A562 at 96 h was normalized first to the value 
obtained at zero time (to correct for plating variability) and then to the value obtained for the 
parental cell line (HEK293T; A) or the cell line carrying the empty vector (EV; B). C, D) The 
effect of TMEFF2 on apoptosis of HEK293T cells was determined in the presence of 
staurosporine or the vehicle, as a control, by analyzing the number of annexin V-positive cells 
and comparing it with the numbers obtained when expressing the empty vector. Shown are 
representative images of the flow cytometry analysis (C) and percentage of apoptotic cells 
(D). E, F) Representative images showing anchorage-independent growth (E) and number of 
colonies formed by HEK293T cells stably expressing TMEFF2-MYC-HIS or the empty 
vector as a control (F) after 14 d of growth. Data are mean ± SD of at least three independent 
experiments with multiple replicates. Several clones were tested to rule out that the effects are 
due to the insertion site. *, p < 0.05, and **, p < 0.01. 
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growth of HEK293T colonies in soft agar. Overexpression of TMEFF2 had no effect on the 
migration or invasion ability of HEK293T cells as measured using Boyden chambers (not 
shown). 
TMEFF2 inhibits sarcosine-induced cell migration of prostate epithelial cells 
    Because the expression of TMEFF2 is mainly restricted to brain and prostate, we sought to 
analyze the effect of TMEFF2 overexpression in prostate cells. We selected RWPE1 cells, 
derived from non-neoplastic human prostatic epithelial cells (Bello et al. 1997), which express 
very low levels of endogenous TMEFF2 as demonstrated by quantitative real time PCR (not 
shown). Full-length TMEFF2 was introduced into the RWPE1 cells by retroviral gene transfer to 
generate an RWPE1 cell line that inducibly expresses TMEFF2 with the addition of doxycycline 
to the growth medium (RWPE1-TMEFF2i). Control cells were transduced with the transactivator 
construct only (RWPE1-tet). High level of expression of TMEFF2 in the RWPE1-TMEFF2i cell 
line upon the addition of doxycycline was demonstrated (Figure 11A). To test whether TMEFF2 
affects the growth rate of RWPE1 cells, RWPE1-TMEFF2i cells were grown in the absence (no 
TMEFF2 expression) and presence (TMEFF2 expression) of doxycycline, and the effect of 
TMEFF2 on the growth rate was determined. No significant effect of TMEFF2 on the growth 
rate of RWPE1 cells was observed when compared with the RWPE1-tet cells (Figure 11B). 
The addition of sarcosine to RWPE cells increases the migration and invasion ability of these 
cells (Sreekumar et al. 2009).We therefore tested whether TMEFF2 can reverse the sarcosine-
induced migration effect. Briefly, RWPE1-TMEFF2i cells were grown in the presence of 
sarcosine or alanine and doxycycline to induce TMEFF2 expression before their migration 
potential was analyzed using a wound-healing assay. The effect of TMEFF2 was investigated by 
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Figure 11. TMEFF2 inhibits migration of RWPE cells. A) Western blot demonstrating the 
induction of TMEFF2 expression in response to doxycycline (Dox; 250 ng/ml) in the 
RWPE1-TMEFF2i cell line. β-Actin was used as a loading control. B) The effect of TMEFF2 
overexpression on the growth of RWPE1 cells was determined using an MTT assay after 96 h 
of growth. The A560 at 96 h was normalized first to the value obtained at zero time (to correct 
for plating variability) and then to the value obtained for same cells grown in the absence of 
doxycycline. C) The effect of TMEFF2 on migration was determined using a 24-h wound-
healing assay. The cells were grown in the presence of 50 μm alanine (ALA) or sarcosine 
(SAR) and 250 ng/ml doxycycline to induce the expression of TMEFF2. The RWPE1-tet cell 
line was used as a control. A representative image (top) and quantification of the results 
(bottom) are shown. D) Migration of cells from a random experimental repeat was also 
analyzed using Boyden chambers. Cells adhering to the bottom of the membrane were fixed, 
stained with crystal violet, and photographed. Single cell clones were analyzed and gave 
similar results. Data shown are mean ± SD of three independent experiments with multiple 
replicates. *, p < 0.05, and **, p < 0.01. 
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comparing the migration of RWPE1-TMEFF2i cells with the migration ability of the control cell 
line, RWPE1-tet, both in the presence of doxycycline. The addition of sarcosine resulted in an 
increase in migration of the RWPE1-tet cells (Figure 11C) when compared with cells grown in 
the presence of alanine. Overexpressing TMEFF2 in these cells blocked the increased migration 
associated with the addition of sarcosine (Figure 11C). The addition of alanine also had a small 
effect on migration that was also reversed by TMEFF2 overexpression. Migration data obtained 
using Boyden chambers confirmed the results of the wound assay (Figure 11D). These results 
suggest that TMEFF2 can block the intrinsic and the sarcosine-induced migration potential of 
RWPE1 cells. In addition, using a Boyden chamber invasion assay, we observed that TMEFF2 
overexpression was also able to reverse the intrinsic and the sarcosine-induced invasion ability of 
the cells (not shown). It is worth noting that although in HEK293T cells TMEFF2 negatively 
affects monolayer and anchorage-independent growth but has no effect on migration or invasion, 
the reverse seems to be true when TMEFF2 is overexpressed in RWPE cells, indicative of the 
cell line-specific effect of TMEFF2. 
The ectodomain region of TMEFF2 acts as a ligand to promote cell growth 
Based on our findings, we also hypothesized that because of the inability of the TMEFF2 
ectodomain to interact with SARDH and to affect the levels of cellular sarcosine, it would not 
demonstrate a tumor suppressor phenotype. We therefore expressed the ectodomain form of 
TMEFF2 (ECTO-MYC-HIS) in HEK293T cells and analyzed its effect on cell growth. As 
reported previously (Ali and Knaüper 2007), overexpression of the ectodomain resulted in 
increased monolayer growth when compared with empty vector transfected cells (Figure 12A). 
In contrast to full-length TMEFF2, overexpression of the ectodomain did not have any effect on 
anchorage-independent growth in soft agar or cellular invasion (not shown). 
55 
 
 
56 
 
       
Figure 12. TMEFF2 ectodomain promotes cell growth. A) The effect of the TMEFF2 
ectodomain on growth was determined in HEK293T cells stably transfected with the ECTO-
MYC-HIS construct using an MTT assay. After 96 h of growth, the A562 was measured and 
normalized first to the value obtained at zero time and then to the value obtained for the cell 
line carrying the empty vector (EV) as control. B) Schematics of the experiment used to 
determine the effect of the secreted ectodomain on cell growth (shown in D). C) Detection of 
ectodomain sequences in the conditioned medium using the specified antibodies. Because the 
ectodomain region is produced by TMEFF2 shedding from the membrane, it is not detected 
by the MYC antibody to the C-terminal region. Specificity was further confirmed by the 
addition of TNFα to induce shedding. D) Effect of the secreted ectodomain on the growth of 
HEK293T and RWPE1 cells was determined by MTT assay after 48 h of growth on 
conditioned medium obtained from cells expressing TMEFF2-MYC-HIS (TMEFF2-CM) or 
the empty vector as control (EV-CM). The A562 at 48 h was normalized first to the value 
obtained at zero time and then to the value obtained for the same cell line grown in the empty 
vector conditioned medium. Data shown are mean ± SD of three independent experiments 
with multiple replicates. *, p<0.05. 
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    The ectodomain region expressed throughout these experiments corresponds essentially to the 
naturally shed ectodomain of the TMEFF2 protein. Because it lacks a transmembrane domain, it 
is directly secreted and can be detected in the conditioned medium (not shown). It was therefore 
likely that the observed effect on monolayer growth was due to the secreted form of the 
ectodomain acting as a ligand from the outside of the cell. To examine this possibility, we 
determined the effect that conditioned medium collected from cell cultures overexpressing full-
length TMEFF2 had on the growth of two different cell lines, HEK293T and RWPE1 (Figure 
12B-D). Exponentially growing HEK293T cells transfected with the TMEFF2-MYC-HIS 
construct were starved for 24 h, and the conditioned medium was collected and supplemented 
with 0.4% FBS. The presence of TMEFF2 sequences in the conditioned medium was analyzed 
by western blot using antibodies against the TMEFF2 ectodomain or against the MYC tag 
(Figure 12C). The collected conditioned medium was used to replace the growth medium of 
cultures of HEK293T and RWPE1 cells, and the growth rate of these cells was measured at 
different time intervals after the medium replacement. As a control, conditioned medium 
collected from vector transfected HEK293T cultures was used. The addition of conditioned 
medium from the TMEFF2-MYC-HIS-overexpressing cultures resulted in a significant growth 
increase of HEK293T and RWPE1 cells (Figure 12D). Similar results were observed when 
conditioned medium from ECTO-MYC-HIS-overexpressing cells was used to feed the 
HEK293T or RWPE1 cell cultures (not shown). These results suggest that the ectodomain may 
act as a ligand to promote increased growth rate of HEK293T and RWPE1 cells. 
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Discussion 
    Deregulated expression of TMEFF2 has been documented in a variety of tumor types. 
However, the relationship of TMEFF2 to the biology of tumor development or suppression and 
the molecular bases of these activities remain unknown. The study in this chapter reveals a novel 
functional and physical interaction between TMEFF2 and SARDH, an enzyme involved in 
sarcosine metabolism, and characterizes the role of this interaction in the tumorigenic activity of 
TMEFF2. We demonstrate that TMEFF2 expression results in a decrease in the level of cellular 
sarcosine and that this effect correlates with its ability to act as a tumor suppressor. 
    SARDH is responsible for conversion of sarcosine to glycine and is therefore one of the 
regulators of sarcosine levels in the cell. Because sarcosine is formed as a result of glycine 
methylation, the decrease in sarcosine levels that we observed with TMEFF2 overexpression 
could be due to an effect on the global cellular amino acid metabolism and/or methylation 
activity or to an effect on the activity of the SARDH enzyme. Our data indicating that TMEFF2 
physically interacts with SARDH favor the latter possibility. This interpretation bestows an 
active role for sarcosine in tumorigenesis consistent with data indicating that in cell culture, the 
addition of sarcosine promotes cell invasion of prostate epithelial cells (Sreekumar et al. 2009). 
Our results demonstrate that the ability of TMEFF2 to decrease the cellular sarcosine levels 
correlates with its function. Expression of full-length TMEFF2 decreases cellular sarcosine 
levels and leads to a tumor suppressor phenotype, whereas expression of the ectodomain does 
not alter sarcosine levels and leads to reversion of the tumorigenic phenotype. These results also 
suggest that the effect of TMEFF2 on sarcosine levels requires the presence of a transmembrane 
domain and/or the cytoplasmic tail and could possibly be mediated by the G protein-activating 
domain present in this region. 
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    As described in Chen et al. 2011, the ectodomain promotes cellular proliferation, confirming 
previous reports (Ali and Knaüper 2007; Horie et al. 2000). Cleavage of the extracellular domain 
of TMEFF2 is induced by pro-inflammatory cytokines and regulated by ADAM17 (Ali and 
Knaüper 2007; Lin et al. 2003) and this effect could contribute to the opposing results described 
for TMEFF2, such as growth suppression dependent on full-length TMEFF2, its ability to 
modulate sarcosine levels, and proliferation dependent on regulated release of the ectodomain, 
which is unable to modulate sarcosine levels. Interestingly, a soluble isoform of TMEFF2 has 
also been described (Quayle and Sadar 2006), and although its role is unknown, we predict that it 
will not modulate sarcosine levels. The identification of proteins with both pro-oncogenic and 
anti-oncogenic activities has been previously described, emphasizing the complexity of cellular 
events that occur during tumorigenesis (Genander et al. 2009; Kang et al. 2008; Murray-
Zmijewski et al. 2006; Niu et al. 2008; Zhu et al. 2007). Several mechanisms account for the 
switch in oncogenic activity including the cellular context, the type of tumor, the activation of 
different pathways, or the presence of different isoforms with opposing roles (Genander et al. 
2009; Kang et al. 2008; Murray-Zmijewski et al. 2006; Niu et al. 2008; Zhu et al. 2007). 
    Similar to TMEFF2, TMEFF1, the only other known member of the TMEFF family, 
demonstrates different activities depending on the presence of the cytoplasmic tail and its 
anchorage to the membrane. In Xenopus, TMEFF1 inhibits TGF-β signaling by blocking the 
nodal co-receptor Cripto (Harms and Chang 2003). The follistatin and EGF motifs contribute to 
this effect; however, anchorage to the membrane is also essential for this function. Conversely, 
TMEFF1 blocking of BMP-mediated signaling requires the cytoplasmic domain of the protein, 
whereas deletion of either the follistatin or the EGF motifs does not interfere with this function 
(Chang et al. 2003). A function for the TMEFF1 ectodomain has not been described. TMEFF1 
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and TMEFF2 grossly differ in their tissue distribution. TMEFF1 is more widely distributed than 
TMEFF2, and even in brain, where both proteins are expressed, they exhibit distinct distribution 
patterns (Kanemoto et al. 2001). Nevertheless, their high level of sequence similarity suggests 
that TMEFF1 and TMEFF2 could be playing similar roles in different tissues and/or 
developmental stages.  
    Using confocal microscopy, we have observed TMEFF2 localization to the membrane but also 
to the cytoplasm, where it appears in a punctate pattern. This vesicle-like immunoreactivity of 
TMEFF2 has also been described in neurons (Siegel et al. 2002, 2006), and it has been proposed 
to correspond to vesicles translocating newly synthesized TMEFF2 to the cell surface and/or 
cleaved TMEFF2 to the nucleus. SARDH has been described essentially as a mitochondrial 
enzyme (Bergeron et al. 1998); however, our results suggest that it can also be found in the 
cytosol and/or the Golgi apparatus, where it could be interacting with TMEFF2 during 
trafficking. We predict that this interaction modifies the activity of SARDH and, ultimately, the 
mitochondrial and/or cytosolic levels of sarcosine. Several mitochondrial enzymes have been 
described as tumor suppressors, for example, succinate dehydrogenase and fumarase hydratase 
(King et al. 2006) or a mitochondrial form of the sirtuin deacetylases, SIRT3 (Kim et al. 2010). 
Similar to these enzymes, SARDH should be considered a tumor suppressor because its 
inactivation leads to sarcosine accumulation and increased invasion. Interestingly, the level of 
SARDH protein has been reported to decrease in hepatocellular carcinoma (Lim et al. 2002). By 
binding to SARDH, TMEFF2 could be modulating the activity of SARDH and therefore the 
cellular level of sarcosine, suggesting that it may function as a “secondary” tumor suppressor. 
Whether the tumor suppressor activity of TMEFF2 depends entirely on SARDH or on additional 
interacting protein/signaling pathways is currently under investigation. 
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    The results presented here indicate that the role of TMEFF2 in tumorigenesis correlates, at 
least partially, with its ability to bind to SARDH and modulate the cellular levels of sarcosine. 
However, how does sarcosine promote tumor invasion? Sarcosine is an endogenous amino acid 
with several important biological functions: a) it participates in one-carbon metabolism essential 
for protein and nucleotide synthesis and DNA methylation (Stover 2009), and b) it is a 
competitive inhibitor of the type I glycine transporter (GlyT1), a glycine transporter found in 
brain (Zhang et al. 2009). It is therefore possible that the addition of exogenous sarcosine and its 
subsequent metabolism affect the methylation and/or synthetic ability of the cell; alternatively, 
sarcosine may have a yet unidentified role, for example, similar to its role on GlyT1, as an 
agonist/antagonist of a factor involved in tumorigenesis. This last possibility is supported by the 
fact that blocking sarcosine metabolism also promotes cellular invasion due to sarcosine 
accumulation. 
    Increasing evidence links sarcosine metabolism with disease state, including cancer (prostate, 
liver) and brain disease. Although the phenotypic expression of altered sarcosine metabolism is 
pleiotropic in several cell types, these cell type and isoform-specific differences suggest that a 
broad range of biologic responses is mediated by TMEFF2 and sarcosine. Because TMEFF2 is 
also differentially expressed in brain, it is reasonable to hypothesize that its role there may also 
be related to sarcosine metabolism. In fact, TMEFF2 was identified in a genome-wide 
association study as a factor involved in schizophrenia. Whether the role of TMEFF2 in 
schizophrenia is related to its ability to modulate the level of sarcosine and therefore the activity 
of GlyT1 is not yet certain, but sarcosine is currently being investigated as a treatment for 
schizophrenia (Javitt 2009). The complex biology of TMEFF2 offers insight into metabolic 
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regulation of cancer and perhaps other disease states. The contribution of different TMEFF2 
isoforms to this biology and the regulation of their expression remain to be defined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR: The TMEFF2 Tumor Suppressor Modulates Integrin Expression, 
RHOA Activation and Migration of Prostate Cancer Cells
2
 
Introduction 
    Prostate cancer is the most commonly diagnosed cancer and the second leading cause of 
cancer deaths in American men (Siegel et al. 2013). While organ-confined prostate cancer is 
successfully treated by surgical methods, no effective treatment is available for the metastatic 
form of the disease, which is responsible for the majority of prostate cancer deaths. Prostate 
cancer cells are known to metastasize to numerous organs, with the bone, liver, and lymph nodes 
being the most common (Shah et al. 2004); however, the molecular mechanisms that drive the 
metastatic cascade in prostate cancer are poorly understood. Understanding these mechanisms 
and the molecules involved in the metastatic cascade is critical to developing strategies for 
metastasis prevention and therefore for efficient treatment of prostate cancer.  
    Integrins are members of a family of transmembrane glycoprotein receptors that mediate cell-
cell and the interactions with the extracellular matrix (ECM). By interacting with actin-
associated proteins, integrins provide a link between the extracellular environment and the 
cytoskeleton inside the cells (Schoenwaelder and Burridge 1999). Integrins are heterodimers 
composed of non-covalently associated α and β subunits. So far, 18 α and 8 β subunits, and 24 
complexes have been identified that can recognize and bind multiple ECM ligands, triggering a 
variety of signal transduction events that modulate diverse cellular responses including 
proliferation, survival, gene expression, adhesion and migration (Hynes 2002; Desgrosellier and 
                                                 
2 This chapter contains work submitted as Xiaofei Chen, Joshua M. Corbin, Greg J. Tipton, Li V. Yang, Adam S. 
Asch and Maria J. Ruiz-Echevarría. The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation 
and migration of prostate cancer cells. 
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Cheresh 2010; Hood and Cheresh 2002). As a result, integrins and their ligands play critical roles 
in biological processes like development, immune response, hemostasis, and cancer. In fact, 
alterations in integrin signaling have been shown in several types of cancer, including prostate 
cancer, and correlate with tumor growth, increased invasion, and metastatic potential (Goel et al. 
2008; Fornaro et al. 2001).  
    Several integrins, α2β1, α3β1, α5β1, α6β1, αvβ1, αIIbβ3, and αvβ3 are expressed in prostate 
cancer cells (Fornaro et al. 2001; Lee et al. 2013). Of those, αvβ3 and β1 seem to play important 
roles in the formation of metastasis to bone, the main site of metastatic prostate cancer (Lee et al. 
2013; Cooper et al. 2002; McCabe et al. 2007). Although not expressed in normal epithelial cells 
(Cooper et al. 2002), integrin αvβ3 is expressed in prostate cancer, and its expression correlates 
with disease progression and metastatic potential (Goel et al. 2008; Fornaro et al. 2001; Cooper 
et al. 2002), and with prostate cancer cell adhesion to, and migration on, vitronectin, a major 
extracellular component of mature bone (Zheng et al. 1999). Moreover, β1 integrins were also 
shown to be upregulated in specimens from prostate cancer patients, and antibodies against β1 
integrins inhibited binding of PC3 cells to human bone marrow endothelial cells (Lee et al. 2013; 
Scott et al. 2001), suggesting that β1 integrins mediates bone metastasis.  
    Integrins are unique in that they may signal bidirectionally. Intracellular stimuli (inside-out 
signaling) can potentially promote a conformational change in the integrin that lead to higher 
affinity for its ligand (Kim et al. 2011; Shen et al. 2012; Ginsberg et al. 2005; Harburger and 
Calderwood 2009). Ligand binding (outside-in signaling) ultimately leads to integrin activation 
and clustering into large mature focal adhesions able to affect downstream signaling events in a 
temporal fashion (Guo and Giancotti 2004; Ginsberg et al. 2005; Harburger and Calderwood 
2009). One of the changes that take place early after integrin activation involves cytoskeletal 
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rearrangements that regulate stress fiber formation and promote cell spreading and initiation of 
migration, which are critical steps in metastasis (DeMali et al. 2003). These processes require 
integrin-mediated activation of specific cellular kinases and inhibition of the small GTPase 
RHOA (Shen et al. 2012; Huveneers and Danen 2009; Schwartz and Shattil 2000). RHOA is 
essential to remodeling actin fibers, regulation of actomyosin contractility, and rear cell 
detachment during motility (Sah et al. 2000; Burridge and Wennerberg 2004). Interestingly, 
RHOA is also activated via G protein-coupled receptors (GPCRs) that couple to the 
heterotrimeric G12/13 proteins, highlighting a cooperative relationship between integrin and 
GPCR signaling, also described for integrin and growth factor receptor signaling (Eliceiri 2001; 
Ivaska and Heino 2011; Miyamoto et al. 1996), to affect cell spreading, migration, growth and 
survival.  
    The transmembrane protein with epidermal growth factor and two follistatin motifs 2 
(TMEFF2) is an evolutionarily conserved type I transmembrane protein expressed in the embryo 
and selectively in the adult brain and prostate (Liang et al. 2000; Glynne-Jones et al. 2001; Gery 
et al. 2002; Afar et al. 2004; Zhao et al. 2005). A role for TMEFF2 in prostate cancer was 
suggested by studies indicating that TMEFF2 expression is altered in a significant fraction of 
primary and metastatic prostate tumors (Glynne-Jones et al. 2001; Afar et al. 2004; Zhao et al. 
2005). We have described that TMEFF2 functions as a tumor suppressor and that this role 
correlates, at least in part, with its ability to interact with SARDH and modulate the cellular 
levels of sarcosine (Chen et al. 2011). TMEFF2 overexpression blocked basal and sarcosine-
induced cellular invasion of prostate epithelial RWPE1 cells, while TMEFF2 knockdown in 
22Rv1 prostate cancer cells, which naturally express TMEFF2, increased cellular 
migration/invasion (Green et al. 2013). While these results highlight a role for TMEFF2 in 
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invasion of prostate cells, the molecular mechanisms involved in this process are not known. 
Using different ECM substrates, here we report that TMEFF2 expression inhibits spreading and 
migration of RWPE2 prostate cancer cells on vitronectin and laminin but not fibronectin or 
collagen. This correlates with a defect in focal adhesion and stress fiber formation and in RHOA 
activation and requires the presence of the cytoplasmic tail of TMEFF2. Importantly, TMEFF2 
expression promoted downregulation of αv and β3 integrin subunits in RWPE2 cells and 
TMEFF2 knockdown caused an increase in αv integrin subunit in 22Rv1 cells, indicating that the 
motility effects observed are integrin-mediated. Decreased expression of integrins was also 
observed in the prostate of a TRAMP mouse model of prostate cancer that has been engineered 
to overexpress TMEFF2 exclusively in the prostate.  All these results point to an important role 
of TMEFF2 in modulating integrin signaling and prostate cell motility. 
 
Results 
The cytoplasmic domain of TMEFF2 is necessary for its tumor suppression role  
    The transmembrane and cytoplasmic domains of TMEFF1 and TMEFF2, the two members of 
the TMEFF family of proteins, are very well conserved at the amino acid level, and contain 
potential GPCR-signaling motifs in the membrane and cytoplasmic domains. For TMEFF1, the 
relevance of these domains is underscored by data that point to different functions of the protein 
depending on their presence/absence (Chang et al. 2003). For TMEFF2, we have shown that 
while the full-length protein interacts with SARDH and promotes tumor suppression, a soluble 
form of the TMEFF2 protein lacking the transmembrane and cytoplasmic domains does not 
interact with SARDH and promotes cellular proliferation (Chen et al. 2011). These observations 
67 
 
suggest that signaling from the membrane and/or the cytoplasmic domain is important for the 
tumor suppressor role of TMEFF2. To examine the role of the TMEFF2 cytoplasmic domain, we 
used a deletion mutant lacking 13 consecutive basic-rich amino acids in the C-terminus of the 
protein (TMEFF2_ΔGA) and determined its ability to interact with SARDH and its tumor 
suppressor function. A plasmid expressing SARDH from a CMV promoter (pCMV-SARDH) 
was transiently transfected into HEK293T cells stably expressing a MYC-HIS tagged full-length 
TMEFF2 (FL_TMEFF2) or TMEFF2_ΔGA protein and anti-TMEFF2 immunocomplexes were 
analyzed for the presence of SARDH by western blotting. SARDH was detected in the TMEFF2-
immunoprecipitates with lysates obtained from cells expressing the TMEFF2-MYC-HIS 
construct (Figure 13A), supporting previous results (Chen et al. 2011). In addition, SARDH also 
associated with the TMEFF2_ΔGA-MYC-HIS protein, indicating that the cytoplasmic tail of 
TMEFF2 is not essential for its interaction with SARDH (Figure 13A). We next analyzed the 
effect of expressing the TMEFF2_ΔGA mutant on cellular sarcosine levels. Cell lysates were 
prepared from HEK293T cells stably transfected with the TMEFF2-MYC-HIS, TMEFF2_ΔGA-
MYC-HIS expression constructs or with the empty vector as a control, and sarcosine levels were 
determined in the resulting cell lines (Figure 13B). As previously reported, overexpression of 
TMEFF2 resulted in a significant decrease in the amount of sarcosine with respect to the lysates 
expressing the empty vector control (Chen et al. 2011); however overexpression of the 
TMEFF2_ΔGA mutant did not affect sarcosine levels (Figure 13B). 
    As we have hypothesized that TMEFF2 inhibits tumorigenic behavior through its ability to 
regulate SARDH activity and therefore the levels of cellular sarcosine, we predicted that the 
TMEFF2_ΔGA protein would not demonstrate these inhibitory effects. Addition of sarcosine to 
prostate epithelial RWPE1 cells promotes their tumorigenic potential by increasing the migration 
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Figure 13. TMEFF2_ΔGA interacts with SARDH but does not affect the levels of cellular 
sarcosine. A) TMEFF2_ΔGA associates with SARDH. Cell lysates from HEK293T cells 
overexpressing SARDH and MYC-tagged FL_TMEFF2, TMEFF2_ΔGA, or the empty vector 
control, were immunoprecipitated (IP) with anti-MYC (left, right), anti-TMEFF2 (middle) or 
control anti-4EBP1 (right) antibodies and immunoblotted (WB) with anti-SARDH-HRP 
antibody. The size of the band corresponding to SARDH is marked with a black arrowhead. 
Note that the results in these blots do not represent quantitative differences. B) 
TMEFF2_ΔGA does not affect intracellular sarcosine levels. HEK293T cells overexpressing 
FL_TMEFF2, TMEFF2_ΔGA, or the empty vector were lysed in sarcosine assay buffer and 
sarcosine was measured in the lysate using a sarcosine assay kit. Data were normalized to the 
level of total L-amino acid and are shown as a box plot of six independent experiments. 
Asterisks indicate outliers. 
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and invasion ability of these cells (Sreekumar et al. 2009; Chen et al. 2011) and TMEFF2 is able 
to inhibit the intrinsic and sarcosine-induced migration potential of these cells (Chen et al. 2011). 
We therefore tested whether TMEFF2_ΔGA can also inhibit migration of the RWPE1 or 
RWPE2 cells, a Ki-ras transformed derivative of RWPE1. For this purpose, we generated cell 
lines that inducibly express FL_TMEFF2 or TMEFF2_ΔGA with the addition of doxycycline to 
the growth medium (Figure 14A, B). Control cells were transduced with the transactivator 
construct only (vector). Using a wound-healing assay, we observed that, as opposed to cells 
expressing the full-length TMEFF2 protein, cells expressing the TMEFF2_ΔGA protein did not 
significantly inhibit migration of RWPE1 or RWPE2 cells (Figure 14C, D). Similar results were 
obtained using Boyden chambers (Figure 14E). These results suggest that the cytoplasmic tail of 
TMEFF2 is necessary for its ability to inhibit migration of prostate epithelial and cancer cells. 
Interestingly, we observed a tendency towards slower migration of cells expressing 
TMEFF2_ΔGA than cells expressing the vector control. This may reflect more than one 
mechanism to inhibit migration. All together these results suggest that the cytoplasmic tail of 
TMEFF2 is important for its tumor suppressor function.  
    To further evaluate the contribution of the TMEFF2 cytoplasmic domain to tumorigenesis, we 
determined the effect of the TMEFF2_ΔGA mutant protein on RWPE1 and RWPE2 cell growth. 
As previously reported for TMEFF2, the TMEFF2_ΔGA mutant did not demonstrate an effect 
on monolayer growth of RWPE1 or RWPE2 cells (Figure 15). 
TMEFF2 promotes cell rounding and reduces cell spreading  
    In order for cells to migrate they must attach and spread. While conducting the experiments 
described above, we observed that expression of TMEFF2 induces cell rounding of RWPE2 and 
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Figure 14. TMEFF2 inhibits migration in RWPE1 and RWPE2 cells. A, B) Cells were grown 
in the presence of 250 ng/ml doxycycline to induce the expression of FL_TMEFF2 or 
TMEFF2_ΔGA. Overexpression of these proteins in RWPE1 (A) and RWPE2 (B) cells after 
doxycycline treatment was assessed by western blot. C, D) Cell migration of RWPE1 (C) or 
RWPE2 (D) cells expressing the different forms of TMEFF2, was determined using a wound 
healing assay, 48 (RWPE1) or 10 hours (RWPE2) after the wound was made. Quantification 
of relative migration (fold over the vector) is presented as mean ± SD of three independent 
experiments. E) TMEFF2 inhibits RWPE2 cell migration as measured using a Boyden 
chamber transwell assay. Cells adhering to the bottom of the membrane were fixed, stained 
with crystal violet and photographed. Shown are representative images of cells after overnight 
migration. 
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Figure 15. TMEFF2_ΔGA does not affect cell monolayer growth in RWPE1 and RWPE2 
cells. The effect of TMEFF2 on growth in A) RWPE1 and B) RWPE2 cells was determined 
using an MTT assay after 48 h of growth. The 562 nm absorbance at 48 h was normalized 
first to the value obtained at 0 time (to correct plating variability) and then to the value 
obtained for the vector cells. Data are presented as mean ± SD of four independent 
experiments 
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several other cell lines (Figure 16A and not shown), suggesting a potential problem on the ability 
of TMEFF2 expressing cells to attach/spread to the substrate, and this could account for the 
TMEFF2 effect on migration. Therefore, we examined attachment/spreading of RWPE2 cells 
expressing the inducible FL_TMEFF2, the TMEFF2_ΔGA proteins or the empty vector as a 
control, to tissue culture plates. As shown in Figure 16B, when grown in the presence of 
doxycycline to induce TMEFF2 expression, over 35% of the RWPE2 cells expressing the 
FL_TMEFF2 have a round shape. In contrast, 85-90% of the cells expressing the TMEFF2_ΔGA 
or the empty vector demonstrate typical epithelial cell morphology with 10-15% presenting 
rounded shape. We next examined the spreading to the ECM proteins vitronectin, fibronectin, 
laminin and collagen type I. RWPE2 cells expressing the empty vector control or the 
TMEFF2_ΔGA behaved similarly, attaching slightly better to fibronectin and collagen type I 
than to vitronectin and laminin (Figure 17A). However, when compared to these cells, 
expression of FL_TMEFF2 significantly reduced the ability of cells to spread on laminin or 
vitronectin coated surface (Figure 17A), this effect being more pronounced in vitronectin. This 
suggests that TMEFF2 blocks spreading to specific ECM substrates, and this could ultimately 
affect migration. Supporting these results, migration of cells expressing FL_TMEFF2 is 
significantly reduced in vitronectin but not in fibronectin (Figure 17B), when compared to cells 
expressing TMEFF2_ΔGA or the empty vector control as measured by transwell assays. All 
together these results suggest that TMEFF2 negatively affects the cell’s ability to spread to 
specific substrates and it requires the presence of the cytoplasmic tail for this inhibitory effect. 
TMEFF2 reduces stress fiber and focal adhesion formation and activation 
    Since the presence of focal adhesions correlates with cell attachment and spreading, we 
investigated the ability of FL_TMEFF2 to inhibit formation of these macromolecular structures. 
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Figure 16. TMEFF2 inhibits RWPE2 cell spreading on tissue culture plates. A) 
Representative images of cell morphology of RWPE2 cells expressing different forms of the 
TMEFF2 protein, or the empty vector, on tissue culture surface. Arrows point to rounded 
cells. Scale bars, 100 μm. B) Quantification of round or spread cells at 3 h after seeding 
40,000 cells/well in a 12-well plate. Data are presented as mean ± SD of three independent 
experiments.  
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Figure 17. Effect of TMEFF2 in different ECM substrates. A) TMEFF2 significantly inhibits 
cell spreading on vitronectin and laminin-coated surfaces. RWPE2 cells expressing 
FL_TMEFF2, TMEFF2_ΔGA, or the vector were plated onto cover glass coated with the 
different ECM substrates. Percentages of spread cells were analyzed 3 h after seeding. Data 
are presented as mean ± SD of five independent experiments. B) TMEFF2 inhibits RWPE2 
cell migration towards vitronectin but not fibronectin as measured in a Boyden chamber 
assay. Shown are representative images of RWPE2 cells expressing the different TMEFF2 
constructs after 48 h migration (top). Quantification of those images by densitometric analysis 
using ImageJ (bottom). The experiment was repeated twice with similar results. 
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RWPE2 cells expressing FL_TMEFF2, TMEFF2_ΔGA or the empty vector control were grown 
on cover glass coated with fibronectin or vitronectin and stained with rhodamine-phalloidin to 
detect polymerized actin and vinculin antibodies to detect focal adhesions. As described above, 
expression of FL_TMEFF2, but not the mutant lacking the cytoplasmic tail, resulted in an 
increase in rounded cells, more so in cells grown in vitronectin. These rounded cells revealed a 
cortical actin cytoskeleton, without stress fibers, and lack of focal adhesions as demonstrated by 
diffuse vinculin staining (Figure 18A). Conversely, the normal attachment of FL_TMEFF2 
expressing RWPE2 cells to fibronectin correlated with stress fiber formation and the presence of 
focal adhesions at the ends of the fibers (Figure 18A). Expression of the TMEFF2_ΔGA mutant, 
did not affect stress fiber or focal adhesion formation when grown in either vitronectin or 
fibronectin. Finally, using western blot analysis, we measured autophosphorylation of focal 
adhesion kinase (FAK) at tyrosine 397 (Y397), which is required for focal adhesion formation 
and cell migration. The results, shown in Figure 18B, indicate that FL_TMEFF2 but not 
TMEFF2_ΔGA inhibit FAK-Y397 phosphorylation. All together these results indicate that 
TMEFF2 interferes with focal adhesion formation/activation and, as a consequence, it inhibits 
cell spreading and migration. The cytoplasmic tail of TMEFF2 is required for these effects. 
TMEFF2 inhibits RHOA activation  
    RHOA activation promotes stress fiber formation and maturation of focal adhesions. Since our 
results indicated that expression of TMEFF2 affects these processes, we determined whether 
TMEFF2 was able to affect RHOA activation. RHO is active in the GTP-bound state, which is 
catalyzed by the Dbl family of guanine nucleotide-exchange factors (GEFs). The amount of 
activated RHOA was determined using the G-LISA kit in RWPE2 cells expressing the different 
forms of TMEFF2 and compared to the activity of cells expressing the vector as control. Cells 
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Figure 18. TMEFF2 reduces stress fiber and focal adhesion formation and activation.  A) 
RWPE2 cells expressing FL_TMEFF2, TMEFF2_ΔGA, or the vector were cultured on cover 
glass coated with fibronectin or vitronectin for 3 h and then stained with anti-vinculin (green), 
rhodamine phalloidin (orange), and DAPI (blue). Scale bar, 20 μm. B) Immunoblotting of 
phosphorylated FAK (Y397), FAK and β-actin (ACTB) in RWPE2 cells. Numbers under the 
western blots represent the densitometry quantifications using ImageJ. 
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were grown in serum-free media and the stimulated with fetal bovine serum (FBS). TMEFF2 
expression significantly reduced the level of active RHOA by 20% of that in the control cells 
(Figure 19A). Deletion of the cytoplasmic tail of TMEFF2 recovered the level of active RHOA, 
to 90% of the RHOA activity of control cells. Although this difference was not significant, we 
observed a tendency towards less RHOA activation in cells expressing TMEFF2_ΔGA. Changes 
in RHOA activation correlated with the formation of stress fibers, since expression of 
FL_TMEFF2, but not TMEFF2_ΔGA, also inhibited stress fiber formation (Figure 19A). These 
results indicate that TMEFF2 decreases RHOA activation in FBS-stimulated conditions and that 
this is in part due to the cytoplasmic tail of TMEFF2. Since RHOA plays a role in migration, it is 
possible that the observed TMEFF2-mediated inhibition of migration is due to its effect on 
RHOA activation. In support of this, treatment of RWPE2 cells with CT04, a RHO inhibitor, 
dramatically reduced stress fiber formation and inhibited cellular migration by 50% (Figure 
19B).  
TMEFF2 inhibits expression of integrins 
    Integrins are the main ECM receptors. They are involved in motility and migration and 
integrin signaling can modulate RHOA activation. We therefore analyzed whether the effect of 
TMEFF2 on migration and RHOA activation is mediated by an effect on integrin expression. 
The human extracellular matrix and adhesion molecules RT
2
 profiler PCR array was used to 
investigate differences in expression of 21 different integrin subunits (15 α and 6 β) -- other 
genes important for cell-cell and cell-matrix interactions are also included in the array -- in 
RWPE2 cells. Expression of FL_TMEFF2 but not TMEFF2_ΔGA in RWPE2 cells reduced the 
levels of some integrin’s mRNA, including αv, β1 and β3 (Figure 20). For those integrins, the 
observed decrease in mRNA levels corresponded with a decrease in total protein levels as 
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Figure 19. TMEFF2 inhibits RHOA activation. A) RWPE2 cells expressing FL_TMEFF2, 
TMEFF2_ΔGA, or the vector were incubated in serum-free EpiLife CF/PRF medium for 3 
days and then stimulated with 10% FBS for 2 min. Levels of GTP-bound RHOA were 
determined by G-LISA RHOA activation assays. Data are presented as mean ± SD of five 
independent experiments (left). Rhodamine phalloidin staining of the cells stimulated with 
10% FBS for 10 min (right) demonstrating lack of stress fibers in the cells expressing 
FL_TMEFF2. Scale bar, 25 μm. B) Inhibition of RHO by CT04 blocks RWPE2 cell migration 
and stress fiber formation. 24 h migration of RWPE2 cells treated with 2 μg/ml CT04 or 
control medium was measured by wound healing assays using ibidi culture inserts. Data are 
presented as mean ± SD of two independent experiments (left). Rhodamine phalloidin staining 
of RWPE2 cells treated with 2 μg/ml CT04 or control medium for 4 h (right). Scale bar, 25 
μm. 
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Figure 20. TMEFF2 decreases the expression of αv and β3 integrin genes. The expression of 
key genes involved in cellular adhesion to the extracellular matrix (ECM) was determined by 
Human Focal Adhesions RT² Profiler PCR Array using the vector and TMEFF2-expressing 
RWPE2 cells. Arrows indicate ITGAV and ITGB3 genes have over 2-fold reduction in 
TMEFF2-expressing cells compared with the vector cells. Fold change in expression of other 
genes is also indicated. 
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measured by western blot (Figure 21A). Expression of these integrins was also analyzed in 
22Rv1/sh_TMEFF2 cells, in which expression of endogenous TMEFF2 is reduced by shRNA, 
and in 22Rv1/sh_scramble control cells (Green et al. 2013). As shown in Figure 21A, decreasing 
the level of TMEFF2 by shRNA promoted an increase in integrin αv protein levels. We did not 
detect expression of the β1 and β3 integrins in these cells (Figure 21A). These results 
demonstrate that FL_TMEFF2 inhibits expression of the αv, β1 and β3 integrins, and that the 
cytoplasmic tail is required for this inhibition.  
TMEFF2 expression inhibits integrin expression in vivo 
    In humans TMEFF2 is expressed mainly in brain and prostate, however, TMEFF2 is not 
expressed in the adult mouse prostate (Afar et al. 2004). We have generated a transgenic 
TMEFF2 mice that expresses TMEFF2 from the probasin promoter and therefore transgene 
expression is restricted to the prostate (Figure 22). As described for the probasin promoter 
expression pattern (Greenberg et al. 1994), TMEFF2 is expressed more in the ventral (V) and 
dorsolateral (DL) prostate with almost no expression in the anterior lobe (A) of the transgenic 
mouse (Overcash and Ruiz-Echevarria, personal communication). The TMEFF2 transgenic 
animals were crossed to a mouse model of prostate cancer designated TRAMP (transgenic 
adenocarcinoma of mouse prostate) and 15 weeks TMEFF2/TRAMP and TRAMP siblings were 
selected for analysis of integrin expression. For this purpose, after euthanasia, the prostates were 
dissected and protein lysates from the anterior, ventral and dorsolateral lobes were prepared and 
analyzed for the expression of αv, β3 and β1 integrin subunits. At least the β1 integrin has been 
shown to be upregulated in the TRAMP mouse (Goel et al. 2005). As shown in Figure 21B, 
expression of TMEFF2 in the TRAMP mouse significantly reduced expression of the αv, β1 and 
β3 integrins indicating that expression of TMEFF2 reduces integrin expression in vivo. We did 
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Figure 21. TMEFF2 modulates the abundance of αv, β1 and β3 integrins in cell lines and in 
mouse prostates. A) Total lysates of the indicated cells lines were subjected to 
immunoblotting with antibodies against the integrins as shown. Note that TMEFF2 did not 
promote changes in α5 integrin levels and that 22Rv1 cells do not express β3 integrin. B) 
Tissue lysates from the anterior (A), ventral (V) or dorsolateral (DL) lobes of the mouse 
prostate were subjected to immunoblotting with antibodies against the specified integrins. 
Arrows indicate the sizes of the individual integrin subunits observed in cell lines. Additional 
bands may represent precursor proteins, which are also decreased by TMEFF2. β-tubulin 
(TUBB) or ribosomal protein S6 (RPS6) were used as a loading controls. Numbers under the 
western blots are the densitometry quantifications of the arrow-pointed bands normalized to 
the loading control using ImageJ. Note that the complexity of the banding pattern for the β3 
integrin in mouse prostate lobes did not allow quantification; however, the decrease in the 
abundance as a result of TMEFF2 expression is clear. 
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Figure 22. Expression of TMEFF2 and large T antigen in the TRAMP/TMEFF2 and TRAMP 
animals. A) Western blot of the ventral (V) and dorsolateral (DL) lobes from the TRAMP and 
TRAMP/TMEFF2 transgenic animals demonstrating the presence of TMEFF2 only in the 
TRAMP/TMEFF2 mice and large T antigen in the TRAMP and TRAMP/TMEFF2 transgenic 
mice (arrow). B) The lower bands with the large T antigen antibody are contaminating bands 
since they also appear in the lobes of wild-type (C57BL/6) non-transgenic siblings (asterisks). 
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not observe changes in the level of the α5 integrin subunit, as it was the case in the prostate cell 
lines tested. 
 
Discussion 
    Cell migration is an essential step in embryonic development as well as in the metastatic 
process during cancer progression and it is usually associated with decreased survival rates and 
limited therapeutic options. While the metastatic process is not clearly understood, increased 
ability to migrate on extracellular matrix (ECM) substrates correlates with increased metastasis. 
Here we present data that indicate that TMEFF2, a transmembrane protein with limited 
expression to embryo and adult brain and prostate, plays a role in cellular adhesion and migration 
by modulating activation of the small GTPase RHOA, and/or integrin expression.   
    In this chapter we demonstrated that expression of TMEFF2 in prostate cancer cells, or in 
prostate lobes of a TRAMP/TMEFF2 transgenic mouse, significantly reduced the expression of 
at least three integrin subunits, αv, β3 and β1. In agreement with this, we observe that TMEFF2 
inhibits prostate cancer cell migration in vitronectin; αvβ3 is the major receptor for vitronectin. 
Importantly, in vitro and in vivo experiments have demonstrated that expression of αvβ3 integrin 
plays an essential role in the metastasis of prostate cancer to bone, where more than 80% of the 
advanced prostate cancers metastasize (Shah et al. 2004). The αvβ3 integrin plays numerous 
roles in prostate cancer metastasis not only by modulating engraftment and survival after bone 
colonization but also, due to the osteoclastic activity of the integrin, allowing bone resorption 
and the metastatic growth of the tumor in the bone (McCabe et al. 2007). Similar results have 
been observed in breast cancer where expression of αvβ3 in a mammary carcinoma line that 
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metastasizes to the lung, but not to bone, was sufficient to promote its spontaneous metastasis to 
bone (Sloan et al. 2006; Schneider et al. 2011). Moreover, in pancreatic cancer an additional 
ligand-independent role for αvβ3 has been described promoting anchorage-independent growth 
in a manner that is therefore also independent of tumor cell adhesion or the activation of FAK 
(Desgrosellier et al. 2009). Expression of αvβ3 has also been associated with metastasis to lungs 
(Duan et al. 2004). Interestingly, preliminary data from our laboratory indicates that formation of 
metastasis to lungs is reduced in the double TRAMP/TMEFF2 transgenic when compared with 
the TRAMP mice (not shown), suggesting that TMEFF2 inhibits metastasis by affecting integrin 
expression. Although the effect was less pronounced, the results presented here indicated that 
expression of TMEFF2 was also able to significantly inhibit attachment/migration to laminin. 
This result was expected since TMEFF2 affects expression of the β1 integrin, and at least four of 
the β1 containing integrins bind to laminin (Hynes 2002; Mecham 1991). In addition, β1 
integrins have been shown to play a role in prostate cancer metastasis (Lee et al. 2013). Laminins 
and the integrin-laminin receptors α6β1 and α6β4 are expressed in normal prostate glands, while 
only the laminin binding receptors α3β1 and α6β1 are expressed in prostate cancer. These 
changes in laminin receptors together with modifications in the laminins during prostate cancer 
progression allow migration of the epithelial cells during prostate cancer progression (Sroka et 
al. 2010). The function of integrin-laminin receptors in prostate cancer metastasis is especially 
relevant since laminins are very abundant in the peripheral nervous system and play an essential 
role in perineural invasion, a process that contributes to prostate cancer metastasis (Sroka et al. 
2010; Liebig et al. 2009). Interestingly, it has been reported that β1 integrin deletion in a 
TRAMP mouse increases prostate epithelial cell differentiation and more aggressive tumors 
while having no effect on metastases occurrence, as determined by visual inspection (Moran-
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Jones et al. 2012). Conversely, in our TRAMP/TMEFF2 transgenic animals, in which expression 
of β1 and other integrins is reduced, we do not observe changes in the latency or grade of the 
tumors but in the occurrence and number of metastasis (Overcash and Ruiz-Echevarria, 
unpublished observations). It is possible that this reflects differences in the balance of integrin 
heterodimer formation. 
    Finally, in this chapter we have demonstrated that expression of TMEFF2 decreased RHOA 
activation and stress fiber formation and this effect also depended on the presence of an intact 
cytoplasmic domain in TMEFF2. Based on a predicted homology of this domain with G protein-
coupled receptors (GPCR), we had initially envisioned that TMEFF2 could be modulating 
RHOA activation by, for example, restricting the function of GPCRs that are involved in 
Gα12/13 or Gαq activation which induce RHO (Dutt et al. 2002), or by promoting the activity of 
the RHO inhibitory Gαz signaling (Dutt et al. 2004; Mei et al. 2011). Although the ability of 
TMEFF2 to modulate any of the G protein α subunit types (Gαs, Gαi/o, Gαq/11, Gα12/13) has 
not been reported and we failed to observe changes in cAMP levels in response to TMEFF2 (not 
shown), an antibody targeting the follistatin domain of TMEFF1 increased cAMP levels in 
hematopoietic cells, suggesting TMEFF1 inhibits cAMP formation (Penning et al. 2006). At this 
point, TMEFF2 may have two independent mechanisms, i.e. independently regulating RHOA 
activation and integrin expression, to control migration. It is also possible that, TMEFF2 may 
downregulate integrin expression through suppression of RHOA activation. Several studies have 
provided evidence that changes in components of the Gα12/13-RHO-SRF pathway lead to 
changes in integrin expression (Brandt et al. 2009; Kong et al. 2010; Leitner et al. 2011; 
Reymond et al. 2012). While our preliminary data indicate RHOA inactivation does not seem to 
affect integrin expression (Figure 23), we have not formally ruled out this possibility. 
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Figure 23. Inhibiting RHOA activity does not decrease integrin expression. RWPE2 cells 
were treated with 2 μg/ml CT04 or control medium overnight and total lysates were subjected 
to immunoblotting analysis with antibodies against the specified integrins. β-tubulin (TUBB) 
and β-actin (ACTB) were used as loading controls. 
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Alternatively, the fact that integrins, either by engaging SRC tyrosine kinases or crosstalk with 
growth factor receptor signaling, can control the activation of RHO GTPases, suggests a 
mechanism in which TMEFF2 by controlling integrin expression may also control RHOA 
activation and therefore affect cell spreading and migration. It is known that by regulating the 
balance between RAC1-mediated membrane protrusion and RHOA-mediated contractility, 
integrins control the actin-driven processes involved in cell adhesion and spreading and therefore 
cell movement and migration (Vicente-Manzanares et al. 2009; Huveneers and Danen 2009).  
In summary, these results demonstrate that TMEFF2 negatively regulates cell adhesion and 
migration to the ECM by affecting integrin expression and RHOA activation, and suggest a 
potentially important role for TMEFF2 as a metastasis suppressor. 
 
 
 
 
 
 
 
 
 
CHAPTER FIVE: TMEFF2 Modulates the AKT and ERK Signaling Pathways
3
 
Introduction     
    Prostate cancer is the most commonly diagnosed non-cutaneous cancer and the second leading 
cause of cancer death in men (Siegel et al. 2013). Despite recent advances in treatment of 
localized prostate cancer, effective therapies for the treatment of the advanced form of the 
disease are limited. The most common being disruption of androgen receptor (AR) signaling via 
hormone deprivation therapy, which although initially effective, ultimately leads to castration-
resistant prostate cancer (CRPC), a highly lethal form of the disease (Karantanos et al. 2013). 
    Essential to the development of new therapies for prostate cancer is the understanding of the 
signaling pathways involved in the disease and the impact that these pathways have on each 
other during disease progression. The PTEN and MAPK pathways are often deregulated during 
prostate cancer progression leading to aberrant activation of the AKT and ERK kinase activity as 
well as their downstream effectors (Kinkade et al. 2008; Grant 2008). Activation of the AKT 
signaling pathway promotes cell survival by inhibiting apoptosis while activation of ERK 
increases cell proliferation and both pathways may function together to promote tumorigenesis 
(McCubrey et al. 2006). In fact, these pathways are known to regulate each other and co-regulate 
downstream functions (Mendoza et al. 2011; Moelling et al. 2002). Interestingly, although in 
some tumors phospho-ERK levels are very high (Bartholomeusz et al. 2012; Gee et al. 2001; 
Kress et al. 2010), it has been reported that advanced prostate cancer correlates with low 
phospho-ERK and high AKT levels (Malik et al. 2002), suggesting that the cross-talk between 
both pathways occurs during tumor progression. 
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    TMEFF2 is a single pass type I transmembrane protein expressed in the embryo (Uchida et al. 
1999; Heanue and Pachnis 2006) and selectively in the adult brain and prostate (Afar et al. 2004; 
Gery et al. 2002; Glynne-Jones et al. 2001). TMEFF2 contains several potential biologically 
important features that suggest a role in signaling (Uchida et al. 1999; Horie et al. 2000; Glynne-
Jones et al. 2001). The extracellular (ecto-) domain, which is cleaved from the membrane in an 
ADAM 17/γ-secretase dependent fashion (Ali and Knaüper 2007; Lin et al. 2003), consists of 
two follistatin modules and an EGF-like domain. The transmembrane domain and short 
cytoplasmic tail have features that resemble a potential G protein-coupled receptor (Uchida et al. 
1999). 
    TMEFF2 is upregulated in a significant fraction of primary and metastatic prostate tumors 
suggesting a role in this disease (Afar et al. 2004; Glynne-Jones et al. 2001; Zhao et al. 2005). 
The full-length TMEFF2 protein functions as a tumor suppressor by inhibiting migration and 
invasion of prostate epithelial and prostate cancer cells (Chen et al. 2011; Green et al. 2013) and 
by modulating apoptosis and growth of HEK293T cells (Chen et al. 2011), prostate cancer cells 
(Gery et al. 2002) and colorectal cancer cells as examined in an anchorage independent growth 
assay and a xenograft model (Elahi et al. 2008). In contrast, a recombinant form of the TMEFF2 
ectodomain promotes cellular proliferation of HEK293 cells and some type of neurons (Ali and 
Knaüper 2007; Horie et al. 2000). In addition, pharmacological inhibition of TMEFF2 shedding 
from the membrane or TMEFF2 siRNA knockdown reduces cell proliferation of the LNCaP 
prostate cancer cell line (Ali and Knaüper 2007). In support of the proliferative role of the 
ectodomain, we have demonstrated that ectodomain-containing conditioned medium from cells 
expressing the TMEFF2 protein promotes growth of prostate and HEK293T cells (Chen et al. 
2011). 
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    At the molecular level, recombinant TMEFF2 ectodomain has been shown to modulate ERK 
activation by promoting phosphorylation of erbB-4 and ERK1/2 and to interfere with platelet 
derived growth factor (PDGF) receptor signaling by binding and sequestering PDGF-AA from 
binding and signaling through its receptor (Uchida et al. 1999; Ali and Knaüper 2007; Lin et al. 
2011). The full-length TMEFF2 protein also interacts with PDGF-AA (Lin et al. 2011), and with 
sarcosine-dehydrogenase (SARDH), the enzyme that catalyzes sarcosine conversion to glycine 
(Chen et al. 2011). The TMEFF2-SARDH interaction modulates sarcosine levels and one carbon 
metabolism leading to changes in cellular invasion, possibly due to changes in the methylation 
potential of the cell (Green et al. 2013). In colon cancer cell lines, TMEFF2 overexpression leads 
to STAT1 upregulation and this appears to be required for the TMEFF2-mediated growth 
suppression effect (Elahi et al. 2008). 
The limited tissue distribution of TMEFF2, mainly expressed in brain and prostate (Afar et al. 
2004; Glynne-Jones et al. 2001; Zhao et al. 2005), has drawn attention as a possible tool for 
conjugated antibody therapies. In addition, the occurrence of secreted forms of TMEFF2 (shed 
and spliced forms) suggests a possible role as a biomarker. The potential therapeutic use of 
TMEFF2 stresses the need for understanding the molecular mechanism of action. Here we 
explore the effect of TMEFF2 full-length and the ectodomain in the ERK and AKT signaling 
pathways. Our results indicate that these two different forms of the protein differentially regulate 
these pathways to either promote growth or to function as a tumor suppressor. 
 
Results 
The full-length TMEFF2 promotes ERK phosphorylation in response to epidermal growth factor 
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Expression of the full-length, membrane-bound TMEFF2 inhibits growth, invasion and 
migration of HEK293T cells and several prostate epithelial and prostate cancer cell lines (Chen 
et al. 2011; Green et al. 2013; Gery et al. 2002) indicating a tumor suppressor role for this 
protein. To further gain insight in the signaling pathways involved in TMEFF2 function, we 
analyzed the effect of the full-length TMEFF2 on RAS/RAF/MEK/ERK, one of the main 
pathways involved in Prostate cancer progression. Of note, a recombinant form of the TMEFF2 
ectodomain has been shown to promote activation of several components of the EGF 
receptor/MEK/ERK signaling pathway, including ERK1/2 phosphorylation (Ali and Knaüper 
2007). Prostate epithelial RWPE1 cells that are induced to express full-length TMEFF2 
(FL_TMEFF2) in response to addiction of doxycycline, along with control cells transfected with 
the empty vector were used in these experiments. In addition, we created a deletion mutant, 
TMEFF2_ΔGA, lacking 13 consecutive basic-rich amino acids in the cytoplasmic domain of the 
protein, to examine its potential role in signaling. As shown in Figure 24A, expression of either 
the FL_TMEFF2 or the TMEFF2_ΔGA did not affect ERK phosphorylation when grown under 
normal conditions (compared to cells expressing the empty vector). However, stimulation with 
EGF, a main EGFR/MEK/ERK activator, of cell cultures growing in KSF basal medium resulted 
in an increase in ERK phosphorylation in RWPE1 cells expressing full-length TMEFF2 as 
compared to cells expressing the empty vector or cells left untreated (Figure 24B). Interestingly, 
deleting the 13 basic-rich amino acids in the cytoplasmic domain (TMEFF2_ΔGA) prevented 
TMEFF2 from promoting ERK activation suggesting that losing this region of the protein affects 
its signaling ability. These results indicate that in RWPE1 prostate epithelial cells, the TMEFF2 
full-length protein promotes ERK phosphorylation in response to EGF and that it requires a 
functional cytoplasmic domain for this effect. 
97 
 
 
 
Figure 24. TMEFF2 promotes ERK1/2 phosphorylation in response to EGF. A) RWPE1 cells 
inducibly expressing FL_TMEFF2, TMEFF2_ΔGA, or the empty vector control were 
growing in complete K-SFM, lysed, and whole cell lysates were subjected to immunoblotting 
with anti-p-ERK1/2, anti-ERK1/2, and anti-β-tubulin (TUBB) antibodies. B) RWPE1 cells 
inducibly expressing FL_TMEFF2, TMEFF2_ΔGA, or the empty vector control were 
growing in basal K-SFM for 3 h and then stimulated with 10 ng/ml of EGF for 10 min. Whole 
cell lysates were then subjected to immunoblotting with anti-p-ERK1/2 and anti-β-tubulin 
antibodies. Representative examples of at least two independent experiments showing similar 
results are shown. 
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PDGF-AA induces sustained phosphorylation of ERK in cells expressing TMEFF2 
As stimulation of PDGF receptors activates the RAS/RAF/MEK/ERK and the AKT/PI3K 
pathways in numerous cells and PDGF-AA has been shown to interact with TMEFF2 (Lin et al. 
2011), we tested the effect of TMEFF2 on ERK and AKT activation using RWPE1 cells 
stimulated with PDGF-AA. RWPE1 cells are known to express the PDGFα and β receptors (Park 
et al. 2011). First, we determined that ERK phosphorylation reaches a limit at a concentration of 
25 ng/ml of PDGF-AA in the medium since increasing concentrations did not result in increased 
ERK phosphorylation (Figure 25A), and established a concentration of 50 ng/ml PDGF-AA in 
subsequent experiments. The addition of PDGF-AA to RWPE1 cells growing in basal K-SFM 
without supplements led to an early and transient phosphorylation of AKT which peaked within 
10 minutes and returned to baseline within an hour (Figure 25B). Increased phosphorylation of 
ERK was not apparent until 1 hour after the stimulation and was highest at the last time point, 
obtained 4 hours after PDGF-AA addition (Figure 25B; of note, it is possible that it is further 
increased). Therefore, these two signaling pathways do not seem to overlap in cells treated with 
PDGF-AA. Similar to the results observed with EGF stimulation, overexpression of TMEFF2, 
while having no significant effect on AKT phosphorylation, promoted an early and robust 
induction of ERK phosphorylation that was apparent 10 minutes after the addition of PDGF-AA 
to the culture and increased progressively throughout the duration of the experiment (up to 4 
hours; Figure 25C). In addition, overexpression of the TMEFF2_ΔGA mutant protein nearly 
completely reversed the effect on ERK phosphorylation to the level observed with the empty 
vector-expressing RWPE1 cells suggesting that the presence of the cytoplasmic tail is required 
for the effect of TMEFF2 on ERK phosphorylation in response to PDGF-AA (Figure 25D). 
RWPE1 cells expressing the ectodomain protein (TMEFF2_ECTO), did not demonstrate an 
99 
 
 
 
 
 
 
100 
 
Figure 25. PDGF-AA induces sustained phosphorylation of ERK in cells expressing 
TMEFF2. A) RWPE1 cells were transferred to basal K-SFM for 30 min and then treated with 
various concentrations of PDGF-AA or 50 ng/ml of EGF. Whole cell lysates were then 
subjected to immunoblotting with anti-p-ERK1/2 antibody. B) RWPE1 cells were transferred 
to basal K-SFM for 30 min and then treated with 50 ng/ml of PDGF-AA for indicated times. 
Whole cell lysates were then subjected to immunoblotting with anti-p-ERK1/2, anti-p-AKT 
S473, and anti-β-tubulin antibodies. C,D,E) RWPE1 cells inducibly expressing TMEFF2-
ECTO, FL_TMEFF2, TMEFF2_ΔGA, or the empty vector control were transferred to basal 
K-SFM for 30 min and then stimulated with 50 ng/ml of PDGF-AA for indicated times. 
Whole cell lysates were then subjected to immunoblotting with anti-p-ERK1/2, anti-p-AKT 
S473, and anti-β-tubulin antibodies. Representative examples of at least two independent 
experiments showing similar results are shown. 
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increase in ERK phosphorylation in response to PDGF-AA (Figure 25E). This result was 
expected since purified recombinant soluble TMEFF2 ectodomain has been shown to interact 
with PDGF-AA inhibiting its interaction with the PDGF receptor (Lin et al. 2011). Since the 
TMEFF2 ectodomain expressed in our cells lacks the transmembrane domain and is secreted into 
the medium, we hypothesized that it sequesters PDGF-AA from its interaction with the receptor 
inhibiting its signaling. 
The ectodomain region of TMEFF2 inhibits ERK phosphorylation 
The results presented above suggest that the TMEFF2 ectodomain may inhibit ERK 
phosphorylation in response to PDGF-AA. To further investigate the role of the ectodomain in 
ERK phosphorylation, we determined whether ectodomain-containing conditioned medium 
could directly modulate the activity of ERK in RWPE1 cells. Ectodomain-containing 
conditioned medium was collected from exponentially growing HEK293T cell cultures 
overexpressing the TMEFF2 ectodomain. The presence of the ectodomain in the conditioned 
medium was analyzed by western blot using antibodies against the TMEFF2 ectodomain (Figure 
26A). The collected conditioned medium was used to replace the growth medium of the RWPE1 
cells, and the ERK1/2 phosphorylation was examined by western blot analysis using a rabbit 
polyclonal antibody. Addition of increasing amounts of conditioned medium from the TMEFF2 
ectodomain-overexpressing cultures resulted in a stepwise decrease in ERK phosphorylation in 
RWPE1 cells (Figure 26B, left lanes). This effect was partially reversed by the addition of a 
monoclonal antibody to TMEFF2 (Figure 26B, central lanes) but not by a polyclonal antibody 
against this protein (Figure 26B, right lanes). Immunoglobulin G (IgG) was used as a control 
(Figure 26B, left lanes). The differential effect of the two antibodies is likely due to different 
binding specificities. These results indicate that inhibition of ERK phosphorylation is, at least in 
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Figure 26. Conditioned medium from HEK293T cells expressing the ectodomain construct 
contains secreted TMEFF2 ectodomain and inhibits ERK phosphorylation. A) Exponentially 
growing HEK293T cells transfected with the TMEFF2 ectodomain construct or the empty 
vector as a control, were grown under serum starvation conditions for 24 h. A sample of the 
conditioned medium was then collected, concentrated and subjected to immunoblotting with 
an anti-TMEFF2 antibody targeting the ectodomain region of the protein. The presence of 
TMEFF2 ectodomain in the conditioned medium is indicated by the arrow. B) RWPE1 cells 
were transferred to basal K-SFM for 30 min before the medium was replaced with different 
amounts of TMEFF2 ectodomain-containing medium. Two different TMEFF2 antibodies 
were added to the conditioned medium (CM) to neutralize the TMEFF2 ectodomain. IgG was 
used as a control. Whole cell lysates were prepared and subjected to immunoblotting with 
anti-p-ERK1/2 antibody. Representative examples of at least two independent experiments 
showing similar results are shown. 
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part, due to the presence of the TMEFF2 ectodomain in the conditioned medium. The presence 
of IgG did not affect the TMEFF2 ectodomain mediated inhibition of ERK phosphorylation, as a 
similar dose-dependent inhibition was observed with increasing amounts of ectodomain-
containing conditioned medium in the absence of IgG (Figure 27A). Finally, using a fixed 
amount of conditioned medium, we compared the effect of ectodomain-containing conditioned 
medium on ERK phosphorylation overtime. Conditioned medium collected from vector 
transfected HEK293T cultures was used as a control. The results (Figure 27B) show that 
although ERK phosphorylation occurred with similar kinetics in cells treated with TMEFF2 
ectodomain-containing or empty vector control conditioned medium, the extent of ERK 
phosphorylation was decreased when RWPE1 cells were treated with TMEFF2 ectodomain-
containing conditioned medium. These results indicate that in RWPE1 prostate epithelial cells, 
the effects of TMEFF2 ectodomain and the full-length protein on ERK activation are reversed 
and this could potentially explain the opposing functional roles of these two forms of the 
TMEFF2 protein. 
TMEFF2 ectodomain promotes AKT activation 
The results presented above were unexpected since previous reports indicate increased ERK 
phosphorylation in response to purified recombinant TMEFF2 ectodomain. Since the RAS-RAF-
MEK-ERK and the PI3K-AKT pathways are known to demonstrate crosstalk, impacting the 
outcome of the pathways (Mendoza et al. 2011), we analyzed whether treatment with 
ectodomain-containing conditioned medium was able to induce changes in AKT activation that 
could ultimately affect ERK phosphorylation. Following the same protocol as described above, 
conditioned medium collected from HEK293T cells transfected with the TMEFF2 full-length or 
the ectodomain constructs was used to replace the growth medium of cultures of RWPE1 cells, 
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Figure 27. TMEFF2 ectodomain inhibits ERK1/2 phosphorylation in a dose-dependent 
manner but does not affect the activation kinetics. A) RWPE1 cells were transferred to basal 
K-SFM for 30 min before the medium was replaced with different amounts of ectodomain 
containing conditioned medium. Whole cell lysates were then subjected to immunoblotting 
with anti-p-ERK1/2 and anti-ERK1/2 antibodies. B) RWPE1 cells were transferred to basal 
K-SFM for 30 min before the medium was replaced with TMEFF2 ectodomain-containing 
conditioned medium for indicated times. Whole cell lysates were prepared and subjected to 
immunoblotting with anti-p-ERK1/2 and anti-β-tubulin antibodies. Representative examples 
of at least two independent experiments showing similar results are shown. 
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and the phosphorylation of ERK and AKT was analyzed 30 minutes after the medium 
replacement. As a control, conditioned medium collected from vector transfected HEK293T 
cultures was used (Figure 28). As described above, ectodomain-containing conditioned medium -
- from the full-length or ectodomain expressing cells -- decreased ERK phosphorylation. 
However, AKT phosphorylation was increased under these conditions, indicating an inverse 
correlation between ERK and AKT phosphorylation in response to the ectodomain in RWPE1 
cells (Figure 28). These results are in agreement with data indicating that a proliferative stimulus 
can modulate the ERK pathway to prevent growth arrest by ERK-dependent upregulation of cell 
cycle inhibitors (Moelling et al. 2002; Reusch et al. 2001) and with the fact that AKT can play a 
positive or negative role in the regulation of ERK depending on several variables, such as growth 
condition, stage of differentiation, etc (Mendoza et al. 2011). Although TMEFF1, the only 
TMEFF2 homolog, has been shown to modulate Nodal signaling (Harms and Chang 2003; 
Chang et al. 2003), we did not observe differences in SMAD2 phosphorylation in response to 
TMEFF2 ectodomain conditioned medium (Figure 28). All together these results indicate that 
different forms of TMEFF2, full-length or ectodomain, distinctly modulate the ERK and/or AKT 
pathways to exert different roles. 
 
Discussion 
    In this study we report that TMEFF2, a protein with a role in prostate cancer, modulates the 
activity of the RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways. Interestingly, while the 
full-length TMEFF2 protein promotes a strong ERK activation in response to growth factors but 
has no effect in AKT activation, a shed form of the protein, the ectodomain, inhibits ERK 
phosphorylation and promotes AKT activation. These opposing effects on ERK and AKT 
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Figure 28. TMEFF2 ectodomain promotes AKT phosphorylation and that inversely correlates 
with its effect on ERK phosphorylation. RWPE1 cells transferred to basal K-SFM for 4 h 
before the medium was replaced with ectodomain-containing conditioned medium obtained 
from HEK293T cells that express the ectodomain (ECTO), the full-length (FL) or the empty 
vector constructs. Whole cell lysates were prepared and subjected to immunoblotting with 
anti-p-ERK1/2, anti-ERK1/2, anti-p-AKT S473, anti-AKT, and anti-p-SMAD2 antibodies 
(left). Densitometry quantification of the results is shown (right).  
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activation reflect a distinct role and effector site for each isoform; the full-length functions as a 
tumor suppressor (Gery et al. 2002; Chen et al. 2011; Green et al. 2013; Elahi et al. 2008) from 
the membrane or from inside the cell after internalization (Afar et al. 2004; Boswell et al. 2012; 
Zhao et al. 2005), while the shed ectodomain promotes growth (Ali and Knaüper 2007; Chen et 
al. 2011; Horie et al. 2000) and functions from outside the cell, potentially as a ligand. 
The RAS/RAF/MEK/ERK and the PI3K/AKT signaling cascades play critical roles in control 
of cell survival, proliferation, differentiation, metabolism and cell motility and they are 
frequently activated during oncogenesis (Kinkade et al. 2008; Grant 2008; McCubrey et al. 
2006). Accumulating evidence indicates that in addition to their independent roles, these 
pathways regulate each other (crosstalk) during normal growth and oncogenesis. For example, 
activated AKT inhibits ERK activation by phosphorylating and inhibiting RAF, upstream of 
ERK (Mendoza et al. 2011; Zimmermann and Moelling 1999), and by facilitating EGFR 
degradation to inhibit signaling to its downstream pathways (Er et al. 2013). This cross inhibition 
by activated AKT is especially relevant to prostate cancer since deregulated expression and/or 
mutations of the PTEN tumor suppressor gene, which lead to activation of AKT, occur with very 
high frequency in prostate cancer (Chow and Baker 2006). In fact, it has been reported that in 
advanced prostate cancer there are high levels of activated AKT, and this is inversely correlated 
with the level of ERK activation (low). In benign lesions, or low grade prostate cancer this 
relationship is reversed, demonstrating high phospho-ERK and low phospho-AKT levels (Malik 
et al. 2002; Graff et al. 2000; Kreisberg et al. 2004). These observations agree with a recently 
identified tumor suppressor role for ERK. High levels of ERK phosphorylation lead to an ERK-
dependent protein degradation process and senescence (Deschênes-Simard et al. 2013). 
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Our results are consistent with these observations. The tumor suppressor full-length TMEFF2 
protein promotes strong ERK phosphorylation and requires the cytoplasmic tail for this effect, 
while the growth-promoting ectodomain activates AKT and inhibits ERK phosphorylation. 
TMEFF2 is cleaved from the membrane by ADAM17/γ-secretase-dependent cleavage that can 
be induced by inflammatory cytokines, i.e. TNFα (Ali and Knaüper 2007; Lin et al. 2011; Chen 
et al. 2011), which are characteristics of the tumor microenvironment. Therefore, regulated 
TMEFF2 cleavage can modulate the function of TMEFF2, as it plays a role during tumor 
establishment and progression. Based on the results presented here, the functional switch from a 
tumor suppressor to a growth-promoting role could be mediated by the activation of the AKT 
pathway and subsequent silencing of the ERK-mediated tumor suppressor function. In addition, 
the distinct functions of the membrane-bound and soluble forms of TMEFF2 suggest that 
TMEFF2 may signal either as a ligand, a membrane bound receptor and/or as a co-receptor. 
Based on these results we propose a model (Figure 29) in which the different TMEFF2 forms 
distinctly modulate AKT and/or ERK signaling to exert different functions: (1) Full-length 
TMEFF2 acting as a receptor or co-receptor promotes ERK phosphorylation. (2) Shedding of 
TMEFF2 leads to ectodomain accumulation that can (3) function as a ligand to an unknown 
receptor to promote AKT activation and subsequent RAF inhibition leading to low ERK 
phosphorylation and (4) interact with growth factors (i.e. PDGF) to prevent interaction with their 
receptor and ERK activation. 
    The data in Figure 26 indicate that the effect of the ectodomain-containing conditioned 
medium on ERK phosphorylation is partly reversed by a TMEFF2 blocking antibody suggesting 
that, at least in part, the effect on ERK phosphorylation is directly mediated by the ectodomain. 
While the non-complete reversion of ERK phosphorylation could be due to failure of the 
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Figure 29. Model of the role of TMEFF2 in AKT and ERK activation. A) Full-length TMEFF2 
acting as a receptor (green bars) or co-receptor (grey and green) promotes ERK 
phosphorylation. B) Shedding of TMEFF2 leads to ectodomain accumulation (green circle) in 
the conditioned medium that can C) function as a ligand to an unknown receptor to promote 
AKT activation and subsequent RAF inhibition leading to low ERK phosphorylation and D) 
interact with growth factors (i.e. PDGF) to prevent interaction with their promoter and ERK 
activation. 
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antibody, a parallel explanation to the function of the TMEFF2 ectodomain, not depicted in our 
model (Figure 29), is that the cleaved TMEFF2 ectodomain may also have an indirect effect on 
ERK phosphorylation. In this role, expression/activity of the TMEFF2 ectodomain in HEK293T 
cells (utilized to collect the conditioned medium used in the experiments) would promote 
secretion of high levels of a factor (e.g. IGF) that can activate AKT in prostate epithelial RWPE1 
cells. Whether direct or indirect, the ectodomain is functioning from the outside of the cell -- 
potentially as a ligand -- and therefore its effect may be cell specific depending on the repertoire 
of receptors present in the cell. In fact, several effects have been described for the ectodomain in 
different cell lines. Purified recombinant ectodomain, promotes growth of neurons (Horie et al. 
2000) and non-transformed HEK293 cells (Ali and Knaüper 2007) and phosphorylation of some 
of the components of the ERK signaling pathway – erbB-4 in MNK28 gastric cancer cells and 
ERK1/2 in HEK293 cells (Uchida et al. 1999; Ali and Knaüper 2007) and corticotroph cells 
(Labeur et al. 2010). Interestingly, in corticotroph cells, ERK activation has been reported to 
occur as a consequence of AKT inhibition (Labeur et al. 2010). In contrast, ectodomain 
containing conditioned medium, although it promotes growth of HEK293T and prostate 
epithelial RWPE1 cells (Chen et al. 2011), this effect, as demonstrated here, correlates with a 
decrease in ERK phosphorylation and an increase in AKT activation in prostate epithelial cells. 
Finally, using NR6 fibroblast, Lin et al. (2011) demonstrated that recombinant ectodomain binds 
to and competes with PDGF-AA from binding to its receptor, inhibiting PDGF-AA promoted 
growth.  
AKT and the androgen receptor (AR) have been shown to cooperate in cancer progression 
(Xin et al. 2006) and it has been suggested that AKT may directly phosphorylate AR inhibiting 
AR transactivation and blocking AR-induced apoptosis (Lin et al. 2001). Based on our results the 
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TMEFF2 ectodomain promotes AKT phosphorylation and thus negatively regulates AR 
activation, which in turn regulates TMEFF2 expression (Gery et al. 2002; Overcash et al. 2013), 
providing an additional link between AKT and TMEFF2 mediated by the AR. 
In conclusion, our results provide evidence of a role for TMEFF2 on AKT and ERK signaling 
pathways that may be relevant to prostate cancer tumorigenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SIX: Discussion 
The oncogenesis of prostate cancer and its progression are thought to occur due to an 
accumulation of mutations in genes related to cell growth, adhesion/migration, and death (Shen 
and Abate-Shen 2010). Because the molecular mechanisms leading to prostate cancer 
progression are poorly understood, searching for the responsible genes is essential for the 
development of novel therapies and disease prevention. In this study, we investigated the 
molecular mechanisms underlying a tumor suppressor of prostate cancer – TMEFF2. We 
uncovered an interaction between TMEFF2 and SARDH, and a correlation between the tumor 
suppressor activity of TMEFF2 and its ability to decrease cellular sarcosine levels as an outcome 
of the TMEFF2-SARDH interaction. With a particular focus on its inhibitory effect on cell 
migration and the knowledge that integrins play a central role in this process, we found that 
TMEFF2 suppresses the expression of several integrin subunits including αv, β1, and β3. 
Consistent with this finding, TMEFF2-expressing cells show defects in cell spreading on 
migration towards vitronectin, whose major receptor is integrin αvβ3, with a concomitant 
reduction in focal adhesion and stress fiber formation, and RHOA activation. Finally, we 
demonstrated that different forms of TMEFF2 differentially modulate ERK and AKT pathways 
and this may contribute to distinct cellular responses of proliferation or tumor suppression. While 
full-length TMEFF2 promotes ERK phosphorylation in response to growth factors EGF and 
PDGF-AA, the ectodomain activates AKT and inhibits ERK phosphorylation. 
At first, the tumor suppressor function of TMEFF2 seems hard to reconcile with the fact that it 
is overexpressed in prostate cancer. The molecular bases described in this study provide some 
plausible explanations. It is interesting to note that the effects that full-length TMEFF2 exerts on 
sarcosine concentration, integrin expression, RHOA activation, and ERK phosphorylation are all 
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dependent on the presence of the GA domain; deletion of the GA domain abolishes these effects. 
Further deletion of the transmembrane domain even has the opposite effect on ERK 
phosphorylation – the ectodomain inhibits ERK phosphorylation possibly due to activation of the 
AKT pathway. Accordingly, full-length and the ectodomain of TMEFF2 have opposing 
oncogenic properties. While the full-length TMEFF2 functions as a tumor suppressor (Chen et 
al. 2011; Green et al. 2013; Elahi et al. 2008; Gery et al. 2002), the ectodomain promotes growth 
and survival (Chen et al. 2011; Ali and Knaüper 2007; Horie et al. 2000). Under physiological 
conditions in vivo, the production of TMEFF2 ectodomain is the result of ADAM17/γ-secretase 
cleavage that can be induce by inflammatory cytokines, which is typical of tumor 
microenvironment. It is possible that the function of TMEFF2 changes during prostate cancer 
progression and is regulated by ectodomain shedding. For example, TMEFF2 expression 
increases as prostate cancer progresses, but the predominant form shifts from the full-length to 
the ectodomain by virtue of the inflammatory tumor microenvironment, therefore promoting 
tumor growth. Moreover, the existence of several alternative splice TMEFF2 isoforms, one of 
them (isoform 2; Figure 3) very similar to the TMEFF2_ΔGA mutant used in this study, further 
complicates the scenario. Alternative splicing of mRNA precursors is a neatly regulated gene 
expression mechanism that allows cells to create protein isoforms with differing or even 
opposing functions from a single gene. It is a ubiquitous phenomenon in normal cells and is 
often taken advantage of by cancer cells to promote their growth and survival. The function and 
expression of TMEFF2 alternative splice isoforms throughout prostate cancer progression are not 
known. Interestingly, although we did not observe any effect from the TMEFF2_ΔGA mutant on 
monolayer growth of RWPE1 or RWPE2 cells, it increased monolayer and anchorage-
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independent growth of HEK293T cells (Chen et al. 2013, submitted manuscript), suggesting this 
mutant can present a gain of function. 
In Chapter 3, we showed the tumor suppressor activity of TMEFF2 correlates with its ability to 
bind SARDH and reduce sarcosine levels. Recently proposed as a prostate cancer biomarker, 
sarcosine is a differential metabolite that is highly increased during prostate cancer progression 
(Sreekumar et al. 2009). The mere addition of exogenous sarcosine imparted an invasive 
phenotype to benign prostate epithelial cells (Chen et al. 2011; Sreekumar et al. 2009). It remains 
unclear how sarcosine promotes cell invasion, but sarcosine is involved in one-carbon 
metabolism essential for DNA synthesis, repair, and methylation. One-carbon metabolism is 
comprised of several connected metabolic pathways that promote the folate-mediated transfer of 
one-carbon units necessary for DNA synthesis and repair. Folate is also essential in its 5-methyl-
tetrahydrofolate (THF) form as a methyl donor in the remethylation of homocysteine to 
methionine, which is then converted to S-adenosyl methionine (SAM), the universal methyl 
donor (Fox and Stover 2008). Sarcosine participates in both the folate cycle and the methionine 
cycle (Figure 30): in the folate cycle, sarcosine contributes to the generation of 5,10-methylene-
THF by either donating a methyl group to THF and becoming glycine in a reaction catalyzed by 
SARDH, or being converted from dimethylglycine by dimethylglycine dehydrogenase 
(DMGDH); in the methionine cycle, excess SAM remethylates glycine into sarcosine in a 
reaction catalyzed by glycine N-methyltransferase (GNMT). This leads to our hypothesis that by 
modulating sarcosine levels, TMEFF2, in a bigger picture, perturbs one-carbon metabolism, thus 
affecting tumor progression. In fact, in our subsequent studies, we demonstrated that sarcosine 
metabolism, not merely its concentration, and thus one-carbon availability are responsible for the 
changes in cell invasion mediated by the function of TMEFF2 and SARDH (Green et al. 2013). 
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Figure 30. Sarcosine and one-carbon metabolism. One-carbon metabolism consists of two 
interconnected cycles – the folate cycle and the methionine cycle. Sarcosine is involved in the 
formation of 5,10-methylene-THF in the folate cycle and the methylation reaction from S-
adenosyl methionine to S-adenosyl homocysteine in the methionine cycle. THF, 
tetrahydrofolate. Numbers for enzymes: (1) dyhydrofolate reductase; (2) dihydrofolate 
reductase; (3) serine hydroxymethyl transferase; (4) thymidylate synthase; (5) 
dimethylglycine dehydrogenase; (6) sarcosine dehydrogenase; (7) glycine cleavage system; 
(8) methylenetetrahydrofolate reductase; (9) C-1-tetrahydrofolate synthase; (10) C-1-
tetrahydrofolate synthase; (11) methionine synthase; (12) methionine adenosyltransferase; 
(13) glycine N-methyltransferase; (14) methyltransferases; (15) S-adenosyl homocysteine 
hydrolase; (16) betaine hydroxymethyltransferase; (17) choline oxidase; (18) cystathionine β-
synthase; (19) cystathionine γ-lyase.  
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    In Chapter 4, we presented data indicating an important role of TMEFF2 in regulating prostate 
cancer cell migration that involves integrin expression and RHOA activation.  The data also 
support the involvement of sarcosine metabolism in the migratory behavior of the cells and a link 
to integrin expression and RHOA activation. While expression of the full-length TMEFF2 
affects sarcosine metabolism and blocks cellular adhesion and migration, TMEFF2_ΔGA does 
not affect sarcosine levels and does not inhibit adhesion and migration of prostate cancer cells. 
Moreover, the ability to inhibit adhesion and migration correlates with the ability of TMEFF2 to 
reduce integrin expression and RHOA activation, which is lost in the TMEFF2_ΔGA mutant. 
Based on these results, and since sarcosine and one-carbon metabolism are responsible for the 
methylation reactions, it is reasonable to speculate that TMEFF2, by affecting one-carbon 
metabolism, may affect expression of integrin genes epigenetically, via methylation. Although 
we have not directly tested this hypothesis, several studies have described epigenetic alterations 
– DNA methylation and histone modifications – that affect integrin expression during tumor 
progression (Park et al. 2004; Uhm et al. 2010; Yang et al. 2009). Similarly, since methylation of 
RHOA impacts its activation (Cushman and Casey 2011), it is also possible that TMEFF2 
inhibits RHOA activation by modulating its methylation status. 
In Chapter 5 we demonstrated that different forms of TMEFF2 distinctly affect AKT and ERK 
activation and this may contribute to a different cellular response of either proliferation or tumor 
suppression. While full-length TMEFF2 activates ERK but has no effect on AKT 
phosphorylation, the ectodomain inhibits ERK phosphorylation concomitantly with AKT 
activation. Since integrins have been shown to induce AKT (Velling et al. 2008; Zeller et al. 
2010) and ERK phosphorylation (Lai et al. 2001; Stupack and Cheresh 2002), it is possible that 
TMEFF2 modulates MAPK and PI3K pathways via its effects on integrin expression. 
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Alternatively, TMEFF2 may modulate the crosstalk between integrins and growth factor 
receptors to control these responses. In this respect, it is known that signaling through receptor 
tyrosine kinases (RTKs) is not only regulated by growth factors but also by functional 
collaboration with integrins, and integrins may activate RTKs in the absence of growth factors 
(Eliceiri 2001; Ross 2004; Streuli and Akhtar 2009). For example, integrins αvβ3 or α5β1 have 
been shown to influence and potentiate PDGF receptor β signaling in cell migration (Schneller et 
al. 1997; Woodard et al. 1998; Veevers-Lowe et al. 2011). Interestingly, TMEFF2 has been 
shown to interact with PDGF-AA and to interfere with PDGF receptor signaling (Lin et al. 
2011). It is possible that by affecting integrin expression and PDGF interaction with its receptor, 
TMEFF2 can modulate the integrin - RTK crosstalk and migration. This mechanism could 
potentially be important regarding prostate cancer metastasis to bone. Although interaction of 
TMEFF2 with PDGF-D has not been documented, PDGF-D is expressed primarily by prostate 
cancer cells in the bone, and inhibition of PDGF receptor autophosporylation reduces tumor 
formation and metastasis in mice (Uehara et al. 2003). TMEFF2 could inhibit migration and 
therefore metastasis by affecting PDGF-dependent and PDGF-independent/integrin-dependent 
signaling. 
    Finally, the role of TMEFF2 in one-carbon metabolism may suggest an additional link to AKT 
and ERK activation. By modulating one-carbon metabolism, TMEFF2 has the potential to 
impact homocysteine levels, which have been reported to modulate the AKT and ERK signaling 
pathways (Lee et al. 2012). 
    In summary, our studies added substantial knowledge about the biological function of 
TMEFF2 and its molecular mechanisms. The full-length TMEFF2 serves as a tumor suppressor 
(Figure 31), possibly through (1) modulating sarcosine metabolism and therefore one-carbon 
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Figure 31. Proposed model of TMEFF2 action in prostate cancer. As a tumor suppressor, full-
length TMEFF2 expression leads to inhibition of cell migration, invasion, and cancer 
metastasis. In this dissertation, we described at least three underlying molecular mechanisms. 
First, TMEFF2 reduces Rho activity, leading to decreased migration. Second, TMEFF2 
interacts with SARDH and reduces sarcosine levels, resulting in decreased migration. Third, 
TMEFF2 downregulates integrin levels and therefore reduces migration. Potential links 
between these three mechanisms are described in the text of Chapter 4 and this chapter. 
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metabolism, (2) inhibiting integrin expression, (3) inhibiting RHOA activation, and (4) 
promoting ERK phosphorylation, or a combination of those. Deletion of the GA domain 
abolishes all those effects, highlighting the importance of this domain in the function of 
TMEFF2. The ectodomain has a growth-promoting effect, consistent with its inability to reduce 
sarcosine levels and to promote ERK phosphorylation.  
  
REFERENCES 
Abate-Shen C and Shen MM. 2000. Molecular genetics of prostate cancer. Genes Dev 
14(19):2410-34. 
Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, 
Wong M, Evangelista F, et al. 2004. Preclinical validation of anti-TMEFF2-auristatin E-
conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 3(8):921-32. 
Ali N and Knauper V. 2007. Phorbol ester-induced shedding of the prostate cancer marker 
transmembrane protein with epidermal growth factor and two follistatin motifs 2 is mediated 
by the disintegrin and metalloproteinase-17. J Biol Chem 282(52):37378-88. 
Barbieri CE, Demichelis F, Rubin MA. 2012a. Molecular genetics of prostate cancer: Emerging 
appreciation of genetic complexity. Histopathology 60(1):187-98. 
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, 
Stojanov P, Van Allen E, Stransky N, et al. 2012b. Exome sequencing identifies recurrent 
SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685-9. 
Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, 
Hortobagyi GN. 2012. High ERK protein expression levels correlate with shorter survival in 
triple-negative breast cancer patients. Oncologist 17(6):766-74. 
Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997. Androgen responsive adult 
human prostatic epithelial cell lines immortalized by human papillomavirus 18. 
Carcinogenesis 18(6):1215-23. 
Belmokhtar CA, Hillion J, Segal-Bendirdjian E. 2001. Staurosporine induces apoptosis through 
both caspase-dependent and caspase-independent mechanisms. Oncogene 20(26):3354-62. 
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, 
Esgueva R, Pflueger D, Sougnez C, et al. 2011. The genomic complexity of primary human 
prostate cancer. Nature 470(7333):214-20. 
Bergeron F, Otto A, Blache P, Day R, Denoroy L, Brandsch R, Bataille D. 1998. Molecular 
cloning and tissue distribution of rat sarcosine dehydrogenase. Eur J Biochem 257(3):556-
61. 
Bianchi F, Dugheri S, Musci M, Bonacchi A, Salvadori E, Arcangeli G, Cupelli V, Lanciotti M, 
Masieri L, Serni S, et al. 2011. Fully automated solid-phase microextraction-fast gas 
chromatography-mass spectrometry method using a new ionic liquid column for high-
throughput analysis of sarcosine and N-ethylglycine in human urine and urinary sediments. 
Anal Chim Acta 707(1-2):197-203. 
121 
 
Boeri Erba E, Bergatto E, Cabodi S, Silengo L, Tarone G, Defilippi P, Jensen ON. 2005. 
Systematic analysis of the epidermal growth factor receptor by mass spectrometry reveals 
stimulation-dependent multisite phosphorylation. Mol Cell Proteomics 4(8):1107-21. 
Bohm L, Serafin AM, Fernandez P, Van der Watt G, Bouic PJ, Harvey J. 2012. Plasma sarcosine 
does not distinguish early and advanced stages of prostate cancer. S Afr Med J 102(8):677-
9. 
Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, 
Polakis P, et al. 2012. Differential effects of predosing on tumor and tissue uptake of an 
111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 53(9):1454-61. 
Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, 
Stainton S, Ulufatu S, et al. 2013. An integrated approach to identify normal tissue 
expression of targets for antibody-drug conjugates: Case study of TENB2. Br J Pharmacol 
168(2):445-57. 
Brandt DT, Baarlink C, Kitzing TM, Kremmer E, Ivaska J, Nollau P, Grosse R. 2009. SCAI acts 
as a suppressor of cancer cell invasion through the transcriptional control of beta1-integrin. 
Nat Cell Biol 11(5):557-68. 
Brucher BL, Geddert H, Langner C, Hofler H, Fink U, Siewert JR, Sarbia M. 2006. 
Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary 
adenocarcinomas of the small bowel. Int J Cancer 119(6):1298-302. 
Brugnera E, Haney L, Grimsley C, Lu M, Walk SF, Tosello-Trampont AC, Macara IG, Madhani 
H, Fink GR, Ravichandran KS. 2002. Unconventional rac-GEF activity is mediated through 
the Dock180-ELMO complex. Nat Cell Biol 4(8):574-82. 
Burridge K and Wennerberg K. 2004. Rho and rac take center stage. Cell 116(2):167-79. 
Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, 
Debruyne FM, Ru N, Isaacs WB. 1999. DD3: A new prostate-specific gene, highly 
overexpressed in prostate cancer. Cancer Res 59(23):5975-9. 
Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, Eckschlager T, Stiborova M, 
Kizek R, Adam V. 2013. Sarcosine as a potential prostate cancer biomarker--a review. Int J 
Mol Sci 14(7):13893-908. 
Chan PC, Chen SY, Chen CH, Chen HC. 2006. Crosstalk between hepatocyte growth factor and 
integrin signaling pathways. J Biomed Sci 13(2):215-23. 
Chang C, Eggen BJ, Weinstein DC, Brivanlou AH. 2003. Regulation of nodal and BMP 
signaling by tomoregulin-1 (X7365) through novel mechanisms. Dev Biol 255(1):1-11. 
122 
 
Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo 
X, et al. 2013. A gain-of-function mutation in DHT synthesis in castration-resistant prostate 
cancer. Cell 154(5):1074-84. 
Chattopadhyay N and Chatterjee A. 2001. Studies on the expression of alpha(v)beta3 integrin 
receptors in non-malignant and malignant human cervical tumor tissues. J Exp Clin Cancer 
Res 20(2):269-75. 
Chen TR, Wang P, Carroll LK, Zhang YJ, Han BX, Wang F. 2012. Generation and 
characterization of Tmeff2 mutant mice. Biochem Biophys Res Commun 425(2):189-94. 
Chen X and Ruiz-Echevarria MJ. 2013. TMEFF2 modulates the AKT and ERK signaling 
pathways. Int J Biochem Mol Biol 4(2):83-94. 
Chen X, Overcash R, Green T, Hoffman D, Asch AS, Ruiz-Echevarria MJ. 2011. The tumor 
suppressor activity of the transmembrane protein with epidermal growth factor and two 
follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol 
Chem 286(18):16091-100. 
Chow LM and Baker SJ. 2006. PTEN function in normal and neoplastic growth. Cancer Lett 
241(2):184-96. 
Colleselli D, Stenzl A, Schwentner C. 2010. Re: Florian jentzmik, carsten stephan, kurt miller, et 
al. sarcosine in urine after digital rectal examination fails as a marker in prostate cancer 
detection and identification of aggressive tumours. eur urol 2010;58:12-8. Eur Urol 
58(5):e51. 
Cooper CR, Chay CH, Pienta KJ. 2002. The role of alpha(v)beta(3) in prostate cancer 
progression. Neoplasia 4(3):191-4. 
Cooper CR, McLean L, Walsh M, Taylor J, Hayasaka S, Bhatia J, Pienta KJ. 2000. Preferential 
adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial 
cells as compared to extracellular matrix components in vitro. Clin Cancer Res 6(12):4839-
47. 
Cote JF and Vuori K. 2002. Identification of an evolutionarily conserved superfamily of 
DOCK180-related proteins with guanine nucleotide exchange activity. J Cell Sci 115(Pt 
24):4901-13. 
Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, 
Klocker H. 1993. Mutant androgen receptor detected in an advanced-stage prostatic 
carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7(12):1541-
50. 
Cushman I and Casey PJ. 2011. RHO methylation matters: A role for isoprenylcysteine 
carboxylmethyltransferase in cell migration and adhesion. Cell Adh Migr 5(1):11-5. 
123 
 
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman 
OB,Jr, Saad F, et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. 
N Engl J Med 364(21):1995-2005. 
Dehm SM, Regan KM, Schmidt LJ, Tindall DJ. 2007. Selective role of an NH2-terminal WxxLF 
motif for aberrant androgen receptor activation in androgen depletion independent prostate 
cancer cells. Cancer Res 67(20):10067-77. 
Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. 2008. Splicing of a novel 
androgen receptor exon generates a constitutively active androgen receptor that mediates 
prostate cancer therapy resistance. Cancer Res 68(13):5469-77. 
DeMali KA, Wennerberg K, Burridge K. 2003. Integrin signaling to the actin cytoskeleton. Curr 
Opin Cell Biol 15(5):572-82. 
Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, 
Rittenhouse H, et al. 2008. PCA3: A molecular urine assay for predicting prostate biopsy 
outcome. J Urol 179(4):1587-92. 
Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, Lessard F, Moiseeva O, Forest V, 
Igelmann S, Mallette FA, Saba-El-Leil MK, Meloche S, et al. 2013. Tumor suppressor 
activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev 
27(8):900-15. 
Desgrosellier JS and Cheresh DA. 2010. Integrins in cancer: Biological implications and 
therapeutic opportunities. Nat Rev Cancer 10(1):9-22. 
Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, Shattil SJ, 
Cheresh DA. 2009. An integrin alpha(v)beta(3)-c-src oncogenic unit promotes anchorage-
independence and tumor progression. Nat Med 15(10):1163-9. 
Duan X, Jia SF, Zhou Z, Langley RR, Bolontrade MF, Kleinerman ES. 2004. Association of 
alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic 
ability of human osteosarcoma cells. Clin Exp Metastasis 21(8):747-53. 
Dutt P, Jaffe AB, Merdek KD, Hall A, Toksoz D. 2004. Galphaz inhibits serum response factor-
dependent transcription by inhibiting rho signaling. Mol Pharmacol 66(6):1508-16. 
Dutt P, Kjoller L, Giel M, Hall A, Toksoz D. 2002. Activated galphaq family members induce 
rho GTPase activation and rho-dependent actin filament assembly. FEBS Lett 531(3):565-9. 
Ebert MP, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J, Röcken C, Schulz 
HU, Malfertheiner P, Lofton-Day C. 2005. Hypermethylation of the TPEF/HPP1 gene in 
primary and metastatic colorectal cancers. Neoplasia 7(8):771-8. 
124 
 
Eib DW, Holling TM, Zwijsen A, Dewulf N, de Groot E, van den Eijnden-van Raaij AJ, 
Huylebroeck D, Martens GJ. 2000. Expression of the follistatin/EGF-containing 
transmembrane protein M7365 (tomoregulin-1) during mouse development. Mech Dev 
97(1-2):167-71. 
Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D. 2008. HPP1-mediated tumor 
suppression requires activation of STAT1 pathways. Int J Cancer 122(7):1567-72. 
Eliceiri BP. 2001. Integrin and growth factor receptor crosstalk. Circ Res 89(12):1104-10. 
Engler DA, Montelione GT, Niyogi SK. 1990. Human epidermal growth factor. distinct roles of 
tyrosine 37 and arginine 41 in receptor binding as determined by site-directed mutagenesis 
and nuclear magnetic resonance spectroscopy. FEBS Lett 271(1-2):47-50. 
Er EE, Mendoza MC, Mackey AM, Rameh LE, Blenis J. 2013. AKT facilitates EGFR trafficking 
and degradation by phosphorylating and activating PIKfyve. Sci Signal 6(279):ra45. 
Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes 
PE, Pampori N, Shattil SJ, Saven A, et al. 2001. Integrin activation controls metastasis in 
human breast cancer. Proc Natl Acad Sci U S A 98(4):1853-8. 
Fornaro M and Languino LR. 1997. Alternatively spliced variants: A new view of the integrin 
cytoplasmic domain. Matrix Biol 16(4):185-93. 
Fornaro M, Manes T, Languino LR. 2001. Integrins and prostate cancer metastases. Cancer 
Metastasis Rev 20(3-4):321-31. 
Fox JT and Stover PJ. 2008. Folate-mediated one-carbon metabolism. Vitam Horm 79:1-44. 
Friedl P, Entschladen F, Conrad C, Niggemann B, Zanker KS. 1998. CD4+ T lymphocytes 
migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 
integrin-independent strategies for polarization, interaction with collagen fibers and 
locomotion. Eur J Immunol 28(8):2331-43. 
Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto 
T. 2007. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen 
receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of 
prostate cancer cells. Cancer Invest 25(1):32-7. 
Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. 2006. 
Combinatorial activities of akt and B-Raf/Erk signaling in a mouse model of androgen-
independent prostate cancer. Proc Natl Acad Sci U S A 103(39):14477-82. 
Gee JM, Robertson JF, Ellis IO, Nicholson RI. 2001. Phosphorylation of ERK1/2 mitogen-
activated protein kinase is associated with poor response to anti-hormonal therapy and 
decreased patient survival in clinical breast cancer. Int J Cancer 95(4):247-54. 
125 
 
Geiger B and Yamada KM. 2011. Molecular architecture and function of matrix adhesions. Cold 
Spring Harb Perspect Biol 3(5):10.1101/cshperspect.a005033. 
Geiger B, Bershadsky A, Pankov R, Yamada KM. 2001. Transmembrane crosstalk between the 
extracellular matrix--cytoskeleton crosstalk. Nat Rev Mol Cell Biol 2(11):793-805. 
Genander M, Halford MM, Xu NJ, Eriksson M, Yu Z, Qiu Z, Martling A, Greicius G, Thakar S, 
Catchpole T, et al. 2009. Dissociation of EphB2 signaling pathways mediating progenitor 
cell proliferation and tumor suppression. Cell 139(4):679-92. 
Gery S, Yin D, Xie D, Black KL, Koeffler HP. 2003. TMEFF1 and brain tumors. Oncogene 
22(18):2723-7. 
Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP. 2002. TMEFF2 is an androgen-regulated 
gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 21(31):4739-46. 
Giancotti FG and Ruoslahti E. 1990. Elevated levels of the alpha 5 beta 1 fibronectin receptor 
suppress the transformed phenotype of chinese hamster ovary cells. Cell 60(5):849-59. 
Ginsberg MH, Partridge A, Shattil SJ. 2005. Integrin regulation. Curr Opin Cell Biol 17(5):509-
16. 
Glynne-Jones E, Harper ME, Seery LT, James R, Anglin I, Morgan HE, Taylor KM, Gee JM, 
Nicholson RI. 2001. TENB2, a proteoglycan identified in prostate cancer that is associated 
with disease progression and androgen independence. Int J Cancer 94(2):178-84. 
Goel HL, Li J, Kogan S, Languino LR. 2008. Integrins in prostate cancer progression. Endocr 
Relat Cancer 15(3):657-64. 
Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A, 
Languino LR. 2005. beta1A integrin expression is required for type 1 insulin-like growth 
factor receptor mitogenic and transforming activities and localization to focal contacts. 
Cancer Res 65(15):6692-700. 
Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. 2008. Trop2 identifies a 
subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc 
Natl Acad Sci U S A 105(52):20882-7. 
Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode 
RG, Sandusky GE, et al. 2000. Increased AKT activity contributes to prostate cancer 
progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 
expression. J Biol Chem 275(32):24500-5. 
Grant S. 2008. Cotargeting survival signaling pathways in cancer. J Clin Invest 118(9):3003-6. 
126 
 
Green T, Chen X, Ryan S, Asch AS, Ruiz-Echevarria MJ. 2013. TMEFF2 and SARDH 
cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells. Prostate 
73(14):1561-75. 
Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, 
Dodd JG, Duckworth ML, Rosen JM. 1994. The rat probasin gene promoter directs 
hormonally and developmentally regulated expression of a heterologous gene specifically to 
the prostate in transgenic mice. Mol Endocrinol 8(2):230-9. 
Gregory CW, Johnson RT,Jr, Mohler JL, French FS, Wilson EM. 2001. Androgen receptor 
stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. 
Cancer Res 61(7):2892-8. 
Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, 
Meyer T, et al. 2006. APTIMA PCA3 molecular urine test: Development of a method to aid 
in the diagnosis of prostate cancer. Clin Chem 52(6):1089-95. 
Guo W and Giancotti FG. 2004. Integrin signalling during tumour progression. Nat Rev Mol 
Cell Biol 5(10):816-26. 
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, et 
al. 2009. A novel androgen receptor splice variant is up-regulated during prostate cancer 
progression and promotes androgen depletion-resistant growth. Cancer Res 69(6):2305-13. 
Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, 
et al. 2006. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer 
Cell 10(4):309-19. 
Hall CL, Dai J, van Golen KL, Keller ET, Long MW. 2006. Type I collagen receptor (alpha 2 
beta 1) signaling promotes the growth of human prostate cancer cells within the bone. 
Cancer Res 66(17):8648-54. 
Hanabata T, Tsukuda K, Toyooka S, Yano M, Aoe M, Nagahiro I, Sano Y, Date H, Shimizu N. 
2004. DNA methylation of multiple genes and clinicopathological relationship of non-small 
cell lung cancers. Oncol Rep 12(1):177-80. 
Hanahan D and Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144(5):646-
74. 
Harburger DS and Calderwood DA. 2009. Integrin signalling at a glance. J Cell Sci 122(Pt 
2):159-63. 
Harms PW and Chang C. 2003. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through 
direct binding to the nodal coreceptor cripto. Genes Dev 17(21):2624-9. 
127 
 
Heanue TA and Pachnis V. 2006. Expression profiling the developing mammalian enteric 
nervous system identifies marker and candidate hirschsprung disease genes. Proc Natl Acad 
Sci U S A 103(18):6919-24. 
Hommel U, Dudgeon TJ, Fallon A, Edwards RM, Campbell ID. 1991. Structure-function 
relationships in human epidermal growth factor studied by site-directed mutagenesis and 1H 
NMR. Biochemistry 30(36):8891-8. 
Hood JD and Cheresh DA. 2002. Role of integrins in cell invasion and migration. Nat Rev 
Cancer 2(2):91-100. 
Horie M, Mitsumoto Y, Kyushiki H, Kanemoto N, Watanabe A, Taniguchi Y, Nishino N, 
Okamoto T, Kondo M, Mori T, et al. 2000. Identification and characterization of TMEFF2, 
a novel survival factor for hippocampal and mesencephalic neurons. Genomics 67(2):146-
52. 
Hosotani R, Kawaguchi M, Masui T, Koshiba T, Ida J, Fujimoto K, Wada M, Doi R, Imamura 
M. 2002. Expression of integrin alphaVbeta3 in pancreatic carcinoma: Relation to MMP-2 
activation and lymph node metastasis. Pancreas 25(2):e30-5. 
Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, 
Isaacs WB, et al. 2009. Ligand-independent androgen receptor variants derived from 
splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1):16-
22. 
Huveneers S and Danen EH. 2009. Adhesion signaling - crosstalk between integrins, src and rho. 
J Cell Sci 122(Pt 8):1059-69. 
Hynes RO. 2002. Integrins: Bidirectional, allosteric signaling machines. Cell 110(6):673-87. 
Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S, Le Magnen C, Guarnieri 
P, Sumazin P, Benson MC, et al. 2013. A molecular signature predictive of indolent prostate 
cancer. Sci Transl Med 5(202):202ra122. 
Issaq HJ and Veenstra TD. 2011. Is sarcosine a biomarker for prostate cancer? J Sep Sci 
34(24):3619-21. 
Ivaska J and Heino J. 2011. Cooperation between integrins and growth factor receptors in 
signaling and endocytosis. Annu Rev Cell Dev Biol 27:291-320. 
Jacob K, Webber M, Benayahu D, Kleinman HK. 1999. Osteonectin promotes prostate cancer 
cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 
59(17):4453-7. 
Javitt DC. 2009. Glycine transport inhibitors for the treatment of schizophrenia: Symptom and 
disease modification. Curr Opin Drug Discov Devel 12(4):468-78. 
128 
 
Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G, Jung K. 2011. 
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer 
aggressiveness and biochemical progression. J Urol 185(2):706-11. 
Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, Lein M, Jung K. 
2010. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer 
detection and identification of aggressive tumours. Eur Urol 58(1):12,8; discussion 20-1. 
Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H. 2007. Murine cell lines 
derived from pten null prostate cancer show the critical role of PTEN in hormone refractory 
prostate cancer development. Cancer Res 67(13):6083-91. 
Kanemoto N, Horie M, Omori K, Nishino N, Kondo M, Noguchi K, Tanigami A. 2001. 
Expression of TMEFF1 mRNA in the mouse central nervous system: Precise examination 
and comparative studies of TMEFF1 and TMEFF2. Brain Res Mol Brain Res 86(1-2):48-55. 
Kang YK, Schiff R, Ko L, Wang T, Tsai SY, Tsai MJ, O'Malley BW. 2008. Dual roles for 
coactivator activator and its counterbalancing isoform coactivator modulator in human 
kidney cell tumorigenesis. Cancer Res 68(19):7887-96. 
Karantanos T, Corn PG, Thompson TC. 2013. Prostate cancer progression after androgen 
deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. 
Oncogene . 
Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, Roy-
Burman P. 2006. Increased expression of osteopontin contributes to the progression of 
prostate cancer. Cancer Res 66(2):883-8. 
Kim C, Ye F, Ginsberg MH. 2011. Regulation of integrin activation. Annu Rev Cell Dev Biol 
27:321-45. 
Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer 
R, Nguyen P, Savage J, Owens KM, et al. 2010. SIRT3 is a mitochondria-localized tumor 
suppressor required for maintenance of mitochondrial integrity and metabolism during 
stress. Cancer Cell 17(1):41-52. 
King A, Selak MA, Gottlieb E. 2006. Succinate dehydrogenase and fumarate hydratase: Linking 
mitochondrial dysfunction and cancer. Oncogene 25(34):4675-82. 
Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, 
Gerald WL, Cordon-Cardo C, et al. 2008. Targeting AKT/mTOR and ERK MAPK 
signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin 
Invest 118(9):3051-64. 
Kiyokawa E, Hashimoto Y, Kobayashi S, Sugimura H, Kurata T, Matsuda M. 1998. Activation 
of Rac1 by a crk SH3-binding protein, DOCK180. Genes Dev 12(21):3331-6. 
129 
 
Kong T, Xu D, Tran M, Denker BM. 2010. Regulation of integrin expression by Galpha12: An 
additional potential mechanism modulating cell attachment. Cell Adh Migr 4(3):372-6. 
Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, Yu K, Albanes D, Chu LW, 
Andriole G, et al. 2013. Prospective evaluation of serum sarcosine and risk of prostate 
cancer in the prostate, lung, colorectal and ovarian cancer screening trial. Carcinogenesis 
34(10):2281-5. 
Kress TR, Raabe T, Feller SM. 2010. High erk activity suppresses expression of the cell cycle 
inhibitor p27Kip1 in colorectal cancer cells. Cell Commun Signal 8(1):1,811X-8-1. 
Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. 2004. 
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in 
prostate cancer. Cancer Res 64(15):5232-6. 
Labeur M, Wölfel B, Panhuysen M, Stalla J, Stalla GK, Paez-Pereda M. 2010. TMEFF2: A new 
endogenous modulator of the CRH signaling in corticotroph cells. Exp Clin Endocrinol 
Diabetes 118(8). 
Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, Cheng SL. 2001. Erk is 
essential for growth, differentiation, integrin expression, and cell function in human 
osteoblastic cells. J Biol Chem 276(17):14443-50. 
Lammermann T, Bader BL, Monkley SJ, Worbs T, Wedlich-Soldner R, Hirsch K, Keller M, 
Forster R, Critchley DR, Fassler R, et al. 2008. Rapid leukocyte migration by integrin-
independent flowing and squeezing. Nature 453(7191):51-5. 
Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, 
Jennnings NB, Kinch MS, et al. 2008. Tumor-selective response to antibody-mediated 
targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10(11):1259-67. 
Lauffenburger DA and Horwitz AF. 1996. Cell migration: A physically integrated molecular 
process. Cell 84(3):359-69. 
 
Lee SJ, Lee YS, Seo KW, Bae JU, Kim GH, Park SY, Kim CD. 2012. Homocysteine enhances 
MMP-9 production in murine macrophages via ERK and Akt signaling pathways. Toxicol 
Appl Pharmacol 260(1):89-94.  
Lee SM, Park JY, Kim DS. 2012. Methylation of TMEFF2 gene in tissue and serum DNA from 
patients with non-small cell lung cancer. Mol Cells 34(2):171-6. 
Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, 
Yeh ET, et al. 2013. Targeting constitutively activated beta1 integrins inhibits prostate 
cancer metastasis. Mol Cancer Res 11(4):405-17. 
130 
 
Legate KR, Wickstrom SA, Fassler R. 2009. Genetic and cell biological analysis of integrin 
outside-in signaling. Genes Dev 23(4):397-418. 
Lehr JE and Pienta KJ. 1998. Preferential adhesion of prostate cancer cells to a human bone 
marrow endothelial cell line. J Natl Cancer Inst 90(2):118-23. 
Leitner L, Shaposhnikov D, Mengel A, Descot A, Julien S, Hoffmann R, Posern G. 2011. 
MAL/MRTF-A controls migration of non-invasive cells by upregulation of cytoskeleton-
associated proteins. J Cell Sci 124(Pt 24):4318-31. 
Leong KG, Wang BE, Johnson L, Gao WQ. 2008. Generation of a prostate from a single adult 
stem cell. Nature 456(7223):804-8. 
Liang G, Robertson KD, Talmadge C, Sumegi J, Jones PA. 2000. The gene for a novel 
transmembrane protein containing epidermal growth factor and follistatin domains is 
frequently hypermethylated in human tumor cells. Cancer Res 60(17):4907-12. 
Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. 2009. Perineural invasion in cancer: A review 
of the literature. Cancer 115(15):3379-91. 
Lilja H, Ulmert D, Vickers AJ. 2008. Prostate-specific antigen and prostate cancer: Prediction, 
detection and monitoring. Nat Rev Cancer 8(4):268-78. 
Lim SO, Park SJ, Kim W, Park SG, Kim HJ, Kim YI, Sohn TS, Noh JH, Jung G. 2002. 
Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 
291(4):1031-7. 
Lin H, Wada K, Yonezawa M, Shinoki K, Akamatsu T, Tsukui T, Sakamoto C. 2003. 
Tomoregulin ectodomain shedding by proinflammatory cytokines. Life Sci 73(13):1617-27. 
Lin HK, Yeh S, Kang HY, Chang C. 2001. Akt suppresses androgen-induced apoptosis by 
phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 98(13):7200-5. 
Lin K, Taylor JR,Jr, Wu TD, Gutierrez J, Elliott JM, Vernes JM, Koeppen H, Phillips HS, de 
Sauvage FJ, Meng YG. 2011. TMEFF2 is a PDGF-AA binding protein with methylation-
associated gene silencing in multiple cancer types including glioma. PLoS One 6(4):e18608. 
Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. 2001. 
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate 
cancer. Cancer Res 61(9):3550-5. 
Linn MM, Ball RA, Maradiegue A. 2007. Prostate-specific antigen screening: friend or foe? Urol 
Nurs 27(6):481-9. 
131 
 
Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST, Wang Z, et al. 2012. 
Identification of novel CHD1-associated collaborative alterations of genomic structure and 
functional assessment of CHD1 in prostate cancer. Oncogene 31(35):3939-48. 
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, 
Nelson CC. 2008. Androgen levels increase by intratumoral de novo steroidogenesis during 
progression of castration-resistant prostate cancer. Cancer Res 68(15):6407-15. 
Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, 
Bettocchi C, Battaglia M, Ditonno P. 2012. Serum sarcosine increases the accuracy of 
prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 
72(15):1611-21. 
Lucarelli G, Ditonno P, Bettocchi C, Spilotros M, Rutigliano M, Vavallo A, Galleggiante V, 
Fanelli M, Larocca AM, Germinario CA, et al. 2013. Serum sarcosine is a risk factor for 
progression and survival in patients with metastatic castration-resistant prostate cancer. 
Future Oncol 9(6):899-907. 
Malawista SE and de Boisfleury Chevance A. 1997. Random locomotion and chemotaxis of 
human blood polymorphonuclear leukocytes (PMN) in the presence of EDTA: PMN in 
close quarters require neither leukocyte integrins nor external divalent cations. Proc Natl 
Acad Sci U S A 94(21):11577-82. 
Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. 2002. 
Immunohistochemical demonstration of phospho-akt in high gleason grade prostate cancer. 
Clin Cancer Res 8(4):1168-71. 
Markert EK, Mizuno H, Vazquez A, Levine AJ. 2011. Molecular classification of prostate cancer 
using curated expression signatures. Proc Natl Acad Sci U S A 108(52):21276-81.  
McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. 2007. Prostate cancer specific integrin 
alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 
26(42):6238-43. 
McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian 
DM, Franklin RA, D'Assoro AB, et al. 2006. Roles of the RAF/MEK/ERK and 
PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme 
Regul 46:249-79. 
McNeal JE. 1988. Normal histology of the prostate. Am J Surg Pathol 12(8):619-33. 
Mecham RP. 1991. Laminin receptors. Annu Rev Cell Biol 7:71-91. 
Mei H, Ho MK, Yung LY, Wu Z, Ip NY, Wong YH. 2011. Expression of galpha(z) in C2C12 
cells restrains myogenic differentiation. Cell Signal 23(2):389-97. 
132 
 
Mendoza MC, Er EE, Blenis J. 2011. The ras-ERK and PI3K-mTOR pathways: Cross-talk and 
compensation. Trends Biochem Sci 36(6):320-8. 
Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. 1996. Integrins can collaborate with growth 
factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: Roles 
of integrin aggregation and occupancy of receptors. J Cell Biol 135(6 Pt 1):1633-42. 
Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. 2002. Regulation of raf-akt 
cross-talk. J Biol Chem 277(34):31099-106. 
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, 
Nelson PS. 2008. Maintenance of intratumoral androgens in metastatic prostate cancer: A 
mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447-54. 
Moran-Jones K, Ledger A, Naylor MJ. 2012. β1 integrin deletion enhances progression of 
prostate cancer in the TRAMP mouse model. Sci Rep 2:526.  
Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. 1998. 
Integrins induce activation of EGF receptor: Role in MAP kinase induction and adhesion-
dependent cell survival. Embo j 17(22):6622-32. 
Murray-Zmijewski F, Lane DP, Bourdon JC. 2006. P53/p63/p73 isoforms: An orchestra of 
isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 
13(6):962-72. 
Nagata S, Hamada T, Yamada N, Yokoyama S, Kitamoto S, Kanmura Y, Nomura M, Kamikawa 
Y, Yonezawa S, Sugihara K. 2012. Aberrant DNA methylation of tumor-related genes in 
oral rinse: A noninvasive method for detection of oral squamous cell carcinoma. Cancer 
118(17):4298-308. 
Nimnual AS, Taylor LJ, Bar-Sagi D. 2003. Redox-dependent downregulation of rho by rac. Nat 
Cell Biol 5(3):236-41. 
Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. 2008. 
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad 
Sci U S A 105(34):12182-7. 
Oshimori N and Fuchs E. 2012. Paracrine TGF-beta signaling counterbalances BMP-mediated 
repression in hair follicle stem cell activation. Cell Stem Cell 10(1):63-75. 
Overcash RF, Chappell VA, Green T, Geyer CB, Asch AS, Ruiz-Echevarria MJ. 2013. 
Androgen signaling promotes translation of TMEFF2 in prostate cancer cells via 
phosphorylation of the alpha subunit of the translation initiation factor 2. PLoS One 
8(2):e55257. 
133 
 
Pappin DJ, Hojrup P, Bleasby AJ. 1993. Rapid identification of proteins by peptide-mass 
fingerprinting. Curr Biol 3(6):327-32. 
Park J, Song SH, Kim TY, Choi MC, Jong HS, Kim TY, Lee JW, Kim NK, Kim WH, Bang YJ. 
2004. Aberrant methylation of integrin alpha4 gene in human gastric cancer cells. Oncogene 
23(19):3474-80. 
Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH. 
2011. Promoter CpG island hypermethylation during breast cancer progression. Virchows 
Arch 458(1):73-84. 
Park YH, Seo SY, Ha M, Ku JH, Kim HH, Kwak C. 2011. Inhibition of prostate cancer using 
RNA interference-directed knockdown of platelet-derived growth factor receptor. Urology 
77(6):1509.e9,1509.15. 
Penning LC, Piek CJ, Eib DW, Schipper RG, Holling TM, Martens GJ. 2006. Induction of 
apoptosis in hematopoietic cells with an antibody against tomoregulin-1. Anticancer Res 
26(1A):339-46. 
Quayle SN and Sadar MD. 2006. A truncated isoform of TMEFF2 encodes a secreted protein in 
prostate cancer cells. Genomics 87(5):633-7. 
Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, 
Zijlstra A, Zutter MM. 2011. The alpha(2)beta(1) integrin is a metastasis suppressor in 
mouse models and human cancer. J Clin Invest 121(1):226-37. 
Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K. 2001. Regulation of raf by akt 
controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 
276(36):33630-7. 
Reymond N, Im JH, Garg R, Vega FM, Borda d'Agua B, Riou P, Cox S, Valderrama F, Muschel 
RJ, Ridley AJ. 2012. Cdc42 promotes transendothelial migration of cancer cells through 
beta1 integrin. J Cell Biol 199(4):653-68. 
Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. 2004. CD133, a 
novel marker for human prostatic epithelial stem cells. J Cell Sci 117(Pt 16):3539-45. 
Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz 
AR. 2003. Cell migration: Integrating signals from front to back. Science 302(5651):1704-9. 
Roovers K, Davey G, Zhu X, Bottazzi ME, Assoian RK. 1999. Alpha5beta1 integrin controls 
cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth 
factor-treated cells. Mol Biol Cell 10(10):3197-204. 
Ross RS. 2004. Molecular and mechanical synergy: Cross-talk between integrins and growth 
factor receptors. Cardiovasc Res 63(3):381-90. 
134 
 
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, 
Piulats JM, Ng S, et al. 2013. Abiraterone in metastatic prostate cancer without previous 
chemotherapy. N Engl J Med 368(2):138-48. 
Sah VP, Seasholtz TM, Sagi SA, Brown JH. 2000. The role of rho in G protein-coupled receptor 
signal transduction. Annu Rev Pharmacol Toxicol 40:459-89. 
Sato F, Shibata D, Harpaz N, Xu Y, Yin J, Mori Y, Wang S, Olaru A, Deacu E, Selaru FM, et al. 
2002. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal 
carcinoma. Cancer Res 62(23):6820-2. 
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, 
Shore ND, et al. 2012. Increased survival with enzalutamide in prostate cancer after 
chemotherapy. N Engl J Med 367(13):1187-97. 
Schneider JG, Amend SR, Weilbaecher KN. 2011. Integrins and bone metastasis: Integrating 
tumor cell and stromal cell interactions. Bone 48(1):54-65. 
Schneller M, Vuori K, Ruoslahti E. 1997. Alphavbeta3 integrin associates with activated insulin 
and PDGFbeta receptors and potentiates the biological activity of PDGF. Embo j 
16(18):5600-7. 
Schoenwaelder SM and Burridge K. 1999. Bidirectional signaling between the cytoskeleton and 
integrins. Curr Opin Cell Biol 11(2):274-86. 
Schwartz MA and Ginsberg MH. 2002. Networks and crosstalk: Integrin signalling spreads. Nat 
Cell Biol 4(4):E65-8. 
Schwartz MA and Shattil SJ. 2000. Signaling networks linking integrins and rho family 
GTPases. Trends Biochem Sci 25(8):388-91. 
Scott LJ, Clarke NW, George NJ, Shanks JH, Testa NG, Lang SH. 2001. Interactions of human 
prostatic epithelial cells with bone marrow endothelium: Binding and invasion. Br J Cancer 
84(10):1417-23. 
Selamat SA, Galler JS, Joshi AD, Fyfe MN, Campan M, Siegmund KD, Kerr KM, Laird-
Offringa IA. 2011. DNA methylation changes in atypical adenomatous hyperplasia, 
adenocarcinoma in situ, and lung adenocarcinoma. PLoS One 6(6):e21443. 
Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, 
Harwood J, Bismar TA, et al. 2004. Androgen-independent prostate cancer is a 
heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 
64(24):9209-16. 
135 
 
Shen B, Delaney MK, Du X. 2012. Inside-out, outside-in, and inside-outside-in: G protein 
signaling in integrin-mediated cell adhesion, spreading, and retraction. Curr Opin Cell Biol 
24(5):600-6. 
Shen MM and Abate-Shen C. 2010. Molecular genetics of prostate cancer: New prospects for old 
challenges. Genes Dev 24(18):1967-2000. 
Siegel DA, Huang MK, Becker SF. 2002. Ectopic dendrite initiation: CNS pathogenesis as a 
model of CNS development. Int J Dev Neurosci 20(3-5):373-89. 
Siegel DA, Davies P, Dobrenis K, Huang M. 2006. Tomoregulin-2 is found extensively in 
plaques in alzheimer's disease brain. J Neurochem 98(1):34-44. 
Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30. 
Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, Anderson RL. 2006. Tumor-
specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast 
cancer to bone. Breast Cancer Res 8(2):R20. 
Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET, Hall CL. 2013. 
Integrin alpha2beta 1 (alpha2beta1) promotes prostate cancer skeletal metastasis. Clin Exp 
Metastasis 30(5):569-78. 
Soung YH, Clifford JL, Chung J. 2010. Crosstalk between integrin and receptor tyrosine kinase 
signaling in breast carcinoma progression. BMB Rep 43(5):311-8. 
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, 
Lonigro RJ, Li Y, et al. 2009. Metabolomic profiles delineate potential role for sarcosine in 
prostate cancer progression. Nature 457(7231):910-4. 
Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE. 2010. The laminin 
binding integrin alpha6beta1 in prostate cancer perineural invasion. J Cell Physiol 
224(2):283-8. 
Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. 
2006. Increased expression of genes converting adrenal androgens to testosterone in 
androgen-independent prostate cancer. Cancer Res 66(5):2815-25. 
Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer 
MD, Kuefer R, Chinnaiyan A, Rubin MA, et al. 2009. Treatment-dependent androgen 
receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer 
Res 69(10):4434-42. 
Stover PJ. 2009. One-carbon metabolism-genome interactions in folate-associated pathologies. J 
Nutr 139(12):2402-5. 
136 
 
Streuli CH and Akhtar N. 2009. Signal co-operation between integrins and other receptor 
systems. Biochem J 418(3):491-506. 
Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. 2010. Serum sarcosine 
is not a marker for prostate cancer. Ann Clin Biochem 47(Pt 3):282. 
Stupack DG and Cheresh DA. 2002. Get a ligand, get a life: Integrins, signaling and cell 
survival. J Cell Sci 115(Pt 19):3729-38. 
Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Frenkel 
EP, Minna JD, Fujisawa T, Gazdar AF. 2005. DNA methylation-associated inactivation of 
TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 
93(9):1029-37. 
Thin TH, Wang L, Kim E, Collins LL, Basavappa R, Chang C. 2003. Isolation and 
characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to 17-beta 
estradiol treatment. J Biol Chem 278(9):7699-708. 
Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. 2009. 
ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 
56(2):275-86. 
Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge 
P, Meinke J, Blase A, et al. 2011. Urine TMPRSS2:ERG fusion transcript stratifies prostate 
cancer risk in men with elevated serum PSA. Sci Transl Med 3(94):94ra72. 
Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, 
Laxman B, Morris DS, et al. 2008. The role of SPINK1 in ETS rearrangement-negative 
prostate cancers. Cancer Cell 13(6):519-28. 
Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, Liu JF, Jamieson GG, Drew PA. 2009. 
Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous 
cell carcinoma. Oncol Rep 21(4):1067-73. 
Uchida T, Wada K, Akamatsu T, Yonezawa M, Noguchi H, Mizoguchi A, Kasuga M, Sakamoto 
C. 1999. A novel epidermal growth factor-like molecule containing two follistatin modules 
stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem 
Biophys Res Commun 266(2):593-602. 
Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, 
Mathew P, Fidler IJ. 2003. Effects of blocking platelet-derived growth factor-receptor 
signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer 
Inst 95(6):458-70. 
137 
 
Uhm KO, Lee JO, Lee YM, Lee ES, Kim HS, Park SH. 2010. Aberrant DNA methylation of 
integrin alpha4: A potential novel role for metastasis of cholangiocarcinoma. J Cancer Res 
Clin Oncol 136(2):187-94. 
Varner JA, Emerson DA, Juliano RL. 1995. Integrin alpha 5 beta 1 expression negatively 
regulates cell growth: Reversal by attachment to fibronectin. Mol Biol Cell 6(6):725-40. 
Veevers-Lowe J, Ball SG, Shuttleworth A, Kielty CM. 2011. Mesenchymal stem cell migration 
is regulated by fibronectin through alpha5beta1-integrin-mediated activation of PDGFR-
beta and potentiation of growth factor signals. J Cell Sci 124(Pt 8):1288-300. 
Velling T, Stefansson A, Johansson S. 2008. EGFR and beta1 integrins utilize different signaling 
pathways to activate akt. Exp Cell Res 314(2):309-16. 
Vicente-Manzanares M, Choi CK, Horwitz AR. 2009. Integrins in cell migration--the actin 
connection. J Cell Sci 122(Pt 2):199-206. 
Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. 2001. Integrin alpha(v)beta(3) 
expression in colon carcinoma correlates with survival. Mod Pathol 14(11):1126-32. 
Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, 
Abate-Shen C, Shen MM. 2009. A luminal epithelial stem cell that is a cell of origin for 
prostate cancer. Nature 461(7263):495-500. 
Woodard AS, Garcia-Cardena G, Leong M, Madri JA, Sessa WC, Languino LR. 1998. The 
synergistic activity of alphavbeta3 integrin and PDGF receptor increases cell migration. J 
Cell Sci 111 ( Pt 4)(Pt 4):469-78. 
Woolf E, Grigorova I, Sagiv A, Grabovsky V, Feigelson SW, Shulman Z, Hartmann T, Sixt M, 
Cyster JG, Alon R. 2007. Lymph node chemokines promote sustained T lymphocyte 
motility without triggering stable integrin adhesiveness in the absence of shear forces. Nat 
Immunol 8(10):1076-85. 
Wu H, Liu T, Ma C, Xue R, Deng C, Zeng H, Shen X. 2011. GC/MS-based metabolomic 
approach to validate the role of urinary sarcosine and target biomarkers for human prostate 
cancer by microwave-assisted derivatization. Anal Bioanal Chem 401(2):635-46. 
Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. 2006. Progression of 
prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the 
androgen receptor. Proc Natl Acad Sci U S A 103(20):7789-94. 
Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, et al. 2009. 
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced 
ubiquitination. Cancer Cell 15(4):270-82. 
138 
 
Yang X, Pursell B, Lu S, Chang TK, Mercurio AM. 2009. Regulation of beta 4-integrin 
expression by epigenetic modifications in the mammary gland and during the epithelial-to-
mesenchymal transition. J Cell Sci 122(Pt 14):2473-80. 
Zaidel-Bar R, Cohen M, Addadi L, Geiger B. 2004. Hierarchical assembly of cell-matrix 
adhesion complexes. Biochem Soc Trans 32(Pt3):416-20. 
Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B. 2007. Functional atlas of the integrin 
adhesome. Nat Cell Biol 9(8):858-67. 
Zeller KS, Idevall-Hagren O, Stefansson A, Velling T, Jackson SP, Downward J, Tengholm A, 
Johansson S. 2010. PI3-kinase p110alpha mediates beta1 integrin-induced akt activation and 
membrane protrusion during cell attachment and initial spreading. Cell Signal 22(12):1838-
48. 
Zhang HX, Hyrc K, Thio LL. 2009. The glycine transport inhibitor sarcosine is an NMDA 
receptor co-agonist that differs from glycine. J Physiol 587(Pt 13):3207-20. 
Zhang XD, Gillespie SK, Hersey P. 2004. Staurosporine induces apoptosis of melanoma by both 
caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 3(2):187-97. 
Zhao BJ, Tan SN, Cui Y, Sun DG, Ma X. 2008b. Aberrant promoter methylation of the TPEF 
gene in esophageal squamous cell carcinoma. Dis Esophagus 21(7):582-8. 
Zhao XY, Liu HL, Liu B, Willuda J, Siemeister G, Mahmoudi M, Dinter H. 2008a. Tomoregulin 
internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. 
Transl Oncol 1(2):102-9. 
Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. 2000. 
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through 
a mutated androgen receptor. Nat Med 6(6):703-6. 
Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, Xuan JA, Sakamoto C, Wada K, 
Schulze M, et al. 2005. Targeting tomoregulin for radioimmunotherapy of prostate cancer. 
Cancer Res 65(7):2846-53. 
Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, 
Clezardin P. 2007. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone 
metastases. Cancer Res 67(12):5821-30. 
Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. 1999. Prostatic carcinoma cell 
migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. 
Cancer Res 59(7):1655-64. 
139 
 
Zhu Q, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, Berdeaux R, Martin GS, Sun 
L, Luo K. 2007. Dual role of SnoN in mammalian tumorigenesis. Mol Cell Biol 27(1):324-
39. 
Zimmermann S and Moelling K. 1999. Phosphorylation and regulation of raf by akt (protein 
kinase B). Science 286(5445):1741-4. 
Zutter MM, Santoro SA, Staatz WD, Tsung YL. 1995. Re-expression of the alpha 2 beta 1 
integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci U 
S A 92(16):7411-5. 
 
